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Abstract 
MicroRNAs (miRNAs) constitute a class of small non-coding RNAs that 
negatively regulate gene expression at post-transcriptional level in a sequence 
specific manner. They are involved in many biological processes, including 
cell proliferation, apoptosis and differentiation, and are considered as 
promising new therapeutic targets for cancer. However, the identity of 
miRNAs involved in apoptosis and their respective targets remain largely 
unknown. Given the elevated complexity of miRNA regulation of gene 
expression, we performed a functional screening as an alternative strategy to 
identify those miRNAs that in lung cancer cells may interfere with the 
apoptotic process. To this aim we generated a derivative of the non-small cell 
lung carcinoma A549 cell line in which caspase-8, a critical upstream initiator 
of apoptosis, can be activated by the administration of the small dimerizer drug 
AP20187. 
We found a number of miRNAs that may rescue cell viability from caspase-8 
activation. They included miRNAs already described as oncogenic such as 
miR-17, miR-135, miR-520, but also some miRNAs such as miR-124-1 and 
miR-34c for which a tumor suppressive role has been instead described or 
expected. Among them, miR-34c-5p markedly increased resistance to 
paclitaxel induced apoptosis. We demonstrate that Bmf (Bcl-2 modifying 
factor) is a target of miR-34c-5p and that its silencing, together with that of c-
myc, a known target of miR-34c-5p, contributes to resistance to apoptosis 
induced by paclitaxel via p53 downregulation. 
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1. Background 
MiRNAs are a class of short endogenous non-coding RNAs that act as key 
regulators of cell proliferation and apoptosis through the control of gene 
expression either inhibiting translation or triggering degradation of multiple 
target mRNAs (Bartel 2009). MiRNAs have been found deregulated in 
different malignancies, implicating them as oncogenes or tumor suppressors 
and thus considered as promising new therapeutic targets for cancers (Farazi et 
al. 2011; Garofalo and Croce 2011). Indeed, the selective induction of cell 
death by oligonucleotide-based drugs is a challenging goal for a rationale 
approach to novel therapeutic strategies in cancer treatment. 
Programmed cell death, or apoptosis, is mediated through two major pathways, 
the death receptor pathway and the mitochondrial pathway. In the death 
receptor pathway, stimulation of death receptors leads to the formation of a 
death-inducing signaling complex which includes the initiator caspases such as 
caspase-8 that drives its activation through self-cleavage and then activates 
several downstream effectors including caspase-9 and the ultimate effector 
caspase-3 (Ashkenazi and Dixit 1998). In the mitochondrial pathway, stimuli 
such as drugs, radiation, infectious agents and reactive oxygen species transmit 
the death signals to mitochondria through the activation of BID, a pro-
apoptotic member of the Bcl-2 family (Hengartner 2000). Caspase-8-mediated 
cleavage of BID thus provides integration of the death-receptor with the 
mitochondrial pathway. 
Identifying miRNAs that selectively regulate the expression of proteins 
involved in apoptosis could be helpful in the development of new tools for the 
diagnosis and the treatment of cancer (Inui et al. 2010). 
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1.1 MiRNAs 
 
1.1.1 The discovery of miRNAs 
MiRNAs were first discovered in mutant larvae of the nematode 
Caenorhabditis elegans as stRNA (small temporal RNA) involved in 
regulating the transition from one stage to another during development. Later it 
became clear that they represent the prototype of a large family of small RNAs 
called miRNAs, highly conserved during evolution. In larvae of C. elegans it 
was observed that the mutation in lin-4 gene caused defects in temporal control 
during the post-embryonic development (Wightman et al. 1993). Lin-4 encodes 
for a small RNA that binds the mRNA of the gene lin-14 and silences its 
expression. During post-embryonic development, C. elegans undergoes four 
larval stages, from L1 to L4. The first stage of larval development, L1, is 
regulated by the transcription factor lin-14 that promotes the expression of key 
genes in this phase and represses that of L2-specific genes. The levels of 
transcription factor lin-14 are high at the beginning of the phase L1 and then 
decrease for the action of lin-4 that blocks the translation of the messenger of 
lin-14 by allowing the L2-specific gene expression. Following these 
observations thousand miRNAs have been identified in different species of 
animals and plants that regulate many biological processes such as 
proliferation, differentiation and programmed cell death. 
 
 
 
1.1.2 MiRNAs: structure and biogenesis 
MiRNAs are small (19-23 nucleotides) non-coding RNA molecules, widely 
conserved through the evolution, that negatively regulate gene expression at 
post-transcriptional level in a sequence specific manner. They bind a specific 
site in the 3’UTR of a target mRNA allowing to degradation of the messenger 
if there is a perfect complementarity between the miRNA and its 3’UTR, or 
translational repression in case of not perfect complementarity. 
MiRNAs are first transcribed into long primary miRNAs (pri-miRNAs) by 
polymerase II or, in few rare cases, by polymerase III. Typically, pri-miRNAs 
display a 33 bp stem and a terminal loop structure with flanking segments. A 
single pri-miRNA may contain a "cluster" of different miRNAs or a single 
miRNA and can contain from 200 to several thousands of nucleotides (Lagos-
Quintana et al. 2003; Cai et al. 2004). Primary miRNAs processing begins in 
the nucleus where an RNAse III enzyme, Drosha, removes the flanking 
segments and 11 bp of the stem region, inducing the conversion of pri-miRNAs 
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into precursor miRNAs (pre-miRNAs) (Lee et al. 2003). Pre-miRNAs are 60-
70 nt long hairpin RNAs with 2-nt overhangs at the 3’ end. They are 
transported into the cytoplasm and subsequently processed by Dicer, a 
cytoplasmic endonuclease RNAse III enzyme, to create a double strand 
structure containing the mature miRNA and its complementary that will be 
degraded. The mature miRNA is then incorporated into the RISC (RNA-
induced silencing complex) which facilitates the interaction between the 
miRNA and its target mRNA and function as an endonuclease that cuts the 
target mRNA, or, for steric hindrance, can block the binding of mRNA with the 
complex of protein synthesis (Figure 1) (Krol 2010).  
 
 
 
 
 
Figure 1. Schematic representation of miRNA processing pathway 
The pri-miRNA, transcribed by the polymerase II, is first clave by the RNAse Drosha 
in a pre-miRNA of ~ 70 nucleotides. The pre-miRNA is then exported into the 
cytoplasm by Exportin-5 and processed by the RNAse III Dicer. Mature single strand 
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miRNA is incorporated into the RISC (RNA-induced silencing complex) which 
facilitates the interaction between the miRNA and its target mRNA . 
 
 
 
1.1.3 MiRNAs and cancer 
Recent studies have shown that miRNAs are involved in different biological 
processes and pathological states, particularly in the development of cancer 
since they can act as ‘‘oncomirs’’ or ‘‘tumor suppressors’’ (Croce 2009). Thus, 
miRNAs represent a new class of promising diagnostic and prognostic 
biomarkers as well as new targets for cancer therapy (Fabbri 2010; Bartels et 
al. 2009). They are more useful tools than proteins and mRNAs, since a great 
fraction of them are regulatory molecules. Furthermore, being shorter than 
mRNAs, they are less vulnerable to degradation by ribonucleases and, because 
miRNAs are not structural modified, they are easier to detect than proteins. To 
date altered expression levels of miRNAs have been linked to various cancers; 
expression studies of various tumor types has revealed specific alterations in 
miRNA profiles, where some miRNAs are overexpressed and others strongly 
repressed, depending on the cancer type, disease stage and response to the 
treatment (Kitade and Akao 2010; Volinia et al. 2006; Esquela-Kerscher and 
Slack 2006; Lu et al.. 2005; Goga and Benz 2007).  
 The first evidence for miRNAs involvement in human cancer comes from a 
study by Calin et al (2002), examining a recurring deletion at chromosome 
13q14 to search for a tumor suppressor gene involved in chronic lymphocytic 
leukemia (CLL). In this study was found that the region of deletion encodes 
two miRNAs, miR-15a and miR-16-1.  Subsequent investigations have 
confirmed the involvement of these two miRNAs in the pathogenesis of CLL 
(Calin et al. 2005; Cimmino et al. 2005). Furthermore, Constinean et al 
reported that a miRNA by itself can induce a neoplastic disease (Costinean et 
al. 2006). In fact, by using a transgenic mouse model, they demonstrated that 
overexpression of miR-155 in B cells induce lymphoma pre-B leukemia.  
Several other miRNAs deregulated in different human cancer types have been 
reported. For example, it has been demonstrated that let-7 family contains 
miRNAs regulating the RAS family of oncogenes (Johnson et al. 2005). 
Petrocca et al. (2008) showed that the miR-106b-25 cluster plays a key role in 
gastric cancer interfering with proteins involved both in cell cycle and 
apoptosis. In other studies, miR-155 was found overexpressed in Hodgkin 
lymphoma, pediatric Burkitt lymphoma and diffuse large B-cell Lymphoma 
(Eis et al. 2005; Kluiver et al. 2005; Metzler et al. 2004); miR-143 and miR-
145 were significantly downregulated in colon cancer tissue compared with 
colonic mucosa (Michael et al. 2003); miR-21 was overexpressed in many  
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tumors (Volinia et al. 2006), including  glioblastoma (Chan et al. 2005), 
cholangiocarcinoma (Meng et al. 2006), multiple myeloma cells (Loffler et al. 
2007) and breast cancer (Si et al. 2007; Zhu et al. 2008).  
Moreover, studies that investigated the expression of the entire microRNAome 
in various human solid tumors and hematologic malignancies have revealed 
differences in miRNA expression profiling between neoplastic and normal 
tissues (Calin et al. 2005, Ciafrè et al. 2005, Pallante et al. 2006, Weber et al. 
2006). These studies show that each neoplasia has a distinct miRNA signature.  
MiRNAs have an important role also in tumor metastasis. Indeed, for example 
miR10-b was found highly expressed in metastatic breast cancer cells (Ma et 
al. 2007) while miR-139 suppresses Metastasis of Hepatocellular Carcinoma 
(Wong et al. 2011). In addition a variety of tumor-specific miRNA expression 
profiles are highly predictive for the response to the therapy (Hummel et al. 
2010).  
More recently, many evidences are emerging that tumor-derived miRNAs are 
present and detectable in serum, plasma, urine and other human body fluids. 
Because of their abundance, tissue specificity and relative stability, circulating 
miRNAs hold a great promise as noninvasive or minimally invasive 
biomarkers in cancer (Kosaka et al. 2010; Laterza et al. 2009). 
 
 
 
1.1.4 MiR-34 family 
MiR-34 family is an evolutionarily conserved miRNA family including three 
different members in vertebrates: miR-34a, miR-34b, and miR-34c. MiR-34a is 
encoded by its own transcript on the human chromosome 1p36, whereas miR-
34b and miR-34c are generated by the processing of a bicistronic transcript 
from the chromosome 11q23. In mice, miR-34a is ubiquitously expressed with 
the highest expression in brain, whereas miR-34b/c is mainly expressed in lung 
tissues. It has been reported that the tumor suppressor gene TP53, one of the 
genes most commonly mutated in cancer, acts as a transcriptional factor to 
induce the expression of a set of miRNAs including miR-34 family, following 
DNA damage and oncogenic stress (Chang et al. 2007; He et al. 2007a; Raver-
Shapira et al. 2007; Tarasov et al. 2007; Bommer et al. 2007; Corney et al. 
2007). Moreover, it has been demonstrated that  miR-34c negatively regulate c-
myc expression, which in turn activates the deacetylase protein Sirt1, that 
positively regulates p53 activity, thus establishing a positive feedback loop 
leading to cell cycle arrest. Still now how this loop is attenuated remains 
unknown. 
11 
 
Several converging evidences demonstrated that miR-34 members mediate p53 
action negatively regulating cell cycle and thus acting as “bona fide” tumor 
suppressor genes (Hermeking 2010; Liu et al. 2011; Li et al. 2009; He et al. 
2007b). In some cases, ectopic expression or delivery of synthetic miR-34 
mimetics resulted in cell cycle arrest or senescence. In other cases, the output 
was apoptosis, with the response being reduced by inhibition or depletion of 
miR-34. (Yamakuchi et al. 2008; Rokhlin et al. 2008). 
However there are also cases in which a different role for miR-34 has been 
demonstrated or suggested.  Indeed, it has been recently shown that the cognate 
miRNA, miR-34a, may confer resistance to bortezomib-induced apoptosis by 
downregulating p53, and this survival and p53 downregulation depend on the 
expression levels of c-myc (Dacic et al. 2010; Lee et al. 2011; Sotillo et al. 
2011). Furthermore it has also been reported that in some tumor miR-34c is 
surprisingly upregulated (Katada et al. 2009; Dacic et al. 2010). Therefore, the 
role of miR-34 family is still not completely clear and probably achieving these 
very different outcomes may depend on the wide spectrum of miR-34 
regulatory targets that are differently expressed in a given cell type or  cell 
conditions.   
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1.2 NSCLC 
Lung cancer is the leading cause of cancer-related death in the world, with non-
small-cell lung cancer (NSCLC) accounting for 80% of all cases (Greenlee et 
al. 2001). NSCLC is divided further into adenocarcinoma, squamous cell 
carcinoma (SCC), and large cell carcinoma histologies (Breuer et al. 2005). All 
share similar treatment approaches and prognoses but have distinct histologic 
and clinical features. Adenocarcinoma is the most frequent non-small cell lung 
cancer in the United States, representing 35-40% of all lung cancers. It 
originates from the bronchial mucosal glands and is the subtype observed most 
commonly in persons who don’t smoke. This type may manifest as multifocal 
tumors in a bronchoalveolar form. Bronchoalveolar carcinoma is a distinct 
subtype of adenocarcinoma with a classic manifestation as an interstitial lung 
disease on chest radiograph. Bronchoalveolar carcinoma arises from type II 
pneumocytes and grows along alveolar septa. This subtype may manifest as a 
solitary peripheral nodule, multifocal disease, or a rapidly progressing 
pneumonic form.  
SCC accounts for 25-30% of all lung cancers. Whereas adenocarcinoma 
tumors are peripheral in origin, SCC is found in the central parts of the lung. 
The classic manifestation is a cavitary lesion in a proximal bronchus. This type 
is characterized histologically by the presence of keratin pearls and can be 
detected with cytological studies because it has a tendency to exfoliate.  
Large cell carcinoma accounts for 10-15% of lung cancers, typically 
manifesting as a large peripheral mass on chest radiograph; it appears to be 
decreasing in incidence because of improved diagnostic techniques. 
Histologically, this type has sheets of highly atypical cells with focal necrosis, 
with no evidence of keratinization (typical of SCC) or gland formation (typical 
of adenocarcinomas). 
Types of lung cancer in the United States, as well as in many other countries, 
have also changed in the past few decades: the frequency of adenocarcinoma 
has risen, and that of SCC has declined. Both exposure (environmental or 
occupational) to particular agents and individual susceptibility to these agents 
contribute to the risk of developing lung cancer. 
The main exposure agents are smoking, occupational exposure to asbestos, 
radon and outdoor air pollution. In addition, preexisting nonmalignant lung 
diseases, such as chronic obstructive pulmonary disease, idiopathic pulmonary 
fibrosis, and tuberculosis have all been shown to be associated with increased 
lung cancer rates. 
Most lung carcinomas are diagnosed at an advanced stage, conferring a poor 
prognosis. Indeed lung cancer is very insidious, and it may produce no 
symptoms until the disease is well advanced. Approximately 7-10% of patients 
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with lung cancer are asymptomatic, and their cancers are diagnosed 
incidentally after a chest radiograph performed for other reasons. The need to 
diagnose lung cancer at an early and potentially curable stage is thus necessary, 
and for this purpose microRNAs represent very promising and innovative 
targets. 
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1.3 Programmed cell death 
Apoptosis is an evolutionary conserved process of programmed cell death that 
occurs in various physiological and pathological situations (Hengartner 2000). 
In mammals apoptosis proceeds through two distinct pathways: the 
mitochondrial pathway, also called intrinsic, and the death receptor pathway, 
also called extrinsic (Figure 2). 
These two pathways, following specific initiator caspases activation, converge 
both in the activation of the same effector downstream caspases. Effector 
caspases are cysteinyl aspartate proteases, which proteolyze different cellular 
proteins and activate the enzyme CAD (caspase activated DNAse) that 
degrades cellular DNA. This process finally cause cellular demolition 
associated with characteristic features, such as chromatin condensation and 
plasma membrane blebbing (Hengartner 2000; Salvesen and Dixit 1997; Shi 
2002). 
 
 
 
Figure 2. Scheme of extrinsic and intrinsic apoptotic pathways 
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In the extrinsic apoptotic pathway signals from death receptors activate the initiator 
caspase-8 which then cleaves and activates downstream effector caspases, such as 
caspase-3. In the mitochondrial pathway pathogenic infection, growth factor 
deprivation and a broad range of cytotoxic stresses lead to permeabilization of the 
outer mitochondrial membrane. Some proapototic proteins are so released, including 
cytochrome c which directly triggers caspase-3 activation through formation of 
cytochrome c/Apaf-1/caspase-9-containing apoptosome complex. 
 
 
 
1.3.1 Extrinsic apoptotic pathway 
In the extrinsic pathway apoptosis activation is a consequence of the 
stimulation of death receptors of the tumor necrosis factor (TNF) superfamily 
such as CD95 (APO-1/Fas) or TNF-related apoptosis-inducinducing ligand 
(TRAIL) receptors (DR4 and DR5). These stimulations lead to the activation of 
the initiator caspase-8 which then cleaves and activates downstream effector 
caspases, such as caspase-3 (Walczak and Krammer 2000). 
TNF receptors superfamily includes more than 20 proteins with a wide range of 
biological functions: regulation of cell death and survival, differentiation and 
immune regulation (Walczak and Krammer 2000; Ashkenazi 2002). 
All these receptors share similar cysteine-rich extracellular domains and a 
cytoplasmic domain of about 80 aminoacids called “death domain”, which 
plays a crucial role in transmitting the death signal from the cell’s surface to 
intracellular signaling pathways. 
Stimulation of death receptors results in receptor trimerization, clustering of 
the death domains and recruitment of adaptor molecules such as Fas-associated 
death domain (FADD) through homophilic interaction mediated by the death 
domain (Walczak and Krammer 2000). Fas-associated death domain in turn 
recruits caspase-8 to the activated receptor to form the death-inducing signaling 
complex (DISC). Oligomerization of caspase-8 upon DISC formation drives its 
activation through self-cleavage. Caspase-8 then activates downstream effector 
caspases, including caspase-3, -6 and -7. For the extrinsic signaling pathway, 
two distinct prototypic cell types have been identified (Scaffidi et al. 1998). In 
type I cells, caspase-8 is activated upon death receptor ligation at the DISC in 
quantities sufficient to directly activate downstream effector caspases such as 
caspase-3 (Scaffidi et al. 1998). In type II cells, however, the amount of active 
caspase-8 generated at the DISC is insufficient to activate caspase-3 and a 
mitochondrial amplification loop, through BID cleavage and activation, is 
necessary for full activation of effector caspases (Scaffidi et al. 1998). 
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1.3.2 Intrinsic apoptotic pathway 
Intrinsic pathway can be activated in response to pathogenic infection, growth 
factor deprivation and different cytotoxic stresses, including DNA damage or 
hypoxia. 
This pathway is regulated by the complex interactions of >15 proteins 
belonging to one pro-survival and two pro-apoptotic sub-groups of the Bcl-2 
family. 
The pro-survival Bcl-2 family members - Bcl-2, Bcl-xL, Bcl-w, Mcl-1, 
A1/Bfl1 and Boo/Diva –  share an amino acid sequence homology across four 
Bcl-2 homology (BH) domains and fold to form similar 3D structures 
(Muchmore et al. 1996; Lessene et al. 2008; Youle and Strasser 2008). The 
pro-apoptotic Bcl-2 family members, instead, can be divided into two distinct 
sub-groups. The so-called “multi-BH domain” pro-apoptotic Bcl-2 proteins, 
including Bax and Bak, that share all four BH domains plus the trans-
membrane region, and the pro-apoptotic BH3-only subgroup, comprising 
Bim/Bod, Puma/Bbc3, Bid, Noxa/Pmaip1, Bad, Hrk/DP5, Bmf and 
Bik/Blk/Nbk that share sequence similarity with each other and the wider Bcl-2 
family only across the BH3 domain.  
Caspases activation is closely linked to permeabilization of the outer 
mitochondrial membrane by pro-apoptotic members of the Bcl-2 family (Green 
and Kroemer 2004). Upon disruption of the outer mitochondrial membrane, a 
set of proteins normally found in the space between the inner and outer 
mitochondrial membranes is released, including cytochrome c, Smac/DIABLO, 
Omi/HtrA2, AIF and endonuclease G (Saelens et al. 2004). Once in the 
cytosol, these apoptotic proteins trigger the execution of cell death by 
promoting caspases activation or by acting as caspase-independent death 
effectors (Saelens et al. 2004). The release of cytochrome c from mitochondria 
directly triggers caspase-3 activation through formation of cytochrome c/Apaf-
1/caspase-9-containing apoptosome complex. 
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2. Aims of the study 
Much of the effort in oncology is devoted to identify new effective molecular 
targets for cancer diagnosis and therapy.  
The selective induction of cell death by drugs or cytokines in cancer treatment 
is a challenging goal for a rationale approach to novel therapeutic strategies. 
However tumor cells often retain the ability to evade drug-induced death 
signals through the activation of antiapoptotic mechanisms, making some 
patients unresponsive toward the therapeutic approaches commonly used. 
Therefore identifying molecular basis of this resistance seems to be of primary 
importance.   
MiRNAs are small non-coding RNAs that negatively regulate gene expression 
and are involved in the control of many biological processes, such as cell 
proliferation and apoptosis. Since miRNAs have been found deregulated in 
different malignancies, acting as oncogenes or tumor suppressors, they are 
considered new promising therapeutic targets for cancers (Farazi et al. 2011; 
Garofalo and Croce 2011). Identifying miRNAs that selectively regulate the 
expression of proteins involved in apoptosis could be helpful in the 
development of new tools for diagnosis and the treatment of cancer. However, 
the potential for combinatorial regulation of gene expression by miRNAs 
makes it difficult to understand what target molecules are involved and what is 
their coordinate mechanism of action. 
To this aim we developed a “functional selection-based screening” as an 
alternative approach to high-throughput screening to identify those miRNAs 
able to rescue cells from apoptosis in lung cancer cells. 
This approach has the advantage to identify unique functional combinations of 
miRNA molecules without any assumption about the targets involved. Since a 
pivotal upstream event in the death receptor pathways is the activation of 
caspase-8, the screening has been based on the use of an engineered lung 
cancer cell line in which the activation of caspase-8 has been placed under the 
control of a dimerizing agent named AP20187. Here we show that this is an 
unbiased approach able to uncover unpredicted effects of miRNA expression as 
in the case of miR-34c, a p53 effector miRNA (Chang, et al. 2007; He, et al. 
2007), that revealed to be able to antagonize paclitaxel-induced apoptosis, with 
obvious  fall-outs in the design of miRNA-based new therapeutic agents for 
cancer treatment. 
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3. Materials and Methods 
 
3.1 Cell Cultures 
Human NSCLC A549 and H460 (American Type Culture Collection) were 
grown in RPMI 1640 (Life Technologies, Karlsruhe, Germany) supplemented 
with 10% heat-inactivated fetal bovine serum (Sigma-Aldrich Corp. Saint 
Louis, MO, USA), 2mM L-glutamine and 100 U/ml penicillin–streptomycin. 
A549-FK, clone Cl-K and clone Cl-T were cultured in the same medium 
supplemented with 5 µg/ml puromycin, while A549 stably silenced for p53 
were cultured in medium supplemented with 1 µg/ml puromycin. 
 
 
 
3.2 Immunoprecipitation and immunoblotting 
Total cell lysates were prepared in JS buffer (50 mM Hepes ph 7.5, 150 mM 
NaCl, 1%Glicerol, 1%Triton X-10, 1.5 mM MgCl2, 5 mM EGTA, 1 mM 
Na3VO4 and protease and phosphatase inhibitors) and then boiled in SDS/β-
mercaptoethanol sample buffer. 40 or 30 µg samples were loaded into 15% or 
12% polyacrylamide gels and the proteins were separated by electrophoresis 
and then blotted onto PVDF membranes (Millipore, Billerica, MA, USA) by 
electrophoretic transfer. The membranes were then blocked with 5% dried milk 
in TBS containing 0,1% Tween 20 and incubated at 4°C overnight with the 
following primary antibodies: anti-caspase 3, anti-caspase 9, anti-BID, anti-
Bcl-Xl, anti-Bmf, anti-Acetyl-p53 (Lys382), anti-cyclin D1 (Cell Signaling 
Technology, Inc., Danvers, MA, USA), anti-procaspase-3 and anti-procaspase-
9 (Abcam plc, Cambridge, UK), anti-c-myc (9E10), anti-p53 (DO-1), anti-
Chk1 (G-4), anti-cyclin B1 (H-433), anti-SIRT1 (H-300) (Santa Cruz, CA, 
USA), anti-α tubulin (Sigma-Aldrich Corp. Saint Louis, MO, USA) and anti-
MDM2 (mAB 2A10) (Calbiochem). 
For Bax activation analysis total cell lysates were, instead, prepared in 1% 
Chaps buffer (5mM MgCl2, 137 mM NaCl, 1 mM EDTA, 1mM EGTA, 1% 
Chaps, 20 mM Tris-HCl ph 7.5 and protese inhibitors. 500 µg  proteins were 
immunoprecipitated with anti-Bax antibody (6A7; BD Pharmingen) at 4°C for 
2 h. Immunoprecipitates were captured by a Protein A/G PLUS-Agarose (Santa 
Cruz, CA, USA) in lysis buffer at 4°C overnight. Immunoprecipitates were 
then recovered by centrifugation and washed three times in 1% Chaps buffer. 
Immunoprecipitates and total extracts (40 µg) were separated on 12% 
polyacrylamide gel. After SDS-PAGE, proteins were transferred onto PVDF 
membranes (Millipore, Billerica, MA, USA) and then blocked with 5% dried 
milk in PBS-0,1% Tween 20. Membranes were then incubated with primary 
anti-Bax (N20) (Santa Cruz, CA, USA) and peroxidase (HRP)-conjugated 
19 
 
secondary antibodies in 10% dried milk in PBS containing 0,1% Tween 20 and 
detected with ECL Western blotting detection reagents (Amersham Bioscience, 
Piscataway, NJ). 
 
 
 
3.3 Cell proliferation and cell death analysis 
Cells were plated in 96-well plates in triplicate and incubated at 37°C in a 5% 
CO2 incubator. 
AP20187 (ARIAD Pharmaceuticals, Inc.,Cambridge, MA, USA) was used for 
3 h, 6 h and 24 h at 10 nM. Cell viability was examined with 3-(4,5-
dimethylthiazol-2-yl)-2,5-dipheniltetrazolium bromide (MTT)-Cell Titer 96 
AQueous One Solution Cell Proliferation Assay (Promega BioSciences Inc. 
San Luis Obispo, CA, USA), according to the manufacturer’s protocol. 
Metabolically active cells were detected by adding 20 µl of MTT to each well. 
After 20 min of incubation, the plates were analyzed in a Absorbance 
Microplate Reader (ELx800 BioTek Instruments, Inc.). Apoptosis was assessed 
using propidium iodide assay followed by flow cytometric analysis and 
caspase-3 and -9 fluorimetric assays. For propidium iodide assay, 24 h after 
transfection, cells were seeded in triplicate in 96-well plates at 3.6×103 cells 
per well and grown overnight at 37°C in a 5% CO2 incubator. Then cells were 
treated with 10 nM AP20187 (ARIAD Pharmaceuticals, Inc.,Cambridge, MA, 
USA) for 6 h or with 100 nM Paclitaxel (Sigma-Aldrich Corp. Saint Louis, 
MO, USA) for 24 h. The next day analysis of DNA content by propidium 
iodide (Sigma-Aldrich Corp. Saint Louis, MO, USA) incorporation was 
performed in permeabilized cells by flow cytometry.  
For caspase-3 and -9 fluorimetric assays, 50 µg of total cell lysates were 
incubated for 1 h at 37°C with DEVD-AFC or LEHD-AFC substrate 
respectively, according to the manufacturer’s protocol (BioVision Inc. 
Mountain View, California). After incubation samples have been read in a 
fluorimeter equipped with 400 nm excitation filter and 505 nm emission filter. 
For cell cycle analysis cells transfected with 70 nM of miRNA precursor hsa-
miR-34c-5p or a scrambled molecule were recovered 48h and 72h post-
transfection, fixed in 70% ethanol, stained with 50 µg/ml propidium iodide 
(Sigma-Aldrich Corp. Saint Louis, MO, USA) and analyzed by FACS 
(Fluorescence-activated cell sorter).. 
 
 
 
 
20 
 
3.4 Cell transfections 
The day before transfection cells were seeded in 10% FBS medium without 
antibiotics. All transfections were performed in serum-free Opti-MEM using 
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s protocol. To alter miRNA level cells were transfected with 70 
nM of miRNA precursor hsa-miR-34c-5p, hsa-miR-34c-3p, hsa-miR-124,  hsa-
miR-124*, hsa-miR-362-5p, hsa-miR-362-3p and Negative Control #1 
(Ambion) or 50 nM of LNA anti-miR-34c-5p, anti-miR-34c-3p and anti-miR 
negative control inhibitor (Exiqon). To alter c-myc and Bmf level cells were 
transfected with 60 nM siRNA c-myc (Sigma-Aldrich Corp. Saint Louis, MO, 
USA) and 120 nM siRNA Bmf (Santa Cruz, CA, USA). 
For p53 stable gene silencing, A549 cells were transfected in 100 mm dishes 
with 10 µg of shRNAp53 or shRNAcntrl (Open Biosystems). For stable clone 
selection RPMI medium supplemented with 1 µg/ml puromycin was used. 
 
 
 
3.5 Luciferase assays 
For target validation the two Bmf 3’ UTR sequences were PCR amplified using 
the following primers: BMF S1 Fw: 5’-CTAGAAGGATTCCTGGCCAGCTC 
CT-3’, BMF S1 Rw: 5’–TCTAGATTTTCCGGCCCCACTGCAAACTTG-3’;  
BMF S2 Fw:  5’-TCTAGAGGATCAAGGTGGTGACAGGCAG-3’ ;  BMF 
S2 Rw: 5’-TCTAGATACCTCCTGGGTTTTGTTGGTGGGGAA-3’; BMF S3 
Fw: 5'-TCTAGAATTGCTTTAACCCAGCAGGGCTTCG-3';  BMF S3 Rw: 
5'- TCTAGACACTGTCCTGGCTTCTTCTGTATCCCA-3'; BMF S4 Fw: 5’-
TCTAGATGGGGCTACTTCTCCCAAGAAGAAG-3’; BMF S4 Rw: 5’-
TCTAGAGAGGGGAGAACAACGTATGTCCCAT-3’ and cloned 
downstream of the Renilla luciferase stop codon in pGL3 control vector 
(Promega BioSciences Inc. San Luis Obispo, CA, USA). We deleted a 
sequence in S2 and S3 miRNA-binding site by using the QuikChange 
Mutagenesis Kit (Stratagene, La Jolla, CA) using the following primers: BMF 
S2 mut Fw  5’-CTGGGGCAGGTGGAAGCTGCACTGTC-3'  BMF S2 mut 
Rw 5'-GACCCCGTCCACCTTCGACGTGACAG-3'; BMF S3 mut Rw: 5’-
GGTTCTTACTTCTCAGCCTGCCACCTCCAGCA-3’; S3 mut Rw:  5'-
TGCTGGAGGTGGCAGGCTGAGAAGTAAGAACC-3'. 
The megakaryoblastic cell line, MEG-01, as widely used efficient recipient was 
use for luciferase assays. Cells were cotransfected with 1,2 µg of each 
generated plasmid and 400 ng of a Renilla luciferase expression construct pRL-
TK (Promega BioSciences Inc. San Luis Obispo, CA, USA) with 
Lipofectamine 2000 (Invitrogen). Cells were harvested 24 h post-transfection 
and assayed with Dual Luciferase Assay (Promega BioSciences Inc. San Luis 
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Obispo, CA, USA) according to the manufacturer’s instructions. Three 
independent experiments were performed in triplicate. 
For p53 promoter activity analysis cells were transfected with Lipofectamine 
2000 (Invitrogen) with 500 ng of pLuc-MDM2 expression vector (kindly 
provided by S. Soddu), 900 ng of miRNA precursor hsa-miR-34c-5p or 
Negative Control #1 (Ambion), together with 40 ng of pCMV-Renilla in 6 well 
plates. Luciferase and Renilla activity were assessed with Luciferase assay 
system and Renilla Luciferase assay system (Promega BioSciences Inc. San 
Luis Obispo, CA, USA) 48 h after the transfection. The Luciferase activity was 
normalized for the Renilla activity. All the experiments were performed three 
times in triplicate and the mean±s.d. was reported. 
 
 
 
3.6 qt-RT-PCR analysis  
Reverse transcription reaction was done starting from 1 µg total RNA and 
using miScript Reverse Transcription Kit (QIAGEN, Milan Italy), according to 
the manufacturer’s protocol. The expression of mature hsa-miR-34c-5p, has-
miR-34c-3p, hsa-miR-362-5p, hsa-miR-362-3p, hsa-miR-124,  hsa-miR-124* 
and of U6 RNA, as housekeeping gene, was assayed using the miScript SYBR 
Green PCR Kit (QIAGEN) and Real-time PCR was done in triplicate for each 
case. MiRNA expression was measured using Ct (threshold cycle). The ∆∆Ct 
method for relative quantization of gene expression was used to determine 
miRNA expression levels. The ∆Ct was calculated by subtracting the Ct of U6 
RNA from the Ct of the miRNA of interest. The ∆∆Ct was calculated by 
subtracting the ∆Ct of the reference sample (A549-FK  cells not transduced 
with miRNAs) from the ∆Ct of each sample. Fold change was generated using 
the equation 2-∆∆Ct.  
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4. Results and Discussion 
 
4.1 Identification of protective miRNAs by functional selection 
In order to identify miRNAs able to rescue cells from caspase-8 induced cell 
death we adopted a functional selection screening based on a FKBP caspase-8 
inducible chimera (puro-DD-FKC8) (Carlotti 2005; Chang and Yang 2003). 
The human non small cell lung cancer (NSCLC) A549 cells have been 
transduced with a retroviral vector with inserted the caspase-8 chimera and the 
most responsive cell clone, the A549-FK, was then transduced with a pooled 
miRNA library and subjected to selection for resistance to caspase-8 induction 
of cell death, as described in Figure 3a.  
In out of 16 cell clones analyzed we found integrated miRNAs already 
described as oncogenic such as miR-17, miR-135 (Nagel et al. 2008), miR-520 
(Huang et al. 2008), but also some miRNAs such as miR-124-1 and miR-34c 
for which a tumor suppressive role has been instead described or expected. The 
most frequent integrated miRNA was miR-34c that was as well the only 
miRNA that was found not only in combination with other miRNAs but also 
alone in two independent cell clones, thus suggesting to be sufficient by its 
own to confer resistance to caspase-8 activation (Figure 3b). Other miRNAs 
were always found to be present as a combination of at least two different 
molecules (not shown). By qt-RT-PCR we thus evaluated in all cell clones the 
expression levels of transduced miRNAs (as compared to non-transduced 
control cells) and assessed that, with the only exception of miR-645 in the 
clone Cl-Y, all transduced miRNAs are expressed in the corresponding 
surviving clones (not shown). In the case of miR-34c we assessed the 
expression levels of both the -5p and -3p strands in all clones analyzed (Figure 
3c). 
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Figure 3. Functional selection of miRNAs 
(a) Schematic representation of the functional selection procedure. A549-FK cells 
were infected with a lenti-miR pooled library containing 330 human pre-miRNAs. In 
infected cells apoptosis was then induced by treatment with AP20187 dimerizer (10 
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nM, 15 nM and 25 nM) for 3h or 6h. Surviving clones were amplified and integrated 
miRNAs were identified by sequencing. (b) Relative abundance of transduced 
miRNAs in cell clones resulting from the screening. Only miRNAs found in at least 
two independent cell clones are reported. With the exception of miR-34c all miRNAs 
were always found only as a combination of multiple miRNAs. (c) Relative 
expression of miR-34c-5p and miR-34c-3p in clones were miR-34c was found alone 
(Cl-T and Cl-8) or in combination with other transduced miRNAs: in Cl-H (miR-17, 
miR-34a, miR-34c, miR-520e, miR-644), Cl-Y (miR-34c, miR-346), Cl-1 (miR-34a, 
miR-34c, miR-346), Cl-2 (miR-34a, miR-34c, miR-135a-2, miR-320a, miR-345, miR-
346, miR-362), Cl-K (miR-34c, miR-124-1, miR-362), Cl-12 (miR-34a, miR-34c, 
miR-135a-2, miR-320a, miR-346), Cl-17 (miR-34c, miR-345 and miR362), Cl-53 
(miR-34a, miR-34c, miR-362). 
 
 
 
4.2 miR-34c-5p protects cells from capase-8 induced apoptosis 
Given the high frequency of integration of miR-34c in surviving clones, we 
wondered if, in our system, forced over-expression of the most expressed 
isoform, miR-34c-5p, might protect cells from caspase-8 induced apoptosis. As 
determined by MTT assay (Figure 4a) all clones transduced with miR-34c are 
resistant to 10 nM AP20187 regardless if it was present alone (in two clones, 
Cl-T; Cl-8) or in combination with other miRNAs (in clones Cl-H; Cl-K; Cl-Y; 
Cl-1; Cl-2; Cl-12; Cl-17; Cl-53) (see legend to Figure 3c). In A549-FK cells, 
caspase-8 dimerization activates caspase-3 (Figure 4b, lanes 1-3) through 
cleavage of the BH3-only protein BID (Figure 4c), that leads to activation of 
Bax (Figure 4d) and caspase-9 (Figure 4b middle panel) (Jost et al. 2009). In 
contrast to parental A549-FK, both cell clones analyzed (Cl-T and Cl-K), in 
which miR-34c was integrated either alone (Cl-T) or together with miR-124-1 
and miR-362 (Cl-K), behave resistant to AP20187-induced apoptosis (Figure 4 
b-d). Resistance is unlikely due to the occurrence of new clonal mutations 
impairing caspases that are indeed activated following cisplatin treatment 
(Figure 4e). Conversely, transfecting the Cl-T and Cl-K with a miR34c-5p 
inhibitor sensitizes cells to AP20187-induced cell death with a consequent 
increase of caspase-3 and caspase-9 activity (Figure 4f and not shown).  
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Figure 4. Cell clones expressing miR-34c-5p are protected from AP20187 induced 
apoptosis 
(a) MTT assay for resistance to AP20187 of cell clones that express miR-34c. A549-
FK (Cntrl) cells and individual cell clones were plated in triplicate in 96-well plates 
and treated with 10 nM AP20187 for 3 h. Values are expressed as the per cent of the 
untreated control; (b) parental A549-FK (lanes 1-3) or Cl-K (transduced with miR-
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34c, miR-362 and miR-124-1) or Cl-T (transduced with miR-34c) were treated for the 
times indicated with AP20187 (10 nM) and levels of caspase-3 and caspase-9 cleaved 
products were analyzed by immunoblot. Filters were hybridized with anti α-tubulin to 
confirm equal loading. (c) the same as in (b) except that levels of BID cleaved 
products were analyzed. (d) A549-FK, Cl-K or Cl-T were treated for 3 h with 
AP20187 (10 nM) or left untreated and cell lysates analyzed by immunoblot with anti 
Bax N-20 antibody. Lysates were either first immunoprecipitated with anti Bax6A7 
antibody, specific for the active conformation of Bax (upper panel) or directly used for 
immunoblot analysis (lower panel). Intensity of bands was measured by ImageQuant 
analysis on at least two different expositions to assure the linearity of each acquisition. 
Values were each normalized for the corresponding values in the direct blot and are 
expressed as the per cent of the intensity measured in the second lane (labeled with 
asterisk). (e) Parental A549-FK cells or Cl-K or Cl-T were treated for 24 h with 
cisplatin (50µg/ml) and levels of caspase-3 cleaved products were analyzed by 
immunoblot. Filters were hybridized with anti α-tubulin to confirm equal loading. The 
blots (in b,c,d,e) are representative of at least four independent experiments. (f) A549-
FK or Cl-T cells were treated for 3 h with AP20187 (10 nM) (white columns) or left 
untreated (black columns). Where indicated either anti-miR-34c-5p inhibitor sequence 
or a corresponding scrambled sequence was transfected and cell lysates analyzed for 
caspase-3 (upper panel) and caspase-9 (lower panel) activity as measured by 
hydrolysis of Ac-DEVD-AFC or Ac-LEHD-AFC respectively. 
 
 
 
Further, upon AP20187 treatment, the presence of miR-34c-5p, but not of miR-
34c-3p (not shown), makes the cells more resistant to caspase-8 induced cell 
death, reducing the per cent of apoptotic cells from 70% (of scrambled control) 
to around 30% (Figure 5a). Consistently, resistance to apoptosis conferred by 
miR-34c-5p is accompanied by the lack of activation of caspase-9 and of its 
effector, caspase-3, with an increase in the overall cell survival (Figure 5 b-d). 
These data indicate that while in a proliferating cell population miR-34c-5p 
may induce an increase in apoptosis (Chang et al. 2007; He et al. 2007), in the 
presence of a strong acute pro-apoptotic signal, as the dimerization of caspase-
8, it may, in contrast, elicit a clear protective effect. 
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Figure 5. miR-34c-5p interferes with AP20187 induction of apoptosis 
(a) A549-FK cells (Cntrl) cells were treated for 3 h with AP20187 (10 nM) (white 
columns) or left untreated (black columns). Where indicated either miR-34c-5p mimic 
sequence or a corresponding scrambled sequence was transfected. The per cent of 
cells in the pre-G1 fraction was determined by FACS analysis as a measure of 
apoptotic cells. (b, c) A549-FK cells were treated for 3 h with AP20187 (10 nM) 
(white columns) or left untreated (black columns). Where indicated either miR-34c-5p 
mimic or a corresponding scrambled sequence was transfected and caspase-9 (b) and 
caspase-3 activity (c) analyzed as in Figure 4f. (d) A549-FK cells (Cntrl) cells were 
treated with AP20187 (10 nM) as indicated. Where indicated two different scrambled 
sequences, miR-34c-5p, miR-34c-3p mimic sequences or both miRNAs together were 
transfected and cell viability was determined by MTT assay as per cent of 
corresponding untreated cells (see legend to Figure 4a). 
 
 
 
This effect is unlikely due to the occurrence of new clonal critical mutations in 
the apoptotic pathway, indeed, 1): in two analyzed cell clones, Cl-K and Cl-T, 
caspase-8 sensitivity is restored by antagonizing miR-34c-5p action with a 
specific antimiR; 2) apoptosis is readily activated by treating the same cell 
clones with an unrelated proapoptotic drug like Cisplatin; and 3) transfecting 
miR-34c-5p mimic protects the A549-FK cells by AP20187-induced cell death.  
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4.3 miR34-c-5p protects cells from paclitaxel induced apoptosis 
We thus determined whether miR-34c-5p has antiapoptotic function toward the 
broadly used chemotherapeutic agents. As shown in Figure 6a, treating parental 
A549 cells with paclitaxel for 24 h (100 nM) induces caspase-3 and caspase-9 
activation that were partially reverted by transfecting cells with miR-34c-5p 
mimic (left panel) but not with miR-34c-3p mimic (right panel) . Consistently, 
transfecting miR-34c-5p in A549 induces a clear reduction in the per cent of 
paclitaxel-induced apoptosis (Figure 6b). On the other hand, antagonizing with 
specific LNA-based miR inhibitors the miR34c-5p, but not the miR34c-3p, 
rescued the sensitivity to paclitaxel-induced apoptosis in Cl-K cells (Figure 
6c). A similar protective effect against paclitaxel is elicited by miR-34c in 
A549-FK, but not in the more sensitive H460 NSCLC cells (not shown). 
Further, differently from what observed with paclitaxel, transfecting miR-34c-
5p mimic doesn’t reduce the levels of active caspase-3 and caspase-9 neither 
upon TRAIL (200 ng/ml) nor cisplatin (50 µg/ml) treatments but, at least in 
transient, miR-34c-5p may cooperate with cisplatin (Figure 6 d-e). Taken 
together these results well support the notion that the protective potential of 
miR-34c may be only unveiled in a cell context and pathway specific manner. 
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Figure 6. miR-34c-5p protects from paclitaxel-induced apoptosis 
(a) A549 cells were transfected with either miR-34c-5p mimic sequence (left panel) or 
miR-34c-3p (right panel) and treated for 24 h with paclitaxel (100 nM). Levels of 
caspase-3 and caspase-9 cleaved products were analyzed by immunoblot. Filters were 
hybridized with anti α-tubulin to confirm equal loading. Each blot is representative of 
at least four independent experiments. (b) A549 cells (Cntrl) cells were treated for 24 
h with paclitaxel (100 nM) (white columns) or left untreated (black columns). Where 
indicated either miR-34c-5p mimic sequence or a corresponding scrambled sequence 
was transfected. The per cent of cells in the pre-G1 fraction was determined by FACS 
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analysis as a measure of apoptotic cells. (c) Cl-K was transfected with LNA anti-miR-
34c-5p, anti-miR-34c-3p or anti-miR negative control inhibitor. Levels of caspase-3 
and caspase-9 cleaved products were analyzed by immunoblot compared to A549-FK 
control cells. Filters were hybridized with anti α-tubulin to confirm equal loading. 
Each blot is representative of at least four independent experiments. (d,e) A549 cells 
transfected with either miR-34c-5p mimic sequence or a corresponding scrambled 
sequence were treated with TRAIL (d) or cisplatin (e) for times and concentrations 
indicated. Levels of caspase-3 and caspase-9 cleaved products were analyzed by 
immunoblot. Filters were hybridized with anti α-tubulin to confirm equal loading. 
Each blot is representative of at least four independent experiments. 
 
 
 
4.4 Targets of miR-34c-5p 
In an attempt to understand the molecular events elicited by high levels of 
miR-34c-5p on apoptosis, and thus what are the target proteins involved, we 
first used a small antibody array to analyze the relative expression of a selected 
number of apoptosis related proteins in A549-FK cells transfected with miR-
34c-5p (not shown). Since, using this assay, no major changes were observed 
we thus decided to take advantage of the information coming from the 
functional screening by assuming that the pathways involved may be shared 
between the different miRNAs selected for their ability to rescue A549-FK 
cells from caspase-8 DD-FKC8 chimera-induced cell death. We thus combined 
the bioinformatics prediction (Diana-microT3 ) for targets common to those 
miRNAs transduced and expressed in three independent cell clones together 
with miR-34c : i.e. in Cl-17 (miR-345 and miR362), in Cl-K (miR-362 and 
miR-124-1), in Cl-Y (miR-346). Among the candidate targets considered, even 
if with different score values (see legend to Figure 7), Bmf (Bcl2-modifying 
factor) was predicted to be a common target for all of miRNAs analyzed. In the 
3’ UTR of Bmf two recognition sites are predicted for miR-34c-5p, one at 
position 737-765, and one at position 2283-2311 (Diana-microT3) (Figure 7a). 
Moreover, in the 3’ UTR of Bmf are also predicted by Diana-microT3two 
recognition sites for miR-34c-3p, the mature form of the microRNA that 
doesn’t seem to protect cells from AP20187- and paclitaxel-induced apoptosis. 
Therefore, at first we determined whether Bmf might be a direct target of miR-
34c-5p. As shown in Figure 7b, transfecting miR-34c-5p either in A549-FK or 
in parental A549 cells resulted in a decrease of Bmf protein (of approximately 
60%). Furthermore, in two miR-34c infected cell clones analyzed, that over 
express miR-34c-5p either alone (Cl-T) or in combination with other miRNAs 
(Cl-K), the levels of Bmf are reduced as compared to parental A549-FK cells 
(Figure 7c). Conversely, by using specific LNA based inhibitors to antagonize 
the miR34c-5p and -3p in clone T we rescued the expression of BMF (Figure 
7d). To prove a direct interaction between miR-34c-5p and Bmf mRNA, two 
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Bmf 3′-UTR sequences (BMF S1 and BMF S2), which include each of the two 
potential target sites for miR-34c-5p, were fused downstream of the luciferase 
gene. The two constructs containing either BMF S1 or BMF S2, either 
individually or in combination, were cotransfected into MEG-01 cells together 
with miR-34c-5p, or a scrambled miRNA as negative control. As shown in 
Figure 7e, luciferase activity of BMF S2 was decreased of around 30% by 
cotransfecting miR-34c-5p. In contrast luciferase activity of both the BMF S1 
and a deletion mutant of BMF S2 are poorly affected by miR-34c-5p 
cotransfection. Taken together these data indicate that miR-34c-5p may 
decrease Bmf expression by recognizing a binding site on its 3’ UTR starting at 
position 2283. As mentioned above, we identified BMF as promising target for 
miR-34c-5p based on the assumption that common messengers should be 
targeted by miRNAs found in independent cell clones together with miR-34c. 
In order to verify this assumption we determined whether miR-362 and miR-
124 may affect as well Bmf levels. As shown transfecting either miR-362 or 
miR-124 decrease Bmf levels (Figure 7f). Further we determined by luciferase 
assay whether miR-362 interacts with the predicted sites for the miR-362-5p 
and -3p strand in the Bmf 3’ UTR (BMF S3 and S4 respectively). As shown in 
Figure 7g, luciferase activity of BMF S3 was decreased of around 60% by 
cotransfecting miR-362-5p, and at much lower extent miR-362-3p. In contrast, 
luciferase activity of the BMF S3 mutant is poorly affected by miR-362-5p 
cotransfection. These results well support the working hypothesis that miRNAs 
for common targets may be preferentially selected during the functional 
screening. 
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Figure 7. Bmf as target of miR-34c-5p  
(a) Bmf 3’UTR contains two predicted miR-34c binding sites. In the figure is shown 
the alignment of the two seed regions (S1 and S2) of miR-34c with Bmf 3’UTR. The 
sites of target mutagenesis (deletion) are indicated by red dashes and red XXX.  (b) 
A549 or A549-FK cells were transfected with either miR-34c-5p or control scrambled 
sequence and cell lysates analyzed for the expression of Bmf. (c) A549-FK, Cl-K and 
Cl-T cell lysates were analyzed for the expression of Bmf. Intensity of bands was 
measured as in Figure 4. In the insert are reported the miRNAs transduced in the Cl-K 
and Cl-T and their relative (as compared to A549-FK control cells) expression levels. 
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Values below the blot (in b and c) indicate signal levels of Bmf relative to control 
cells (lane 1, labeled with asterisk). Quantization was done as in Figure 4. (d) Cl-K 
was transfected with LNA anti-miR-34c-5p, anti-miR-34c-3p or anti-miR negative 
control inhibitor and levels of Bmf were analyzed compared with that of A549-FK 
control cells. (e) pGL3-Bmf luciferase constructs, containing a wild type (left side of 
the histogram) or mutated (right side of the histogram) Bmf 3’ UTRs, are transfected 
into MEG01 cells. Relative repression of firefly luciferase expression was 
standardized to a transfection control. The reporter assays were performed three times 
with essentially identical results. The predicted recognition site of BMF at position 
737-765 (S1) is less conserved (only bosTau2 genome) than that at position 2283-
2311 (S2) that is conserved in bosTau2 and rat (rn4). The predicted free energies were 
calculated and are: -15.1 kJ for BMF S1 and -24.2 kJ for BMF S2, (f) A549 cells were 
transfected with miR-124, miR-124*, miR-362-5p, miR-362-3p or a control scrambled 
sequence and Bmf protein levels were analyzed at indicated times by immunoblot. (g) 
Bmf 3’UTR contains predicted binding sites for miR-362-5p and miR-362-3p. In the 
figure is shown the alignment of the two seed regions (S3 for miR-362-5p and S4 for 
miR-362-3p) of miR-362-5p and miR-362-3p with Bmf 3’UTR. The sites of target 
mutagenesis (deletion) are indicated by red dashes and red XXX. pGL3-Bmf 
luciferase constructs, containing wild type (either for miR-362-5p and miR-362-3p) or 
mutated (for miR-362-5p) Bmf 3’ UTRs, are transfected into MEG01 cells. Relative 
repression of firefly luciferase expression was standardized to a transfection control. 
The reporter assays were performed three times with essentially identical results. 
Diana Lab: miTG score for Bmf (miR-34c, 5.72; miR-124, 10.89; miR-362-5p, 3; 
miR-362-3p, 2.11; miR-345, 5.0; miR-346, 2). 
For all the blots shown anti α-tubulin was used to confirm equal loading. The blots are 
representative of at least four independent experiments. 
 
 
 
4.5 Mechanism of action 
In order to understand if the decrease of Bmf levels by miR-34c-5p is sufficient 
to cause protection to apoptosis, we transfected A549-FK cells with either the 
miR-34c-5p or with an siRNA for Bmf and analyzed the activation of caspases-
9 and -3 after forced dimerization of caspase-8. Interfering with Bmf 
expression, either by miR-34c-5p or by Bmf specific siRNA protects the cells 
from AP20187-induced caspases activation even if the Bmf siRNA is less 
effective than miR-34c-5p mimic (Figure 8a). Intriguingly, miR-34c, belongs 
to a family of evolutionarily conserved miRNAs (miR-34a, miR-34b, and miR-
34c), whose expression has been shown to be under the transcriptional control 
of the tumor suppressor protein p53 and known to be implicated in the negative 
control of the cell cycle, senescence and apoptosis (Corney et al. 2007; 
Bommer et al. 2007; He et al. 2007; Hermeking 2010). Therefore, with the aim 
to reconcile this with the protective effect of miR-34c-5p on paclitaxel-induced 
apoptosis we asked whether c-myc, a known target of miR-34c (Cannell and 
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Bushell 2010), may as well participate to inhibit apoptosis. Indeed, c-myc, 
acting on the protein deacetylase Sirt1, regulates p53 acetylation, and thus its 
activity (van Leeuwen and Lain 2009). As expected, transfecting A549-FK 
cells either with miR-34c-5p, or with a c-myc specific siRNA, resulted in a 
partial decrease of c-myc protein levels (Figure 8b). Interestingly, attenuation 
of c-myc expression protects cells from AP20187 and most importantly from 
paclitaxel-induced caspase-3 activation (Figure 8c). In order to determine 
whether c-myc downregulation mediates miR-34c-induced protection, we 
depleted A549 cells of c-myc by transfecting a specific siRNA. As shown in 
Figure 8d, we found that miR-34c-5p become poorly efficient to further 
increase protection over that induced by c-myc silencing. Even though, the 
contribution to protection of the passenger -3p strand remains to be elucidated, 
we show that the miR-34c-3p mimic we used decreases the Bmf levels, but is 
less effective on c-myc (Figure 8e). This suggests that c-myc is a critical target 
of miR-34c-5p that may act by protecting cells from paclitaxel-induced 
apoptosis. 
Paclitaxel is a microtubule destabilizer and cell cycle integrity has been shown 
to be required for sensitization (Chabalier et al. 2006; Zachos et al. 2007). We 
thus determined whether perturbation of c-myc levels by miR-34c-5p affects 
cell cycle thus providing an explanation for resistance. As assessed by FACS 
analysis, cell cycle is not appreciably impaired by the transfection of miR-34c-
5p (Figure 8f). Accordingly, as determined by immunoblot, no drastic changes 
were observed upon transfection of the miR-34c-5p, neither in cyclins B1, D1 
nor in Chk1 levels (Figure 8g). Similarly, cyclin B1 induction following 
treatment with paclitaxel is not impaired by miR-34c-5p thus indicating that 
resistance is unlikely attributable to abnormal mitotic checkpoint response 
(Figure 8h). On the other hand, the levels of cyclin D1, that mediates p53-
dependent cell cycle arrest, were increased by paclitaxel, while increasing is 
impaired in the presence of  miR-34c-5p (Figure 8h). 
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Figure 8. c-myc mediates miR-34c-5p effects 
(a, b) A549-FK cells transfected with the control scrambled sequence, the miR-34c-5p 
mimic and a Bmf siRNA (a), or a c-myc siRNA (b) and the levels of caspase-3 and 
caspase-9 products were analyzed after AP20187 treatment by immunoblot as 
indicated. (c) A549 cells were transfected with a c-myc siRNA or a control siRNA and 
the levels of caspase-3 cleaved products were analyzed by immunoblot after treatment 
with paclitaxel as indicated. Values below the blots a,b,c indicate signal levels relative 
to control cells (lane 1, labeled with asterisk). Quantization was done as in Figure 4. 
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(d) A549 cells were cotransfected with a c-myc siRNA and a scrambled sequence or 
miR-34c-5p mimic as alternative. Levels of caspase-3 cleaved products, c-myc and 
Bmf were analyzed by immunoblot. (e) A549 cells were transfected with miR-34c-3p 
mimic or with a scrambled sequence and levels of Bmf and c-myc were analyzed by 
immunoblot 72h post-transfection. The target prediction algorithm (Diana-microT3) 
predicts Bmf but not c-myc as target of miR-34c-3p. (f,g) A549 cells were transfected 
with miR-34c-5p mimic or with a scrambled sequence and 48h or 72h post-
transfection cells were recovered, stained with 50 µg/ml propidium iodide and 
analyzed by FACS (f), or cell lysates were extracted for cyclin B1, cyclin D1 and 
Chk1 analysis by immunoblot (g). (h) A549 cells transfected with miR-34c-5p mimic 
or with a scrambled sequence were treated with paclitaxel as indicated and cyclin B1, 
cyclin D1 and Chk1 levels were evaluated by immunoblot analysis. For all the blots 
shown anti α-tubulin was used to confirm equal loading. The blots are representative 
of at least four independent experiments. 
 
 
 
We then wondered whether transfecting miR-34c-5p may act on the activity of 
p53, monitoring p53 acetylation that is essential for maximal p53-dependent 
apoptosis (Sykes et al. 2006; Tang et al. 2006; Mellert et al. 2011). As shown 
in Figure 9a in untreated, exponentially growing, A549 cells the levels of 
acetylated p53 are very low and are strongly induced by paclitaxel treatment 
(24 h). Interestingly, transfecting miR-34c-5p counteracts paclitaxel by 
reducing the induction of acetylated p53 levels to less than 2 fold over basal. 
The interference of miR-34c-5p on the levels of acetylated p53 is well mirrored 
by the corresponding decrease in the paclitaxel-induced expression of total 
p53. This suggests that miR-34c-5p, by regulating p53 synthesis or stability, 
may indirectly act on its activity. To confirm that miR-34c-5p may interfere 
with the induction p53 activity by paclitaxel we performed luciferase assays 
transfecting a construct expressing the luciferase reporter gene under the 
transcriptional control of the p53-responsive human MDM2 promoter. As 
shown in Figure 9b transfecting miR-34c-5p abolishes the induction of p53 
activity by paclitaxel as assessed by the corresponding levels of luciferase 
activity. Consistently, miR-34c-5p abolishes as well the induction of the 
MDM2 protein and decreases the levels of SIRT-1, a known direct target of 
miR-34c (Yamakuchi et al. 2008) (Figure 9c). Therefore, in the attempt to 
understand how MDM2 is implicated in the attenuation of p53 response to 
paclitaxel we inhibited MDM2 activity. Treating A549 cells with Nutlin-3a, a 
direct inhibitor of MDM2, increases the levels of p53, likely by increasing its 
stability. At difference of what happens with paclitaxel-induced p53, 
transfecting miR-34c-5p in the absence of MDM2 doesn’t result in the 
attenuation of p53 (Figure 9d, upper panel). Conversely, we show that 
following inhibition of MDM2 the balance between miR-34c-5p and p53 levels 
cannot be interfered by antagonizing miR-34c-5p with a specific LNA based 
inhibitor (Figure 9d, lower panel). 
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Based on these results the question arises of why miR-34c-5p is unable to 
protect cells from cisplatin. Indeed, as shown in Figure 9e both cisplatin and 
paclitaxel-induced activation of caspase-3 is reduced in stable A549 cells 
silenced for p53 (Figure 9e). However, at difference of paclitaxel, the cisplatin-
induced levels of p53 are unaffected by miR-34c-5p (Figure 9f). 
Taken together these data indicate that transfecting miR-34c-5p in the presence 
of a proapoptotic insult, as paclitaxel, may protect cells from apoptosis likely 
by interfering with the levels of  p53 likely by tuning the levels of c-myc and 
suggest that miR-34c-5p-induced p53 attenuation depends on MDM2 activity. 
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Figure 9. miR-34c-5p attenuates p53 activity 
(a) A549 cells were treated with paclitaxel 100 nM for 24h. Cell lysates of 
untransfected cells (Cntrl) and of cells transfected with a control scrambled sequence 
or with miR-34c-5p mimic were analyzed with anti-acetyl–p53 and anti-p53 
antibodies. Values below the blot indicate signal levels of acetyl–p53 and p53 relative 
to control cells (lane 1, labeled with asterisk). Quantization was done as in Figure 4. 
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(b) A549 cells were transfected with a reporter construct containing the promoter 
region of MDM2 gene fused to luciferase. Luciferase activity was measured after 
treatment with Paclitaxel in cells in which the reporter gene is transfected together 
with miR-34c-5p mimic or with a scrambled sequence as control. (c) A549 cells were 
treated with paclitaxel and either scrambled transfected or miR-34c-5p mimic 
transfected cells were analyzed for MDM2 and SIRT-1 protein expression. Filters 
were hybridized with anti α-tubulin to confirm equal loading. Each blot is 
representative of at least four independent experiments. (d) A549 cells were 
transfected with a control scrambled sequence and with miR-34c-5p mimic (upper 
panel) or with an LNA anti-miR negative control inhibitor and an anti-miR-34c-5p 
inhibitor (lower panel). After treatment with 10 µM Nutlin-3a for 24h p53 protein 
levels were analyzed by immunoblot compared to untransfected cells (Cntrl). Filters 
were hybridized with anti α-tubulin to confirm equal loading. (e) p53 stable silenced 
A549 cells (shRNAp53) or mock stable transfected cells (shRNAcntrl)  were treated 
with Paclitaxel or cisplatin as indicated and levels of caspase-3 and caspase-9 cleaved 
products were analyzed by immunoblot. Filters were hybridized with anti α-tubulin to 
confirm equal loading. (f) A549 cells were transfected with either miR-34c-5p mimic 
or with a scrambled sequence and treated for 24 h with cisplatin (50 µg/ml). Levels of 
p53 were analyzed by immunoblot. Filters were hybridized with anti α-tubulin to 
confirm equal loading. The blots are representative of at least three independent 
experiments. 
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5. Conclusions 
In order to identify miRNAs implicated in the pro-apoptotic pathway we 
engineered a NSCLC derived cell line to induce caspase-8 dependent cell 
death. By using a functional selection we identified miRNAs whose expression 
may protect cells to undergo apoptosis. Eleven different miRNAs have been 
selected that if expressed, either alone or in combination, confer resistance to 
caspase-8 dimerization. Among these miRNAs, miR-34c revealed to be of 
particular interest. MiR-34c belongs to a conserved miRNA family consisting 
of three members: miR-34a, miR-34b and miR-34c that are under the direct 
positive control of p53 (Chang et al. 2007; He et al. 2007a; Raver-Shapira et al. 
2007; Tarasov et al. 2007; Bommer et al. 2007; Corney et al. 2007). Several 
converging evidence demonstrated that miR-34 members mediate p53 action to 
negatively regulate cell cycle thus acting as “bona fide” tumor suppressor 
genes (Hermeking 2010; Liu et al. 2011; Li et al., 2009; He et al. 2007b). 
Though exceptions exist (Dacic et al. 2010; Lee et al. 2011), miR-34a/b/c have 
been consistently found poorly expressed in several tumor and tumor derived 
cell lines (He et al. 2007a; Corney et al. 2010).  
In apparent contradiction with its tumor suppressive potential, here we 
demonstrate that forced expression of miR-34c may confer resistance to 
caspase-8-induced apoptosis. Indeed, in A549-FK cells, the drug induces the 
activation of the mitochondrial pathway through the activation of several pro-
apoptotic members of the Bcl2 family, including BID, Bmf, and Bax, that are 
clearly impaired by miR-34c ectopic expression. Furthermore, we 
demonstrated that miR-34c is also able to protect cells from paclitaxel-induced 
apoptosis. Recently it has been reported (Sotillo et al. 2011) that miR-34a, 
belonging to the same family of miR-34c, may confer resistance to bortezomib-
induced apoptosis by downregulating p53 in a c-myc dependent way. Indeed, 
c-myc is a key regulator of cell proliferation since its induction sustains cell 
proliferation and transformation. However, in concert with p53, elevated levels 
of c-myc may sensitize tumor cells to proapoptotic stimuli and promote cell 
death (Maclean et al. 2003; Cannell et al. 2010; Murphy et al. 2008; Soucek 
and Evan, 2010; Allen et al., 2011).  
In an attempt to understand what are the critical targets of miR-34c, we 
assumed that, given the protocol of functional selection used, some of these 
targets should be common to multiple miRNAs selected and found in 
combination with miR-34c. Based on this assumption, we identified among the 
genes with predicted consensus sites for miR-34c, the proapoptotic protein 
Bmf. Indeed, attenuation of Bmf expression, even poorly, protects cells from 
caspase-8-induced apoptosis and thus is a promising target candidate of miR-
34c, likely by directly targeting one of the predicted consensus sites in its 3’ 
UTR at position 2283. 
According with recent reports that indicate c-myc as target of miR-34a/c 
(Cannell and Buschell 2010; Christoffersen et al. 2010; Kress et al. 2011) here 
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we show that c-myc is downregulated by miR-34c-5p and that its 
downregulation seems by its own to be sufficient to mediate much of the 
protective effects of miR-34c, thus proving that in A549 cells downregulation 
of c-myc is critical to mediate survival. On the other hand, our results indicate 
that the effects of miR-34c involve, besides c-myc, the MDM2 and p53 loop, 
the link between c-myc and MDM2 remains to be determined since A549 cells 
carry a deletion of the MDM2 regulatory protein, p14/Arf (Xie et al. 2005). 
Indeed, miR-34c attenuates the paclitaxel-dependent induction of p53 by a 
mechanism that is unlikely determined by a decrease in the extent of p53 
acetylation since the levels of the deacetylase SIRT-1 (a target of miR-34c) are 
as well decreased. Our results rather show that inhibiting MDM2 with Nutlin-
3a induces p53 expression in a way insensitive to the intracellular levels of 
miR-34c thus indicating that MDM2 activity could be required for attenuation. 
Therefore, a plausible explanation of the fact that miR-34c is unable to 
attenuate the levels of cisplatin-induced p53, while the silencing of p53 confers 
resistance to both cisplatin and paclitaxel, may likely rely on the genotoxic 
action of cisplatin that, at difference of paclitaxel, causes MDM2 inhibition. On 
the other hand, it has been shown that active p53 directly induces miR-34c 
expression that in turn indirectly increases p53 activity thus establishing a 
positive feedback loop leading to cell cycle arrest (Corney et al. 2007; 
Yamakuchi et al. 2008; Yamakuchi et al. 2009; Hermeking 2010). How this 
loop is attenuated is still unknown. In light of our results, it seems reasonable 
to hypothesize that increased levels of miR-34c may contribute to switch off 
the loop and thus interfering with paclitaxel-induced cell cycle arrest. 
These results can be relevant both for the understanding of molecular 
mechanisms that governs the interplay between miR-34c, p53 and c-myc to 
control cell proliferation and apoptosis and for the development of targeted 
specific new therapeutic agents. 
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Abstract: Aptamers are short non-naturally occurring single stranded DNA or RNA able to bind tightly, due to their 
specific three-dimensional shapes, to a multitude of targets ranging from small chemical compounds to cells and tissues. 
Since their first discovery, aptamers became a valuable research tool and show great application to fundamental research, 
drug selection and clinical diagnosis and therapy. 
Thanks to their unique characteristics (low size, good affinity for the target, no immunogeneicity, chemical structures that 
can be easily modified to improve their in vivo applications), aptamers may represent a valid alternative to antibodies 
particularly for the treatment of neurological disorders that urgently need modalities for drug delivery through the blood 
brain barrier. Aptamers have excellent potential as reagents for the targeted delivery of active drug substances, either 
through direct conjugation to the aptamer, or through their encapsulation in aptamer-coated vesicles. 
We will review here the recent and innovative methods that have been developed and the possible applications of 
aptamers as inhibitors or tracers in neurological disorders and brain cancer. 
Keywords: Alzheimer's disease; Aptamers; Blood-brain barrier; brain cancer; Central nervous system; Parkinson's disease; 
Prion diseases; SELEX. 
INTRODUCTION 
 Anomalous protein misfolding and aggregation, with an 
accompanying "toxic gain of function" occurs in several 
neurodegenerative conditions including Prion diseases, 
Alzheimer's disease (AD), Parkinson's disease (PD), and 
Huntington's disease and is central to their pathogenesis. For 
example, in AD, misfolded amyloid beta peptide 1-42, a 
proteolytic product of amyloid precursor protein metabolism, 
accumulates in the neuronal endoplasmic reticulum and 
extracellularly as plaques. In PD cases there is abnormal 
accumulation of alpha-synuclein in neuronal cell bodies, 
axons, and synapses. Prion diseases, as well, are caused by a 
transmissible agent that is able to induce abnormal folding of 
normal cellular prion proteins in the brain, leading to brain 
damage and the characteristic signs and symptoms of the 
disease. Furthermore, in the case of brain cancers, the 
complex heterogeneity of malignant cells make it difficult, to 
distinguish between even close tumor types with high 
accuracy. 
 Hence, finding specific ligands capable of detecting and 
measuring the altered pattern of gene expression and to 
discriminate between different disease phenotypes, is a 
strategic and plausible objective for the diagnosis and 
therapy of important diseases. 
 Furthermore, the presence of the tight blood-brain barrier 
(BBB) has turned out to be the major constraint to any  
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strategy of safe, non-invasive delivery of therapeutics to the 
brain, either of viral or non-viral origin and enlarge the need 
to find new therapeutic and diagnostic modalities for central 
nervous system-related pathologies. To date, antibody-based 
approaches have been developed for in vivo applications but, 
in most cases, adequate sensitivity has not yet been reached; 
they show toxicity in vivo and are not able to efficiently 
cross the BBB. 
 Promising alternative approach to antibodies is now 
represented by single-stranded nucleic acid ligand molecules, 
named aptamers. They are isolated from combinatorial 
libraries by a selection procedure, the Systematic Evolution 
of Ligands by EXponential enrichment (SELEX) technology 
[1, 2], which, in the last few years, has yielded several high-
affinity ligands and potential antagonists of disease 
associated proteins [3-6]. Unlike other small noncoding 
RNAs either natural or artificial (antisense, ribozymes, 
siRNAs, miRNAs) that inhibit gene expression, aptamers 
can be raised against a variety of targets and act by directly 
binding the protein target without interfering with its 
expression. Indeed, they assume three-dimensional shapes 
that dictate high-affinity binding to a given target thus 
frequently modulating its function [5-7]. They display the 
following unique properties that render them promising tools 
for the treatment of a multitude of diseases: (i) ability to 
discriminate between different conformations of the same 
target proteins; (ii) capability to quantify the level of 
expression of the altered versus the physiologic forms; (iii) 
low molecular weight and chemical structures ideal for in 
vitro and in vivo purposes; and finally, for therapeutic 
applications they (iv) may interfere with the altered target 
product. 
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 Here we will discuss the properties of aptamers as 
suitable tools to detect disease-associated biomarkers in vivo 
and on the possible applications of aptamers as 
diagnostic/therapeutic agents in central nervous system 
related pathologies. 
APTAMER PRODUCTION 
 The starting point of the SELEX technology for the 
aptamer production is the synthesis of a high complexity 
library of single-stranded oligonuleotides (RNA, DNA or 
modified RNA), as schematized in Fig. (1). Randomisation 
of a sequence stretch from 22 up to 100 nucleotides in length 
is used to create an enormous diversity of possible 
sequences, which in consequence generate a vast array of 
different conformations with different binding properties, 
from which ligands are isolated which may stably interact 
with specific target molecules by forming highly specific 
contacts. The SELEX method includes steps of (i) incubating 
the library with the target molecule under conditions 
favourable for binding; (ii) partitioning unbound nucleic 
acids from those bound specifically to the selector molecule; 
(iii) dissociating the nucleic acid-protein complexes; and (iv) 
amplifying the nucleic acids pool enriched for specific 
ligands. After the final round of the aptamer selection 
process, the PCR products are cloned into a vector and 
sequenced to allow for the identification of the best binding 
sequences and for screening of conserved sequences and 
structural elements indicative of potential binding sites. A 
typical aptamer library has a complexity of 10
14
, which is of 
several orders of magnitude higher than that of the phage 
display libraries used to screen for antibodies. As a result, 
SELEX usually requires eight or more rounds of screening to 
isolate aptamers with nanomolar affinities. 
 The broad utility of aptamers derives both from their 
versatility, with high selectivity and sensitivity, and their 
ease of screening and production. They are entirely 
chemically synthesized, thus avoiding complex 
manufacturing processes using cell-based (eukaryotic or 
prokaryotic) expression systems that are required for 
antibodies production. The dissociation constants of RNA 
aptamers/target molecules are in the nanomolar/picomolar 
range. Values are therefore better than those determined for 
protein/protein interactions detected by phage display 
experiments, and are comparable to dissociation constants 
measured in antigen/antibody interactions. The size of 
aptamers (8-15 kDa) is between that of a single chain 
antibody fragment and a small peptide and thanks to their 
structure and low molecular weight are not immunogenic-a 
very useful property for reagents that need to be 
administered repeatedly to the same individual for therapy or 
diagnostics when studying disease progression. 
 One particularly attractive feature of these synthetic 
molecules is that they can support chemical modifications, 
whilst maintaining their structure and function. Since 
aptamers, especially RNA-based aptamers, are rapidly 
degraded by nucleases in whole organisms major efforts 
have therefore been addressed to improve their stability by a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Steps employed in the SELEX process. The single-stranded (ss) DNA library is amplified by Polimerase Chain Reaction (PCR) in 
order to generate the double-stranded DNA pool that will be transcribed by T7 RNA Polymerase. The pool of RNA molecules with different 
conformations will be used for the selection process (see text for details). 
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variety of approaches [8]. RNA aptamers with 2?-fluoro 
(amino) pyrimidine modifications, 2?-O-alkyl nucleotides, 
3?end cap and locked nucleic acids, LNA [9] modifications, 
that significantly enhance their stability, may survive for 
several hours in vivo against degradation by nucleases [10]. 
 Furthermore, protocols have been also developed that 
allow the targeting of intracellular proteins with aptamers 
(so-called intramers) that are delivered into intra-cellular 
compartments either by direct transfection or through the use 
of expression systems for the aptamer sequences [11, 12]. 
The cytoplasmic expression of intramers can be used to 
probe cellular processes and demonstrates the aptamers 
striking potential as rapidly generated intracellular 
modulators of biomolecules. 
APTAMERS IN DIAGNOSIS AND THERAPY 
 In 1990, Tuerk and Gold selected aptamers of T4 RNA 
polymerase by SELEX [1]. In the same year, Ellington and 
Szostak isolated from a population of random sequence RNA 
molecules, aptamers specific for a variety of organic dyes 
[2]. To date, aptamers achieve the specific recognition in 
many diagnostic applications and are in several clinical 
studies as therapeutic agents. 
 For example, nucleic acid aptamers have been reported as 
useful tools for curing thrombus and inhibiting endometrium 
hyperplasia and angiogenesis [13-15]. The potential clinical 
utility of aptamers might be best appreciated by considering 
that, despite being discovered less than two decades ago, an 
aptamer-based therapeutic (known as pegaptanib or 
Macugen, marketed by Pfizer) has already received US FDA 
approval for the treatment of age-related macular 
degeneration. This is a RNA aptamer that binds to and 
antagonizes the action of vascular endothelial growth factor, 
by blocking vascular endothelial growth factor binding to its 
receptor [16]. 
 Great promise in developing specific molecular probes 
for disease biomarker discovery and for diagnostic and 
therapeutic applications is recently represented by the intact 
cell-based SELEX strategy that allows for the selection of 
nucleic acid aptamers against living cells [see 17 for a 
review]. Indeed, cell-SELEX to target proteins expressed on 
the cell surface, can be used to develop aptamers that are 
able to bind preferentially to diseased cells compared with 
normal cells or to discriminate among different phenotypes 
of the same cell type. This strategy has the advantage of a 
direct selection of ligands without prior knowledge of the 
target molecules and enables the identification of aptamers 
that bind large cell surface-specific markers, in their native 
conformation. By applying the SELEX technology against 
whole-living cells in culture, for the first time we succeeded 
in demonstrating that even by using a target as complex as 
an intact cell, it is possible to obtain aptamers against even 
rare antigens if specifically expressed on the target cell [18, 
19]. We adopted this strategy to generate nuclease resistant 
RNA-aptamers specific for PC12 cells expressing the human 
receptor tyrosine kinase, Ret and selected aptamers that bind 
specifically to Ret and inhibit its downstream signaling 
effects [18]. 
 Aptamers to multiple targets have been simultaneously 
isolated by using red blood cell membrane preparations as 
target [20]. By using living cells as targets, aptamers able to 
discriminate cells from distant tumor types like T-cell ALL 
versus B-cell lymphoma [21] and small lung cancer cells 
versus large cell lung cancer [22] have been generated. 
APTAMERS IN NEURODEGENERATIVE DISEASES 
Prion Diseases 
 Prion diseases, also known as transmissible spongiform 
encephalopathies (TSEs), are neurodegenerative disorders 
usually rapidly progressive and always fatal. TSEs 
essentially comprise Creutzfeldt-Jakob disease in humans, 
scrapie in sheep and goats, and bovine spongiform 
encephalopathy in bovines. Other encephalopathies have 
been demonstrated in the Felidae, in mink or certain wild 
animals, such as deer or elk. These diseases are caused by 
unconventional transmissible agents that are called prions. A 
distinguishing feature is the conversion of the normal 
cellular isoform of the host prion protein (PrPC) into an 
insoluble, proteinase K-resistant isoform (PrPSc) which is 
deposited as aggregates in the brain and other tissues. The 
molecular details of the process by which PrPC is converted 
into the disease-associated homologue are unclear. 
Investigations of prion isoforms led to the conclusions that 
variations in disease phenotype are determined by the 
conformation of PrPSc. Since prion strains replicate, 
suggesting that PrPSc must act as a template for the 
refolding of PrPC into a second molecule of PrPSc, thus 
causing an exponential accumulation of the pathogenic 
protein [23, 24]. 
 Much of the effort in this field is devoted to finding 
specific reagents able to differentiate the prion isoforms 
associated with specific neuropathologies or disease 
phenotypes, and allow differential diagnosis. Currently, 
antibody-based approaches have been developed but 
adequate sensitivity has not yet been reached. Furthermore, 
several agents have been found to interfere with PrPSc 
biogenesis. They include polyanionic drugs, derivatives of 
polyene antibiotics or anthracycline and synthetic peptides, 
porphyrin compounds, soluble lymphotoxin beta receptor, 
lipophilic agents and anti-PrP antibodies. Most of these 
compounds are highly toxic in vivo, do not discriminate 
between PrPC and PrPSc and are not able to efficiently cross 
the BBB. Recently DNA and RNA aptamers have been 
selected against the prion protein and some of them are able 
to efficiently discriminate the aberrant from the normal form 
of the protein (as schematized in Fig. 2). 
 The group of Famulok [25] selected nuclease-resistant 2'-
amino-2'-deoxypyrimidine-modified RNA aptamers which 
recognize a peptide comprising amino acid residues 90-129 
of the human prion protein with high specificity. This 
domain of the prion protein is thought to be functionally 
important for the conversion of PrPC into its pathogenic 
isoform PrPSc and is highly homologous among prion 
proteins of various species including mouse, hamster, and 
man. One of the selected aptamers, named DP7, binds to the 
full-length human, mouse, and hamster prion protein. 
Despite the use of the epitope 90-129 from human PrP as 
target for the selection, the aptamer binds as well the human 
full-length PrP, thus confirming what has already been 
observed for others aptamers [see 26, 27 as examples] that 
have been selected to bind an accessible peptide epitope, and 
which are also capable of recognizing that epitope when 
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present in the complete protein. Interestingly, at low 
concentrations in the growth medium of persistently prion-
infected neuroblastoma cells, DP7 aptamer significantly 
reduced the level of PrPSc accumulation [25]. 
 Furthermore, 2'-fluoro-modified RNA aptamers have 
been selected on infectious material by using purified, non-
proteinase K-treated scrapie-associated fibrils (SAF) that are 
expected to include all variant PrP conformations and PK 
sensitivities associated with infectivity of prion [28]. This 
SAF preparation thus represent an appropriate target to 
investigate the capacity of PrPSc as well as other proteins 
that co-purify with it to retrieve high affinity aptamer ligands 
from a complex combinatorial RNA library. Intriguingly, the 
best ligand selected on this material, named SAF-93, binds 
to a site of the prion protein that overlaps with the binding 
site of DP7 aptamer even if the two ligands do not share any 
similarity in either the primary or the secondary structures. 
SAF-93 as well, is able to interfere with the conversion of 
PrPC into PrPSc in a near physiological cell-free conversion 
assay, producing about 2-fold inhibition of conversion at a 
concentration of 40 nM. Furthermore, the aptamer has been 
modified by reducing its size and by derivatizing it with 
biotin in order to generate a ligand to be applied in multiple 
formats for the detection of abnormal forms of PrP in vitro 
[29]. In addition to its diagnostic use, the molecule may in 
the future have potential therapeutic application in TSE 
diseases by inhibiting conversion of PrPC to the pathological 
PrPSc isoform. 
 In addition to these promising findings, a panel of DNA 
aptamers has been identified which binds at different degrees 
to prions derived from a variety of host species [30, 31]. 
 These aptamers, generated against recombinant human 
PrPC, specifically bound to PrPC in its native form 
conformation but did not bind to PrPSc and other 
neuroproteins. These results indicate that these ligands could 
be successfully applied to differentiate prion isoforms, 
helping in the diagnosis of TSEs. 
 Aptamers are good molecular recognition elements for 
biosensors. Their conformational change, which is induced 
by the binding to the target molecule, enables the 
development of several types of useful detection systems. 
Recently, a detection system based on the conformational 
change in a prion-specific DNA aptamer has been developed 
and its application to simple bound/free separation has been 
reported [32]. The system is based on the properties of the 
so-called “capturable aptamers” to change their 
conformation upon binding to the target molecule and 
thereby expose a single-strand bearing the complementary 
sequence to a capture DNA probe immobilized onto the 
support. 
Alzheimer's Disease 
 AD is a progressive neurodegenerative disorder leading 
to the most common form of dementia in elderly people. 
Central to the pathogenesis of AD is the deposition in the 
brain of extracellular plaques containing aggregated of ?-
amyloid (?A) peptide that occurs as 40 and 42 amino acid 
containing fragments. This peptide is generated by 
proteolytic processing of the ?-amyloid precursor protein by 
?-secretase (BACE1) and ?-secretase [33]. The longer more 
hydrophobic ?A (1-42) folds much faster into the insoluble 
?-sheet conformation than the shorter one and forms the core 
of the plaques, which then act as seeds for the aggregation of 
the much more abundant ?A (1-40) [34]. The amyloid 
aggregates can be found in fibrillar and diffuse forms. 
Whereas the amorphous plaques seem not to be pathological, 
it is known that fibrillar aggregates are neurotoxic [35]. 
Since the deposition of the ?A (1-40) in the brain of patients 
is a process that starts long before any symptoms are 
detectable, the development of early diagnosis for AD is of 
major interest. Therefore, much of the effort in this field is 
devoted to designing ligands able to identify with high 
specificity and affinity the amyloid fibrils in order to 
generate new diagnostic and eventually therapeutic tools. 
 To date, the development of conformation-sensitive 
polyclonal, monoclonal or recombinant anti-?A antibodies 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Schematic mode of action of the prion protein-specific aptamers. A distinguishing feature in Prion diseases is the conversion of 
the normal cellular isoform of the host PrPC into an insoluble, proteinase K-resistant PrPSc, which is deposited as aggregates in the brain and 
other tissues. Aptamers selected against the prion protein and are able to:1) specifically bind to PrPC (SSAP-aptamers); 2) interfere with the 
conversion of PrPC into PrPSc (SAF-93 aptamer); 3) reduce the level of PrPSc accumulation (DP7 aptamer). 
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allowed the identification of specific conformational 
epitopes in ?A fibrils or in ?A oligomers, that are often 
found to be conformationally related to fibrils or oligomers 
from unrelated proteins [36, 37]. In this contest, the 
generation of nucleic acid aptamers specific for ?A 
detection/neutralization seems to be a promising task. A 
schematic mode of action of the AD-related aptamers is 
reported in Fig. (3). 
 Ylera et al. [38] selected RNA aptamers against 
immobilized ?A (1-40) that display affinities in the range of 
29-48 nM. Furthermore, the sequence with the lowest 
dissociation constant, aptamer ?55, has been labeled with 
colloidal gold and applied to visualization of the amyloid 
fibrils by electron microscopy, thus introducing a new 
diagnostic approach to detect and mark the fibers in AD 
[38]. 
 Besides their use for diagnostic and visualization 
purposes, the aptamers may also have therapeutic potential. 
Since BACE1 initiates ?A generation, it represents a 
valuable target to interfere with ?A production and treatment 
of AD [39]. To date, small interfering RNA approaches have 
been reported for ?-secretase proteins and in some cases 
their targeting ameliorates disease neuropathology in animal 
models [40]. BACE1 is a transmembrane protein 
characterized by an extracellular domain containing the 
enzymatic activity, and a short cytoplasmic tail (B1-CT). 
This tail, containing a single phosphorylation site, serves as a 
binding site for two proteins, the copper chaperone for 
superoxide dismutase-1 and the Golgi-localized, ?-ear-
containing, ADP ribosylation factor-binding (GGA1) 
protein. Phosphorylation and GGA1 binding to B1-CT 
regulate BACE1 transport [41, 42], suggesting that 
modulation of BACE localization or interference with 
protein factors that interact with the cytoplasmic domain 
might also affect ?-amyloid precursor protein processing and 
?A formation. Rentmeister et al. [43] isolated RNA aptamers 
that selectively target the B1-CT, by using as target of the 
selection an immobilized 24 aminoacid peptide representing 
the entire cytoplasmic domain of the BACE1. Among these 
aptamers, the best binders, S10 and TH14, endowed with a 
dissociation constant of 360 and 280 nM, respectively, share 
a structurally identical domain of 27 nucleotides in 
conserved loop and bulge motifs. Importantly, the S10 
aptamer, recognizes cellular authentic full-length BACE1 
from HEK269 cells and the binding site is restricted to the 
membrane-proximal half of the C terminus. Consistently 
with its selective binding site, S10 interferes with the 
recruitment of copper-chaperone for superoxide dismutase 
whereas it does not block the association of B1-CT with 
GGA1, nor does it inhibit the phosphorylation of B1-CT. 
The finding that a short aptamer can discriminate binding 
regions within a 3-kDa peptide suggests that this aptamer 
may provide a useful tool for elucidating functions 
associated with this epitope without affecting other 
important biological activities elicited by the C-terminal half 
of the BACE1 cytoplasmic domain. In this regard, these 
inhibitors, provide a rational for further functional 
investigation in order to develop new therapeutic modalities 
to block ßA formation. 
Parkinson's Disease (PD) 
 Considerable effort has been devoted to the search for 
molecules that might promote neuronal survival, and 
potentially be of therapeutic value in the treatment of PD. 
 One such candidate is the glial cell line-derived 
neurotrophic factor (GDNF) given its potent trophic effects 
on dopaminergic nigral neurons, indicating that this factor 
could provide neuroprotection in patients with early PD. In 
various animal models of PD, GDNF can prevent the 
neurotoxin-induced death of dopamine neurons and can 
promote functional recovery [44], and more importantly, the 
clinical use of GDNF for the treatment of the PD in humans 
is currently under evaluation [45]. GDNF signals through a 
multisubunit system in which the glycosyl-
phosphatidylinositol-linked protein GFR?1 and the 
transmembrane tyrosine kinase Ret, function as the ligand-
binding and signaling components, respectively. Ret 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Schematic mode of action of the Alzheimer's disease-related aptamers. Central to the pathogenesis of AD is the deposition in 
the brain of extracellular plaques containing aggregated of ?-amyloid. In order to detect/neutralize ?A, aptamers have been selected able to: 
1) bind with high specificity and affinity the ?A (?55 aptamer); 2) specifically recognize the C terminus of ?-secretase (SP10 aptamer). 
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activation is necessary for GDNF-dependent neuronal cell 
survival. In vitro studies have shown that following GDNF 
binding to GFR?1 the resulting complex recruits Ret leading 
to its activation by dimerisation and autophosphorylation 
[46]. The expression of the Ret receptor is highly localized 
in the human substantia nigra to dopaminergic neurons and 
evidence indicates that Ret is an essential component of the 
GDNF receptor complex in other populations of neurons in 
human brain. Ret-like immunoreactivity was observed in 
many of surviving dopaminergic neurons in substantia nigra 
of PD cases [47]. 
 Based on these findings, aptamer ligands for Ret receptor 
could be promising diagnostic/therapeutic tools for PD 
disease and neurodegeneration. One such candidate appears 
to be the RNA-aptamer, named D4, that we have generated 
by applying a whole-cell SELEX strategy, as highly specific 
ligand of human Ret receptor [18]. D4 is a 93-base 2'-
fluoropyrimidine-RNA aptamer that specifically bind the 
extracellular domain of Ret, displaying a Kd of 30 nM, thus 
interfering with ligand induced stimulation of its intrinsic 
tyrosine kinase activity [18]. 
 Works is in progress in our group to reformulate the D4 
structure in order to allow the aptamer to cross the BBB and 
directly target brain neurons expressing the transmembrane 
tyrosine kinase receptor Ret in PD. 
APTAMERS IN BRAIN TUMORS 
 The hope of success of therapeutic interventions in brain 
tumors, characterised by a high cellular heterogeneity, 
largely relies on the possibility to distinguish with high 
accuracy between tumor cells and normal healthy cells and 
even between cells of close tumor types. Given the high 
affinity and specificity of the aptamers, they could be 
usefully applied as diagnostic/therapeutic tools in cancer. 
 Aptamers have been isolated against tenascin-C (TN-C), 
an extracellular matrix protein over-expressed during 
different cellular processes including tumor growth [48, 49]. 
Since TN-C levels in tumors are significantly higher than in 
normal tissue and are correlated with invasiveness [50, 51] 
these ligands could be developed as clinically useful tumor-
targeting agents. Hicke et al. [49] selected RNA aptamers by 
combining protein-SELEX on purified TN-C with cell-
SELEX on TN-C-expressing U251 glioblastoma cells. A 13 
kDa-size nuclease-stabilized aptamer, named TTA1, binds to 
the fibrinogen-like domain of human TN-C with a 
dissociation constant of 5 nM and does not cross-react with 
mouse TN-C. Intriguingly, the radio-labelled TTA1 aptamer 
is able to bind tumor tissue that expresses TN-C but does not 
bind to tissue that lacks TN-C. Thus, this aptamer has been 
proposed as a new ligand for targeted delivery of 
radioisotopes or chemical agents to diseased tissues [49]. 
 In order to select a brain tumor-targeting tool, Blank et 
al. [52] reported a fuorescence-based SELEX procedure 
against transformed endothelial cells (EC) as a complex 
target. Neoangiogenic EC, associated with tumor 
development, differ from pre-existing quiescent EC by 
qualitative and quantitative changes in expression of 
molecular endothelial proteins. Thus, such molecules could 
serve as molecular addresses differentiating the tumor 
vasculature from those of the normal brain. Single-stranded 
DNA aptamers have been generated against a pathologic 
endothelial target, represented by Adenovirus-12 SV40-
transformed YPEN-1 rat endothelial cells. Among the 
selected aptamers, the aptamer III.1 selectively bound 
microvessels of rat brain glioblastoma but not the 
vasculature of the normal rat brain including peritumoral 
area. The target protein recognised by this aptamer was 
isolated from endothelial cells by ligand-mediated magnetic 
DNA affinity purification and identified by mass 
spectrometry as rat homologue of mouse pigpen, a not 
widely known endothelial protein whose expression parallels 
the transition from quiescent to angiogenic phenotypes in 
vitro. Thus, the selected aptamer can be used as a probe to 
analyze pathological angiogenesis of glioblastoma and 
provide important insights for tumor diagnostics. 
 Neuroblastoma is the most common solid tumor of 
childhood outside the central nervous system; it is made of 
neural crest cells that can occur at any point along the 
sympathetic ganglia or the adrenal medulla [53]. It has been 
shown that the expression of the neurotrophic factor 
receptors TrkA and TrkB as well as the receptor for GDNF, 
Ret, is induced upon retinoic acid (RA) treatment in 
neuroblastoma cells [54, 55]. Using the D4 aptamer and a 
truncated Ret protein as specific inhibitors of Ret, we have 
shown that RA-induced differentiation of human 
neuroblastoma cells is mediated by a positive autocrine loop 
that sustains Ret downstream signaling and depends on glial 
cell-derived neurotrophic factor expression and release. 
Furthermore, in neuroblastoma cells expressing functional 
Ret and TrkB receptors, the RA-induced cell differentiation 
depends on the signaling interplay by TrkB and Ret. Indeed, 
by promoting Ret phosphorylation in a GDNF independent 
manner, the BDNF-stimulated TrkB, induces neurite 
outgrowth and expression of differentiation-specific 
molecular markers. This is the first report describing the 
need of a functional transactivation between two unrelated 
receptor tyrosine kinases to achieve the final cell phenotype, 
in addition, this work provides important insights on the 
molecular mechanism of RA action, which might be relevant 
for the development of biologically based therapeutic 
strategies [56, 57]. 
PERSPECTIVES 
 As discussed above, the number of generated aptamers of 
potential medical importance in central nervous system-
related pathologies is rapidly increasing, and, the possibility 
to introduce changes in their structure through defined 
chemical modifications that will enhance their in vivo 
applications represents a great advantage with respect to the 
use of antibodies. Due to their relatively small size in 
comparison to antibodies, the isolated aptamers should be 
better suited for rapid tissue penetration and blood clearance, 
two excellent characteristics for contrast agents in imaging. 
In this regard, a notable example of aptamer plasticity is 
represented by the use of the DNA aptamer inhibitor of the 
human neutrophil elastase for in vivo imaging of 
inflammation [58]. Remarkably, a better signal-to-noise ratio 
was achieved by the aptamer, labelled with Technetium-
99m, compared to the rat anti-elastase antibody. 
 In addition, it is possible to attach to nucleotides 
functional groups such as fluorescent dyes or chemically 
reactive groups allowing aptamers to be conjugated with 
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enzymes, beads or radiotracers in diagnostic assays [59], or 
with siRNAs [60] or toxins [61] for therapeutic applications. 
 Also the development of a safe, efficient, specific, and 
non-pathogenic system for the delivery of 
diagnostic/therapeutic aptamers is highly desirable. Indeed, 
to be successfully applied in vivo aptamers must possess 
defined molecular properties needed to cross the collagen 
microfibrillar network of the extracellular matrix, and reach 
the target tissue or cells and, most importantly, also penetrate 
the cell membrane. Coupling aptamers to inert large 
molecules, such as cholesterol or polyethylene glycol, has 
been used to keep them in circulation anchored to liposome 
bilayers [62]. For example, with the attempt to develop a 
therapeutic approach to treat experimental autoimmune 
encephalomyelitis, the animal model of multiple sclerosis, an 
RNA aptamer that blocks midkine function has been 
generated and reformulated in its structure for in vivo 
application [63]. The administration of a 49-mer RNA 
aptamer, stabilized with ribose-2' modifications and 
cholesterol, neutralizes midkine induced expansion of 
CD4
+
CD25
+
 regulatory T cells and reduces the symptoms of 
experimental autoimmune encephalomyelitis. 
 More recently, and still in preclinical development, 
aptamers have begun to find applications at the interface of 
nanotechnology and medicine in the form of aptamer-
nanoparticle conjugates [64, 65]. Aptamers conjugated to 
nanoparticles resulted in increased targeting and more 
efficient therapeutics, as well as more selective diagnostics. 
For example, nanoparticle-aptamer bioconjugates with RNA 
aptamers have been developed that bind at high specificity to 
the prostate-specific membrane antigen, a well-known 
prostate cancer tumor marker that is overexpressed on 
prostate acinar epithelial cells. This was the first report of 
targeted drug delivery with nanoparticle-aptamer 
bioconjugates [66]. 
APTAMERS AS DELIVERY AGENTS TO CROSS 
THE BBB 
 The study of brain drug delivery has lagged behind but is 
now rapidly progressing and is predicted to become a "hot 
topic" within the next few years. Currently, it is not practical 
to administer neurotrophins to humans by invasive 
procedures such as intracerebroventricular infusion or 
intracerebral injection, on the other hand, non-invasive 
intravenous administration of brain neurodiagnostic or 
neurotherapeutic agents remains a challenge because of the 
low permeability of the BBB. Indeed, the same mechanisms 
that protect the brain against intrusive chemicals can also 
frustrate therapeutic interventions. The anatomical basis of 
the BBB arises from the special cellular features of the brain 
capillary endothelial cells which exhibit high-resistance tight 
junctions acting as zippers that close the inter-endothelial 
pores, and connect and seal the cells thereby restricting the 
free movement of substances between the blood and the 
cerebral interstitial fluid [67]. Although approximately 100% 
of large molecules do not cross the BBB, the problem is 
nearly as severe for small-sized drugs since more than 98% 
of these do not cross the BBB. However, peptides, protein or 
nucleic acids therapeutics may be delivered to the brain by 
using a chimeric strategy in which the active drug is 
conjugated to a transporter molecule. Indeed, the so-called 
“brain drug-targeting technology” allows the coupling of a 
molecule that is not normally transported across the BBB to 
a transport vector that crosses the BBB by means of 
receptor-mediated transcytosis. Several recent papers 
describe the possibility to apply the brain drug-targeting 
technology to the diagnosis or therapy of many brain 
disorders [68-70]. Peptidomimetic monoclonal antibodies 
(MAbs) that bind endogenous transport system within the 
BBB, such as the insulin receptor, the transferrin receptor or 
the leptin receptor, have been used for targeting 
neuropeptides or antisense agents through the BBB in vivo. 
 As an example, human GDNF was re-engineered by 
fusion of the mature GDNF protein to the carboxyl terminus 
of the chimeric MAb to the human insulin receptor (HIR). 
The HIRMAb-GDNF fusion protein is bi-functional, and 
both components binds the HIR, to trigger receptor-mediated 
transport across the BBB, and binds the GDNF receptor 
GFR?1, to activate GDNF neuroprotection pathways behind 
the BBB [71]. 
 In this context, it appears a challenging goal to 
reformulate the receptor-mediated approach, and to 
substitute natural neurotrophins and antibodies with 
synthetic, small RNA-based aptamers, by designing new and 
original chimeric molecules. Indeed, with respect to 
antibodies, non-immunogenic and low size aptamers appear 
as suitable tools to cross the BBB using receptor-mediated 
transcytosis and to bind with high affinity to specific brain 
targets. Furthermore, aptamers may be linked together, thus 
enabling the construction of a custom designed targeting 
molecule of choice. 
 Recently, with ultimate objective of introducing 
therapeutic enzymes across the blood-brain barrier, RNA-
aptamers and DNA-aptamers have been selected to bind to 
the extracellular domain of the mouse transferrin receptor. 
After selection, these molecules were modified with biotin 
and linked to dye-labeled streptavidin to demonstrate their 
ability to deliver streptavidin to mouse fibroblast cells Ltk- 
cells. Furthermore, the DNA aptamer was able to deliver a 
lysosomal enzyme into deficient mouse fibroblasts and 
correct the defective glycosaminoglycan degradation in these 
cells [72]. 
 These results support the possibility that peptides, 
proteins or nucleic acids conjugated to aptamers that bind to 
the extracellular domain of the transferrin receptor can 
undergo receptor-mediated transcytosis. 
CONCLUSION 
 With the understanding of molecular mechanisms 
underlying central nervous system diseases, the use of 
aptamers as bio-recognition and inhibiting elements offers 
several advantages over classical methods mainly based on 
antibodies. Moreover, the enormous diversity of random 
oligonucleotide libraries can exceed the diversity of 
antibodies in the mammalian genome by several orders of 
magnitude. In this regard, numerous aptamers have already 
been selected against a wide array of proteins, and the 
possibility of acquiring aptamers against proteomes has been 
advanced by automation of the in vitro selection procedure. 
These considerations, explain why now the aptamer-based 
technology for protein detection is in advanced stages of 
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development as useful tools in clinical diagnosis and 
therapy. 
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Abstract: MicroRNAs (miRNAs) are short non-protein-coding RNA molecules that 
regulate the expression of a wide variety of genes. They act by sequence-specific base 
pairing in the 3‟ untranslated region (3‟UTR) of the target mRNA leading to mRNA 
degradation or translation inhibition. Recent studies have implicated miRNAs in a wide 
range of biological processes and diseases including development, metabolism and cancer, 
and revealed that expression levels of individual miRNAs may serve as reliable molecular 
biomarkers for cancer diagnosis and prognosis. Therefore, a major challenge is to develop 
innovative tools able to couple high sensitivity and specificity for rapid detection of 
miRNAs in a given cell or tissue. In this review, we focus on the latest innovative 
approaches proposed for miRNA profiling in cancer and discuss their advantages 
and disadvantages. 
Keywords: microRNA; biomarker; cancer 
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1. Introduction 
MiRNAs are a class of small (19–25 nucleotides) non-coding RNA molecules widely conserved 
through evolution. MiRNAs are first transcribed into long primary miRNAs (pri-miRNAs) by 
polymerase II or, in few rare cases, by polymerase III. Typically, pri-miRNAs display a 33 bp stem 
and a terminal loop structure with flanking segments. Primary miRNAs processing begins in the 
nucleus where an RNAse III enzyme, Drosha, in complex with other proteins processes the  
pri-miRNAs, inducing the conversion into precursor miRNAs (pre-miRNAs). Pre-miRNAs are 60–70 nt 
long hairpin RNAs with 2-nt overhangs at the 3‟ end. They are transported into the cytoplasm by 
exportin-5, a RanGTP-dependent dsRNA-binding protein, and subsequently processed by Dicer, a 
cytoplasmic endonuclease RNAse III enzyme, that generates a miRNA duplex. The functional strand 
of the mature miRNA is then incorporated into the RISC (RNA-induced silencing complex), a 
ribonucleoprotein effector containing a catalytic endonuclease core, Argonaute2 (Ago2); Dicer; a 
dsRNA-binding protein named transactivating response RNA-binding protein (TRBP) and a protein 
activator of protein kinase R (PACT). The RISC mediates the degradation or the translation inhibition 
of the target mRNA (Figure 1). To produce the functional mature miRNA the duplex generated after 
Dicer-mediated cleavage need to be unwound, but to date it remains unclear when (i.e., before or after 
RISC loading) and how the two strands are separated [1,2]. 
Figure 1. Scheme of miRNA processing pathway. 
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Recent studies have shown that miRNAs are involved in different biological processes and 
pathological states, particularly in the development of several cancers. Altered expression levels of 
miRNAs have been correlated with cancer type, tumor stage and response to treatments [3]. Thus, 
miRNAs represent a new class of promising diagnostic and prognostic biomarkers as well as new 
targets for cancer therapy [4,5]. 
On this basis, it is important to develop analytical methods for rapid and sensitive identification of 
miRNAs present in a particular cell or tissue or fluids (such as serum and plasma) samples. A key 
issue is the ability to distinguish between the precursor and mature form of a miRNA, since the mature 
form is the functional one and cellular levels of miRNA precursors does not necessarily correspond to 
cellular concentration of functional miRNAs [4]. 
To date, several methodologies have been applied to profile miRNAs including Northern blotting, 
in-situ hybridization, oligonucleotide microarrays, quantitative Reverse-Transcription-Polymerase 
Chain Reaction (qRT-PCR) and deep-sequencing [6]. Although Northen blot and in-situ hybridization 
continues to be used as the standard methods, these detection approaches have low sensitivity and 
generally require many steps, resulting laborious time-consuming procedures that are difficult for 
routine miRNA analysis. 
In this review, we analyze in detail the recent advances in microarray-based detection platforms and 
next generation methods based on nanotechnologies. Innovative qRT-PCR, amplification and 
enzymatic-based methods as well as deep sequencing strategies are also discussed. In addition, in the 
final section we focus on the detection and characterization of circulating miRNAs as cancer biomarkers. 
2. Alterations of miRNAs in Cancer 
MiRNAs are expressed in a tissue-specific manner and changes in miRNA expression within a 
tissue type can be correlated with disease status. The tissue concentrations of specific miRNAs have 
been associated with response to therapy, metastatic potential and other clinical features in various 
types of cancer [5,7]. 
The first evidence for miRNAs involvement in human cancer comes from a study by Calin et al. [8], 
examining a recurring deletion at chromosome 13q14 to search for a tumor suppressor gene involved 
in chronic lymphocytic leukemia (CLL). This study describes that the region of deletion encodes two 
miRNAs, miR-15a and miR-16-1. Subsequent investigations have confirmed the involvement of these 
two miRNAs in the pathogenesis of CLL [9]. Furthermore, Constinean et al. reported that a miRNA by 
itself can induce a neoplastic disease [10]. In fact, by using a transgenic mouse model, they 
demonstrated that overexpression of miR-155 in B cells induce lymphoma pre-B leukemia. 
Several other miRNAs dysregulated in different human cancer types have been reported. For 
example, it has been demonstrated that let-7 family contains miRNAs regulating the RAS family of 
oncogenes [11]. Petrocca et al. [12] showed that the miR-106b-25 cluster plays a key role in gastric 
cancer interfering with proteins involved both in cell cycle and apoptosis. In other studies, miR-155 
was found overexpressed in Hodgkin lymphoma, pediatric Burkitt lymphoma and diffuse large B-cell 
Lymphoma [13-15]; miR-143 and miR-145 were significantly downregulated in colon cancer tissue 
compared with colonic mucosa [16]; miR-21 was overexpressed in many tumors [7], including 
glioblastoma [17], cholangiocarcinoma [18], multiple myeloma cells [19] and breast cancer [20,21]. 
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Moreover, studies that investigated the expression of the entire microRNAome in various human 
solid tumors and hematologic malignancies have revealed differences in miRNA expression profiling 
between neoplastic and normal tissues [9,22-24]. These studies indicate that neoplastic tissues may be 
distinguished by the expression of specific signatures of as few as 20–30 different miRNAs and 
expression profiles may be highly predictive for the degree of response to several therapeutic agents [25]. 
Further, being much shorter than mRNAs, miRNAs are less vulnerable to degradation by ribonucleases 
and, unlike proteins, are not post-synthetic structural modified, and therefore easier to detect. 
MiRNAs play a key role also in tumor metastasis. Indeed, for example miR-139 suppresses 
metastasis of hepatocellular carcinoma [26], while miR10-b was found highly expressed in metastatic 
breast cancer cells [27] even if its clinical utility is still questioned [28]. 
More recently, many evidences are emerging that tumor-derived miRNAs are present and detectable 
in serum, plasma, urine and other human body fluids (Table 1). Because of their abundance, tissue 
specificity and relative stability, circulating miRNAs hold a great promise as noninvasive or minimally 
invasive biomarkers in cancer [29,30]. 
Table 1. Circulating miRNAs upregulated in cancer. 
miRNA Body Fluids Diseases References 
miR-155, miR-210, miR-21 
miR-141 
miR-25, miR-223 
miR-155 
miR-155, miR-21 
miR-21, miR-141, miR-200 family 
miR-17-3p, miR-92 
miR-126, miR-182 
miR-125a, miR-200a 
Serum 
Plasma 
Serum 
Serum 
Plasma (exosomes) 
Plasma (exosomes) 
Serum 
Urine 
Saliva 
Diffuse large B-cell lymphoma 
Prostate cancer 
NSCLC 
Breast cancer 
Lung cancer 
Ovarian cancer 
Colorectal cancer 
Bladder cancer 
Oral squamous cell carcinoma 
[31] 
[32] 
[33] 
[34] 
[35] 
[36] 
[37] 
[38] 
[39] 
3. Methods for miRNA Detection 
Various strategies for miRNA detection have been developed. Here we discuss some of the most 
innovative ones remarking their advantages and limits (Table 2). Moreover we analyze methods used 
for detection and characterization of circulating miRNAs as new highly promising biomarkers for 
cancer diagnosis. 
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Table 2. Comparison of various methods for miRNA profiling 
 Method Sensitivity Specificity Throughput Cost Relevant Features 
 
 
Microarray-based 
Microarray Low Low High Relatively High  Can be used for clinical diagnosis 
  Can only measure miRNA relative abundance 
 Requires 0.2-2 µg of total RNA 
 Specificity and sensitivity can be improved by  
LNA modification of probes 
 
 
 
 
 
 
 
 
Nanotechnology-based 
ENT High High Medium High  Capable of identifying miRNAs with < 2  
fold difference in expression level 
 Detection limit at fM level 
 Requires sophisticated instruments 
 No amplification and no labeling are required 
SPRI High High Medium High  Detection limit at attomole level 
 Requires sophisticated instruments 
 No amplification and no labeling are required 
Gold nanoparticles-based High High Low Relatively Low  Relatively simple 
 Detection limit at fM level 
 Does not require sophisticated instruments 
 No amplification and no labeling are required 
SERS High High Low High  Simple to perform 
 Requires sophisticated instruments 
 No amplification and no labeling are required 
 Detection limit at fM level 
 Complicated data interpretation 
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Table 2. Cont. 
 
 
 
 
 
 
 
 
qRT-PCR-based 
Stem-loop qRT-PCR High High Low High  Can be used for clinical diagnosis 
 Can be multiplex for high- throughput 
 Specific for mature miRNA 
 Requires only few pg of starting RNA 
 Very sensitive to mismatches 
SYBR Green qRT-PCR High High Low High  Can be used for clinical diagnosis 
 Can be multiplex for high- throughput 
 Specific for mature miRNA 
 Detection limit at fM level 
miR-Q High High Low Low  Can be used for clinical diagnosis 
 Specific for mature miRNA 
 Detection limit at fM level 
Poly(A)-Tailed Universal 
RT 
High Medium Low Low  Can be used for clinical diagnosis 
 Requires only few pg of starting RNA 
Molecular beacons 
 
Medium High Medium Low  Can be used for clinical diagnosis 
 Simple to perform 
 Detection limit at low nM level 
 Can be used for mature miRNA detection 
 Very sensitive to mismatches 
 
Amplification-based 
 
Padlock-probes and 
rolling-circle amplification 
Medium High Low Low  Requires radioactive labeling 
 Very sensitive to mismatches 
 Requires few ng of starting RNA 
Bead-based flow 
cytometry 
Medium High High Low  Can be used for clinical diagnosis 
 Detection limit at pM level 
 Requires sophisticated instruments 
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Table 2. Cont. 
 
 
 
 
 
Enzymatic-based 
Splinted ligation Low High Medium Low  Requires radioactive labeling 
 Requires from ng to µg of starting RNA 
ELONA Medium Medium High Low  Requires very short time 
 Requires more than 30 ng of starting RNA 
Bioluminescence detection High Medium High Low  Simple and rapid 
 Detection limit at fM level 
RAKE High High High Medium  Relatively complex 
 Requires as low as 10 pg of starting RNA 
Invader assay Medium High Low Low  Can be modified for high throughput 
 very simple and rapid 
 able to discriminate between precursor and  
mature miRNAs 
 Very sensitive to mismatches 
 Requires at least 50 ng of total RNA 
 
 
 
 
 
Deep sequencing-based 
454 pyrosequencing Low High High High  Allow also to discovery new miRNAs 
 Requires multiple steps 
 Results must be validated by alternative methods 
 Requires at least 2–10 µg of total RNA 
SOLiD Low High High High  Allow also to discovery new miRNAs 
 Requires multiple steps 
 Results must be validated by alternative methods 
 Requires at least 2–10 µg of total RNA 
Solexa Low High High High  Allow also to discovery new miRNAs 
 Requires multiple steps 
 Results must be validated by alternative methods 
 Requires at least 2–10 µg of total RNA 
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3.1. Microarray-Based Methods 
To date the most widely used techniques in literature to study the expression profile of miRNAs in 
cancer, are based on microarray analysis. These approaches are particularly attractive for miRNA 
profiling since they allow multiplexed detection of miRNAs [40].  
Microarray technologies are based on the hybridization between target molecules and their 
respective complementary probes. Oligonucleotide probes are immobilized on a support platform 
through a covalent link and fluorescent labeled miRNAs are hybridized with the array. The specific 
link between miRNAs and probes generates fluorescent signals that are revealed and quantified as 
discrete spots on the slide. This technique is very attractive because it allows the analysis of a large 
number of miRNAs at the same time obtaining a miRNA expression profile of specific cancer samples. 
The trickiest steps in microarray analysis are the design of probes used for capture of miRNA 
molecules and labeling procedure of biological samples. Several modifications in both these steps have 
been introduced during the last years that have permitted to improve this technique.  
The probe design is influenced by a number of matters related to the nature of miRNAs. Indeed, 
miRNAs are small molecules that represent only a tiny fraction of total cellular RNA with many of them 
belonging to the same family and differ only by few nucleotides. These characteristics make it difficult 
to design multiple probes with a suitable melting temperature (Tm), thus optimizing hybridization 
conditions without compromising specificity. Moreover, because there are often hundreds to thousands 
of probes in the same miRNA microarray, Tm normalization is absolutely required.  
Different strategies have been proposed to overcome these problems. Recently locked nucleic acids 
(LNA) [41,42] have been used to increase melting temperature, probe affinity for its target and 
mismatch discrimination. This approach provides high sensitivity and specificity. Otherwise, 
Baskerville et al. reported a strategy for Tm normalization by adjusting the length of the probes. In this 
method, appropriate adaptor sequences are linked to either one or both ends of the miRNA molecules 
and, based on the adaptor sequence, the probe is suitably lengthened or appropriately truncated if the 
original Tm is either too low or too high [43]. 
The procedure used for miRNAs labeling is another pivotal step for the success of microarray 
analysis. Different ways for direct or indirect labeling of miRNAs have been proposed [44]. Indirect 
methods are based on the labeling of the reverse transcribed miRNA or the RT-PCR product. This 
increases the labeling stability and sensibility. Direct methods (such as the use of guanine reagents, 
T4-RNA ligase or chemical labeling) are usually easier to use and help to avoid errors introduced by 
the reactions of reverse transcription and PCR amplification, even though they require a considerable 
amount of RNA (in the order of micrograms). 
To date, various companies (such as Affymetrix, Inc., Santa Clara CA, USA; Agilent Technologies, 
Inc., Santa Clara CA, USA; Applied Biosystems, Inc., Foster City CA, USA; Exiqon A/S, Vedbaek 
Denmark; and Rosetta Genomics, Inc., Rehovot, Israel) provide different microarray platforms for 
miRNA detection with a great potential applicability in clinical field. 
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3.2. Nanotechnology-Based Methods 
In recent years different strategies based on nanoparticles have been developed for mature miRNA 
profiling. All these methods are direct approaches able to minimize artifacts due to sample 
amplification and labeling. 
A number of nanotechnology-based approaches proposed in recent years are based on the use of 
electrical detection techniques. In a first approach Gao Z. and Yang Z. [45] employed the 
Elettrocatalytic Nanoparticle Tags (ENT) strategy that is based on amplified chemical ligation utilizing 
an indium tin oxide electrode and isoniazid-capped OsO2 nanoparticle tags. MiRNAs are oxidized with 
sodium periodate and then hybridized to DNA capture probes on the electrode. The signal is then 
chemically amplified through a ligation reaction to tag miRNAs with the OsO2 nanoparticles that 
efficiently catalyze the oxidation of hydrazine resulting in an electrocatalytic activity at 0.10 V. This 
procedure greatly enhances the sensitivity leading to detect amounts of miRNAs as low as 80 fM. The 
assay was successfully applied to analyze let-7b, mir-106 and mir-139 in total RNA extracted from 
HeLa cells reducing the amount of sample needed to nanograms [45]. The same group developed 
another electrical detection strategy based on a microscopic platform made with interlocking gold and 
titanium microelectrodes with wells in between. Capture probes of peptide nucleic acid (PNA) are 
chemically fixed into these wells and hybridized with the target miRNAs. The anionic nature of the 
miRNA phosphate backbone then catalyzes the formation of polyaniline (PAn) nanowires from a 
solution of cationic aniline particles, so that the conductance of the deposited PAn nanowires 
correlates directly with the amount of the captured miRNAs. By using total RNA extracted from 
different cancer cell lines, the target miRNAs can be quantified in a range from 10 fM to 20 pM with a 
detection limit of 5.0 fM [46]. 
More recently Peng et al. [47] further ameliorated this strategy proposing a novel protocol enabling 
electrical detections with minimal background. In this approach, target miRNAs are tagged with RuO2 
nanoparticles that serve as a catalyst for the polymerization of aniline, allowing selective PAn 
deposition exclusively at the hybridized miRNA strands thus producing a clean background and a high 
signal-to-noise ratio. 
An innovative nanotechnology-based method that utilizes Surface Plasmon Resonance Imaging 
(SPRI) has been developed by Fang et al.[48]. They described a novel approach that combines surface 
poly(A) enzyme chemistry and nanoparticle-amplified SPRI measurements for the miRNA detection on 
LNA microarrays. The target miRNAs are hybridized on LNA microarray and poly(A) tails are added to 
the miRNAs by poly(A) polymerase reaction. Poli(T) oligo-modified gold nanoparticles (GNPs) are then 
adsorbed onto poly(A) tails for signal amplification and subsequently detected with SPRI. This 
methodology can be used to measure miRNAs present in total RNA samples with excellent sensitivity at 
attomole levels, resulting about 50 times more sensitive than the fluorescence-based microarray [48]. 
In order to develop a simple read-out and high sensitive method that does not require expensive 
equipment, Yang et al. [49] proposed a colorimetric approach based on gold nanoparticles. This 
method utilizes two probes, a biotinylated probe (capture probe) and a gold nanoparticle probe 
hybridized to the complementary target miRNAs in a sandwich assay format. The complex is then 
immobilized onto the surface of a streptavidin-coated microplate and the signal of absorbed gold 
nanoparticles is amplified by silver enhancement and recorded with colorimetric absorbance by a 
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microplate reader. By this method, distribution of miR-122a/miR-128 in total RNA from mouse brain 
and liver tissue was detected and synthetic miRNA-122a was quantified with a detection limit of 10 
fM miRNA or 2 ng of total RNA [49]. 
Recently, the Raman enhancing property of GNPs has been exploited to develop a surface-enhanced 
Raman scattering (SERS)-based assay for miRNAs. However, SERS platforms based on GNPs has 
proven to be not useful for quantitative diagnostic assays due to low reproducibility [50]. To overcome 
this problem, alternative SERS enhancing substrates have been proposed. Driskell J. D. et al. examined a 
silver nanorod (AgNR) array prepared via oblique angle vapor deposition [51-53]. In their approach 
miRNA sequences are incubated with the silver nanorod array SERS substrate and SERS spectrum 
was analyzed. Different synthetic miRNAs (such as let-7 miRNAs, miR-16, miR-21, miR-24a,  
miR-133, miR-218 and miR-224) were analyzed with high specificity [53]. 
To date the number of new strategies that employ nanomaterials are growing rapidly [54,55], 
revealing these approaches to be the most promising for the development of miRNAs-based prognostic 
and diagnostic tools in cancer. 
3.3. qRT- PCR-Based Methods 
Among the several advantages of qRT-PCR, widely used for gene expression quantization [56,57], 
are the high level of sensitivity (only few picograms of starting material are needed), accuracy and 
practical ease that make qRT-PCR a powerful tool for miRNA detection as well. 
On the other hand, the main limit to extend this method to miRNA detection is represented by the 
very short length of mature miRNAs. In fact, the first approach used allowed to detect and quantize 
precursor molecules rather than mature miRNAs [58]. 
A stem-loop qRT-PCR based on TaqMan assay was developed by Chen and colleagues from 
Applied Biosystems and is currently commercialized [59]. This approach, obviously, shows all the 
advantages of conventional TaqMan qRT-PCR, such as sensitivity (only 25 picograms of starting RNA 
are needed), but it involves the use of a stem-loop primer during the reverse transcription reaction. 
Such an approach is specific for mature miRNA identification and allows discriminating between 
strictly related miRNAs. This method is also better than conventional TaqMan qRT-PCR in terms of 
reverse transcription efficiency and specificity. To date, stem-loop qRT-PCR is successfully and 
widely utilized to detect miRNA dysregulation in different cancer types [60-63]. 
In the same year, Raymond et al. [4]developed a very sensitive (femtomolar concentrations of 
starting RNA) SYBR Green qRT-PCR for the detection of mature miRNAs using Locked Nucleic 
Acid (LNA)-modified primers. Both stem-loop and SYBR Green qRT-PCR methods have the 
disadvantage to be quite costly.  
To develop a new cost-effective qRT-PCR approach for mature miRNA detection,  
Sharbati-Tehrani et al. [64] proposed a highly specific and sensitive method (called miR-Q), which 
neither requires the use of fluorophore probes, nor LNA-modified oligonucleotides. MiRNAs are first 
reverse transcribed and simultaneously elongated using a miRNA-specific oligonucleotide with 
5‟ overhang and then cDNA molecules are amplified using three DNA-oligonucleotides at different 
concentrations. This approach has been utilized to quantify miRNAs in different cancer cell lines and 
then for miRNA expression profiling of in vitro-fertilized bovine embryos [64,65]. A very simple and 
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convenient method is based on Poly(A)-Tailed Universal Reverse Transcription [66,67]. In this 
approach total RNA is first polyadenylated by poly(A) polymerase and then cDNA is synthesized by 
using a specific primer containing oligo dTs flanked by an adaptor sequence. Finally, the cDNA is 
amplified using a miRNA-specific primer and a universal primer.  
The above approaches are all low throughput methods. However in more recent years these 
approaches have been modified by high-throughput miRNA profiling. For example, Applied 
Biosystems Inc. provide TaqMan Low Density Array cards that simultaneously quantifies hundreds of 
miRNAs by TaqMan qRT-PCR reactions using Megaplex™ stem-loop primer pools for the miRNA 
reverse transcription step. Furthermore, Signosis Inc. has developed a highly sensitive and specific 
platform that combine oligo-ligation and SYBR green based qRT-PCR for multiple miRNA detection. 
These platforms are particularly attractive since they can be used extensively for clinical diagnosis.  
An example to simultaneously quantify different miRNAs in the same qRT-PCR reaction is the use 
of innovative probes, named molecular beacons. Molecular beacons are single-stranded probes with a 
stem-loop structure that recognize a specific target molecule [68,69]. The complementary sequence to 
the target is in the loop of the molecule, while the stem is formed by the annealing of two 
complementary sequences with a fluorophore linked to the end of one arm and a quencher linked to the 
end of the other one. Molecular beacons emit fluorescence only when they hybridize with the target, 
undergoing a spontaneous conformational reorganization that forces the fluorophore and the quencher 
to move away from each other. This approach is very sensitive to mismatches and, since probes can be 
linked with different fluorophores, is also helpful to simultaneously detect different target miRNAs. 
Molecular beacons have also been modified [70] to specifically quantify mature miRNAs. In this case 
when the probes hybridize with pre-miRNA or pri-miRNA, its fluorescence is quenced by a guanine in 
the target sequence, while hybridization of the probe with mature miRNA which has no 
complementary guanine results in fluorescent emission. This approach has been recently utilized for 
detection of miRNAs overexpressed during myogenic differentiation [71]. 
3.4. Amplification-Based Methods 
Here we discuss some promising miRNA detection strategies that require a PCR amplification step 
but do not involve real time quantitative analysis.  
The padlock-probes and rolling-circle amplification technology was initially developed by  
Nilsson et al. [72,73] and more recently improved by Jonstrup et al. [74] for detecting and quantifying 
miRNAs. Padlock probes are linear DNA probes where the terminal sequences are designed to be 
exactly antisense to the 5‟-end and the 3‟-end of a specific miRNA. After annealing with the miRNA 
the padlock-probe is circularized by a DNA ligase and then the miRNA is used as primer for rolling 
circle amplification. The method is very sensitive to mismatches and has the power to discriminate 
between closely related miRNAs. Moreover this technology is highly quantitative, specific and very 
inexpensive, since no specific equipments required. This approach has been successfully used to 
quantify different miRNAs including miR-16, miR-17-5p, miR-20a, miR-21, miR-27a and miR-92 [74]. 
Another example of amplification-based approach is the bead-based flow cytometric miRNA 
expression profiling [75]. In this approach miRNAs are first processed with a ligation reaction that 
adds adapter oligos to both 3‟ and 5‟ ends and then reverse transcribed with primers complementary to 
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the adaptor oligos. The resulting cDNA is amplified with biotinlyated forward primers, PCR products 
are hybridized with specific probes on fluorescent beads and finally analyzed by flow cytometry. This 
method has high accuracy, low costs and is useful for high-throughput miRNA profiling. This 
technique has been successfully applied to carry out a systematic expression analysis of  
217 mammalian miRNAs from 334 samples, including multiple human cancers [75]. In this work the 
data from the bead-based miRNA profiling allowed to distinguish tumors of different developmental 
origin and at different stages. Thus bead-based flow cytometric miRNA expression profiling seems to be 
a very interesting diagnostic tool for cancer, since it is also easy to implement in a routine clinical setting. 
3.5. Enzymatic-Based Methods 
In this section we analyze examples of miRNA profiling strategies that involve enzymatic activities 
different from DNA polymerase.  
A first promising approach included in this category is the splinted ligation method. It was 
originally developed by Moore and Query [76] and then Maroney et al. [77,78] adapted the technology 
to detect and quantify miRNA expression. Splinted ligation method is a sensitive and simple approach 
that also allows simultaneous processing of multiple samples. This method is based on the use of a 
couple of oligonucleotides named, the bridge and the ligation oligonucleotide respectively. The bridge 
oligonucleotide hybridize with the target miRNA and with a 5‟-end-radiolabeled ligation 
oligonucleotide. This allows the formation of a double-stranded structure with a nick on one strand that 
is ligated by T4 DNA ligase, thus labeling the template miRNAs while the unligated oligonucleotides 
is treated with a phosphatase to remove the 5‟-end labeling. Following the splinted-ligation reaction, 
labeled miRNAs and any residual-labeled ligation oligonucleotides can be separated and analyzed by 
denaturing gel electrophoresis. This approach has been successfully validated for different miRNAs 
including miR-21, miR-1, miR-9, miR-16, miR-20a, miR-21, miR-26a, miR-124a and miR-37 [77,78]. 
The main disadvantages of this technique are the use of radioactive labeling and the relatively low 
sensitivity. Other enzymatic-based methods that avoid the use of radioactive labeling have been proposed.  
For example, the enzyme-linked oligonucleotide assay (ELONA) was developed by Mora and  
Getta [79]. This assay is based on the use of miRNA probes and miRNAs labeled at the 3‟ end with a 
31-base oligonucleotide complementary to the outer arms of horseradish peroxidise (HRP)-conjugated 
DNA dendrimers. MiRNA probes are first spotted onto microtiter plates and then are hybridized with 
labeled miRNAs. HRP-conjugated dendrimers are finally used as detection molecules for signal 
amplification. ELONA takes very short experimental time, it is no expensive and it has a high sample 
throughput, but it has relatively low sensitivity (require more than 30 ng/well of sample). This 
approach has been successfully used to quantify tissue-specific expression of miR-1 in heart tissue, 
miR-122 in liver and miR-124a in brain [79]. 
An alternative to ELONA is the Bioluminescence miRNA detection method [80]. It is a competitive 
solid-phase hybridization-based method that makes use of the bioluminescent protein Renilla (Rluc) as 
label. This method is simple, rapid and sensitive with a detection limit in the order of 1 fmol. This 
approach has been successfully applied for determination of miR-21 in both human breast 
adenocarcinoma MCF-7 and non tumorigenic epithelial MCF-10A cellular extracts [80]. 
Cancers 2011, 3              
 
1889 
Other interesting enzymatic-based methods are the RNA-primed Array-based Klenow Enzyme 
assay (RAKE) [81] and the invader assay [82]. RAKE is a new method for high-throughput miRNA 
detection that is even more specific than other microarray-based expression profiling platforms. An 
oligonucleotide with a 5‟ spacer, covalently linked onto a glass platform, followed by a antisense 
probe complementary to the target miRNA that permits forming double stranded hybrids. Following 
exonuclease I degradation of unbound single stranded oligos, the miRNA bound to the probe is used as 
primer for Klenow fragment of DNA polymerase I, which catalyzes the addition of biotin-conjugated 
dATP onto the spacer template with an increase of the signal without any need of PCR amplification 
of the template. RAKE assay was used to profile miRNAs from normal human adult and fetal brains 
and from reactive astrocytosis and oligodendroglial tumors. It is also a sensitive method since it 
requires as low as 10 pg of starting RNA [81]. 
The invader assay is a detection technology developed by Allawi et al. [82] and based on the use of 
a structure-specific 5‟ nuclease (Cleavase) and a final fluorescence measurement. The miRNA target is 
first hybridized with a specific probe and an Invader oligonucleotide, designed to form an overlap-flap 
structure, substrate of the Cleavase. After the cleavage the flap fragment is released and a second 
overlap-flap structure is formed by the annealing of the flap fragment and a FRET oligonucleotide, 
linked to a fluorophore and a quencher, to a secondary reaction template. Then the Cleavase separate 
the fluorophore from the quencher on the FRET oligonucleotide, thus generating a fluorescence signal. 
This is a very simple and rapid approach (requiring only 2–3 hours of incubation), able to discriminate 
between precursor and mature miRNAs and also between closely related miRNAs, but it has the 
disadvantage to be less specific and sensitive than qRT-PCR-based methods (at least 50 ng of total 
RNA as template are required). Invader assay has been successfully applied for the detection of several 
miRNAs in cancer [13] and has been also modified for high-throughput miRNA profiling [83,84]. 
3.6. Deep Sequencing-Based Methods 
In recent years innovative deep sequencing technologies, originally used for genomic sequencing [85], 
have been also applied for simultaneous sequencing of up to millions of miRNA molecules. These 
include the 454 Genome Sequencer (Roche Applied Science, Basel CH) based on pyrosequencing, the 
Illumina Genome Analyzer (Illumina Inc., San Diego, CA, USA) based on Solexa technology and the 
SOLiD platform (Applied Biosystems, Inc., Foster City, CA, USA), a ligation-based sequencing. For 
all different high-throughput systems small RNA cDNA library preparation is a critical point and the 
following basic steps are required: (1) total RNA isolation; (2) small RNAs enrichment; (3) 3‟ and a 5‟ 
adaptor ligation (platform-specific); (4) reverse transcription; (5) PCR amplification by minimal 
rounds to avoid library bias; (6) sequencing [86]. 
In the 454 and in the SOLiD technologies an adaptor-flanked library is amplified by an emulsion 
multi-template PCR using a single primer pair, corresponding to the adaptor sequences. One PCR 
primer is 5‟-linked to the surface of micron-scale beads, included in the reaction. After PCR 
amplification, each bead will bear on its surface PCR products corresponding to a single molecule 
from the template library. These clonally amplified beads can then be used as template for features for 
454 or SOLiD sequencing platform. 
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With the 454 platform beads are randomly deposited on the wells of a microarray and sequenced by 
pyrosequencing. In this approach in each cycle a single nucleotide is introduced and then a substrate 
(luciferin, adenosine 5‟-phosphosulphate) is added to produce light signal at wells where polymerase 
drives the incorporation of the nucleotide. 
Instead, with the SOLiD platform, beads are used to create a disordered, dense array of sequences 
and in each sequencing cycle is introduced a partially degenerate population of fluorescently labeled 
octamers. In this population the label correlates with the identity of the central 2 bp of the octamer. 
Several such cycles will iteratively interrogate an evenly spaced, discontiguous set of bases. 
Finally in the Solexa technology an adaptor-flanked library is amplified by a bridge PCR, in which 
primers are linked to the surface of a solid substrate by a flexible linker. At the end of the PCR 
reaction are generated different clonal clusters each containing ~1,000 copies of a single member of 
the starting library. These clusters are then sequenced. Each sequencing cycle includes the 
simultaneous addition of a mixture of four fluorescent labeled deoxynucleotides modified with a 
reversibly terminating moiety at the 3‟ position. A modified DNA polymerase drives synchronous 
extension of primed sequences and then the results are acquired by imaging in four channels. 
These strategies allow fast evaluation of absolute miRNA levels and are also able to identify novel 
miRNAs, but to date they are still costly. In addition, since some errors can be introduced at several 
steps, limiting the accuracy of the analysis, sequencing results must be validated by alternative 
methods such as qRT-PCR. 
3.7. Methods for Detection and Characterization of Circulating miRNAs 
Recently, circulating miRNAs are emerging as very promising biomarkers for cancer [29,30], since 
they are abundant, tissue specific and relatively stable. Thus, several methods have been recently 
proposed to detect miRNAs in serum, plasma, urine and other human body fluids (Figure 2). 
Noteworthy the use of body fluids as biological materials for miRNA assays has the main advantage to 
be noninvasive or minimally invasive approaches.  
High-throughput profiling techniques such as Solexa sequencing, miRNA microarray and bead-based 
miRNA profiling are effective tools for quantification of circulating miRNAs. However, because of the 
rather high amounts of serum required, high-throughput techniques are mainly used for initial screening 
analysis. For circulating miRNA detection a higly promising strategy has been recently developed which 
combines Solexa sequencing or oligonucleotide microarray with the qRT-PCR [33,87,88] thus 
exploiting the high specificity and sensitivity of the TaqMan stem-loop qRT-PCR based method. 
In addition, to make easier the detection of circulating miRNAs, new techniques have been recently 
developed. By performing miRNA detection through an electrochemical genosensor, Lusi et al. [89] 
were able to directly detect miRNAs without the need of PCR and a labeling reaction, with an assay 
simple, very fast and ultrasensitive (detection limit of 0.1 pmol). Further developing these and other 
approaches will certainly enable the application of circulating miRNAs as biomarkers for cancer 
diagnosis. 
However, a common drawback of all these approaches remains the lack of a house-keeping miRNA 
for normalization of circulating miRNAs that, in contrast to tissue or cellular miRNAs, cannot be 
normalized against U6 since it is present in a very low concentration in serum and plasma [31,90]. 
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Nevertheless, the normalization of the volume of serum or plasma samples has been proposed as an 
effective way to overcome such problems. The best approach is to normalize experimental miRNA 
data using spiked-in synthetic, nonhuman mature miRNA from C. elegans or plants as control [91]. 
Figure 2. Main methods used for circulating miRNA detection. 
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4. Conclusions 
In the last decade the biologic role of miRNAs as „„oncomirs‟‟ or „„tumor suppressors‟‟ has 
generated an enormous expectation for their use in cancer diagnosis, prognosis and treatment. As a 
consequence the demand for miRNA profiling strategies continues to increase exponentially. 
An effective method for miRNA profiling should: (i) involve easy and rapid experimental 
protocols; (ii) require minimum sample quantity; (iii) have a high specificity and sensitivity with a 
large measurement dynamic range from sub-femtomolar to nanomolar concentrations and (iv) have 
low cost. Even if this ideal technique does not yet exist, all the methods summarized in this review 
address these issues through various strategies. 
Furthermore the detection of circulating miRNAs in serum, plasma, urine and other body fluids is 
now emerging as a promising novel tool to improve cancer screening. Although the field of circulating 
RNA research is still in its infancy, they show a great potential since they are stable molecules, easily 
accessible and they can be collected in a relatively noninvasive manner. 
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Abstract: Nucleic acid-based aptamers have been
shown as high-affinity ligands and potential antago-
nists of disease-associated proteins. Aptamers, iso-
lated from combinatorial libraries by an iterative in
vitro selection process, discriminate between closely
related targets and are characterized by high speci-
ficity and low toxicity thus representing a valid
alternative to antibodies to target specific proteins of
biomedical interest. Moreover, they are non-
immunogenic and can be easily stabilized by chemi-
cal modifications thus expanding their therapeutic
potential. Here, we will focus on the structural and
functional features of aptamers that have entered
the clinical development pipeline together with those
aptamers holding great potential as therapeutics in
preclinical studies. The future perspectives of
aptamers as therapeutics will be discussed as well.
[Discovery Medicine 11(61):487-496, June 2011]
Introduction 
Innovative targeted therapeutic strategies aim at devel-
oping new molecules with high affinity and specificity
with suitable pharmacokinetic properties for in vivo
applications. In this perspective an emerging attractive
class of targeting molecules is represented by single-
stranded nucleic acid ligands, named aptamers, being
able to bind with high affinity to specific protein or
non-protein targets by folding into complex tertiary
structures.
Aptamers have a number of important advantages over
proteins as therapeutic reagents (Cerchia and de
Franciscis, 2010; Missailidis and Hardy, 2009). Most
importantly, they are readily synthesized chemically,
thus avoiding the use of animal cells, and therefore are
easier to characterize than antibodies produced by
recombinant means. The SELEX (Systematic Evolution
of Ligands by EXponential enrichment) technology for
the production of aptamers starts with the synthesis of a
nucleic acid library of a large sequence complexity
(generally between 1013 and 1015 members) followed
by the selection for oligonucleotides that are able to
bind at high affinity to the target molecule. As schema-
tized in Figure 1, a typical SELEX experiment includes
reiterated rounds of: (1) incubating the library with the
target molecule; (2) partitioning nucleic acids bound
specifically to the target molecule from unbound
sequences; (3) dissociating the nucleic acid-protein
complexes; and (4) amplifying of the nucleic acids pool
enriched for specific ligands. After the final round, the
PCR products are cloned and sequenced to subsequent-
ly identify the best binding sequences. Due to the fact
that the specific, three-dimensional arrangements of a
small number of contact points of the aptamer, rather
than a general affinity for the sugar-phosphate back-
bone of the nucleic acid, mediate the target-aptamer
interaction. Aptamers can achieve high target selectivi-
ty. In addition, the binding characteristics of aptamers
can be influenced by the type of the experimental sys-
tem used for the selection and counter-selection (deple-
tion of aptamers that bind to non-target molecules). As
a result, aptamers show binding affinities in the low
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nanomolar to picomolar range and are thus comparable
to those of antibodies; but different from antibodies,
they are sufficiently stable and can be readily modified
chemically to further enhance their stability, bioavail-
ability, and pharmacokinetics (Keefe and Cload, 2008).
Moreover, aptamer immunogenicity has never been
reported (Foy et al., 2007). This property is based on
the fact that antibodies to synthetic oligonucleotides are
not generally produced and, in addition, the innate
immune response against non-self RNAs does not
hinder aptamer therapy because 2′-modified
nucleotides abrogate Toll-like receptor responses (Yu et
al., 2009).
Since their first description in the early 1990s
(Ellington and Szostak, 1990; Tuerk and Gold, 1990),
aptamers have been generated against a wide variety of
targets (Keefe et al., 2010; Thiel and Giangrande, 2009)
ranging from small chemical compounds to cells,
including parasites and bacteria, tissues, and more
recently, by means of in vivo-SELEX, even a tumor
implanted in mice (Mi et al., 2010).
In this review we will focus on aptamers generated
against targets of therapeutic interest with a major
emphasis on those that are currently in clinical develop-
ment. Their structural and functional features will be
discussed and compared to traditional therapies.
Translating Aptamers to Clinic
One main advantage of using aptamers for applications
in clinic is that nucleic acids can support chemical mod-
ifications apt to optimize their in vivo stability and per-
sistence in physiological condi-
tions, whilst maintaining their
structure and function.
Since oligonucleotides, especially
RNAs, are rapidly degraded by
nucleases in whole organisms
resulting in a very short half-life in
the blood, a variety of approaches
have been recruited to improve
their stability (Keefe and Cload,
2008). The most effective modifica-
tions to circumvent this limitation
are the substitutions at the 2′-ribose
of the pyrimidines that are mainly
affected by serum nuclease degra-
dation. RNA-aptamers containing
2′-fluoro and 2′-amino pyrimidine
(2′-F-Py and 2′-NH2-Py, respec-
tively) can be generated by per-
forming the selection in the
presence of 2′-modified nucleotides
(Chelliserrykattil and Ellington,
2004). Even if pyrimidine-modified
aptamers show considerable
increase in serum stability in the
absence of other modifications,
introduction of 2′-O-Metyl purines
(Burmeister et al., 2005) and
changes in the internucleotide link-
ages (such as the use of phospho-
rothioate) and in the nucleobases
(for example, the substitution of
uridine at position 5) as well as the
capping at the oligonucleotide 3′-
terminus, have been reported
Discovery Medicine, volume 11, Number 61, June 2011
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Figure 1. Schematic representation of SELEX technology. The RNA/DNA
aptamer library contains a variable region flanked by two constant regions.
These constant regions include primer sites for PCR amplification and a
consensus promoter for the T7-RNA polymerase (in the case of an RNA
library). The library is used for the selection process (see text for details).
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(Keefe and Cload, 2008).
Further, the use of locked nucleic acids (LNA), contain-
ing a methylene bridge to connect the 2′-O to the 4′-C,
increases the stability of base pairing, stabilizing the
duplex and enhancing the resistance to nuclease. For
example the introduction of LNA-modifications in the
anti-tenascin C (TN-C) aptamer significantly improves
its plasma stability of approximately 25% and enhances
the tumor uptake (Schmidt et al., 2004).
An interesting application of the SELEX process is
based on the use of the mirror-image of an intended tar-
get molecule (e.g., an unnatural D-amino acid peptide)
as target for the selection, followed by the chemical
synthesis of the mirror-image of the selected sequence,
named spiegelmers (Eulberg and Klussmann, 2003).
Since they are enantiomers of natural nucleic acids,
they are not recognized by nucleases. Two aptamers in
clinical trials (NOX-A12 and NOX-E36) are
spiegelmers (see below and Table 1).
Even if the low molecular weight of aptamers allows
cost-effective chemical synthesis, low immunogenicity,
and good target accessibility, it renders them suscepti-
ble to a rapid clearance by renal filtration. To overcome
this problem, the most used strategy is to increase the
size of the aptamers by conjugation with polyethylene
glycol (PEG) (Healy et al., 2004). As an example, 40
kDa PEG conjugation to anti-vascular endothelial
growth factor (VEGF) aptamer enhances its half-life
from 2 hours to 1 day in rodents (Burmeister et al.,
2005) whereas the half-life was 10 days when adminis-
tered to humans (see prescribing information for
Macugen).
As discussed below, the U.S. Food and Drug
Administration (FDA)-approved aptamer, Macugen, as
well as all the aptamers in clinical trials, except for one
(Nu172), possess several of these modifications.
Aptamers in Clinical Trials
To date, nine RNA and DNA-aptamers have entered the
clinical development pipeline for treating a number of
diseases in different pathologic states (Table 1).
Developing aptamers for age-related macular degen-
eration (AMD)
The most successful therapeutic application of an
aptamer is represented by the RNA-aptamer commer-
cially known as Macugen (or pegaptanib, marketed by
Eyetech Pharmaceuticals/Pfizer) for the treatment of
exudative AMD, the form of AMD characterized by the
formation of a neovascular membrane leaking blood
and fluid under the retina with consequent destruction
of the macula and loss of vision (Ng et al., 2006). The
Table 1. Aptamers in Clinical Trials
Aptamer Name Company Target Indication Clinical Stage
Macugen
(Pegaptanib)
Eyetech Pharmaceuticals/
Pfitzer
VEGF-165 AMD
Diabetic retinopathy
Approved
Phase III
E10030 Ophthotech
Corp./Archemix Corp.
PDGF-B AMD Phase II
ARC1905 Ophthotech
Corp./Archemix Corp.
C5 AMD Phase I
ARC1779 Archemix Corp. vWF TMA Phase II
NU172 ARCA Biopharma/
Archemix Corp.
Thrombin Acute coronary artery bypass surgery Phase II
REG-1
(RB006/RB007)
Regado Biosciences/
Archemix Corp.
Factor IXa Percutaneous coronary intervention Phase II
NOX-A12 NOXXON Pharma SDF-1α Lymphoma patients (undergoing
autologous stem cell transplantation)
Phase I
NOX-E36 NOXXON Pharma CCL2 Type 2 diabetes and diabetic
nephropathy
Phase I
AS1411
(AGRO001)
Antisoma/Archemix Corp. Nucleolin AML Phase II
490
Discovery Medicine, volume 11, Number 61, June 2011
New Insight into Clinical development of Nucleic Acid Aptamers
aptamer, approved by the FDA in December 2004,
binds and antagonizes the action of VEGF-165, the
VEGF isoform preferentially involved in pathological
ocular neovascularization. With the intent to improve
the pharmacodynamic and pharmacokinetic properties
of this 28-mer aptamer, it was chemically modified
with 2′-F-Py and 2′-OMe-Pu, capping, and linkage to a
40 kDa branched PEG molecule (Figure 2), which
increases the intravitreal residence time of the molecule
(Ng et al., 2006). Clinical effectiveness of Macugen
was studied in two controlled, double-masked, random-
ized studies in patients with exudative AMD. Patients
were randomized to receive sham or 0.3 mg (licensed
dose), 1 mg, or 3 mg Macugen, administered by intrav-
itreal injections every 6 weeks for 48 weeks. In both of
these studies, one year of 0.3 mg Macugen treatment
resulted in decreasing of the growth of mean total
lesion size and choroidal neovascular network size.
Further, patients who were re-randomized to discontin-
ue Macugen after one year lost visual acuity during the
second year (Chakravarthy et al., 2006).
Different studies have been recently carried out to
assess the clinical effectiveness and cost-effectiveness
of Macugen and ranibizumab (Lucentis, Genentech), a
monoclonal antibody targeting all isoforms of human
VEGF-A and approved in 2006 by the FDA for the
treatment of exudative AMD. Both drugs show compa-
rable therapeutic efficacy and mild adverse events,
while the economic evaluation varies considerably
depending on the methodology for cost-effectiveness
used in different studies (Colquitt et al., 2008; Mitchell
et al., 2011).
In phase III clinical trials Macugen demonstrated to be
effective for diabetic retinopathy treatment, resulting in
improved vision and reduced macular edema.
Furthermore, Macugen is also a potential candidate for
the treatment of highly vascularized tumors, even if the
effectiveness of a systemic administration is still
unclear.
In addition to the RNA-aptamer Macugen, a DNA-
aptamer directed against the platelet-derived growth
factor-B (PDGF-B) has been proposed for exudative
AMD treatment (Green et al., 1996). This aptamer,
named E10030 (Ophthotech Corp./Archemix Corp.), is
a 29-mer oligonucleotide containing 2′-F-Py and 2′-
OMe-Pu, 5′-conjugation with a 40 kDa PEG molecule,
and capping at the 3′-terminus with an inverted
nucleotide. In an open-label phase I clinical study,
E10030, administered to AMD patients intravitreously
as a monotherapy or in combination with ranibizumab,
demonstrated to be effective and well tolerated with no
evidence of adverse events. As these results are prom-
ising, phase II clinical trials are currently being devel-
oped.
Although anti-VEGF therapy is the first line of defense
against exudative AMD, anti-inflammatory agents may
provide an adjunct or alternative mechanism to sup-
press the inflammatory processes driving AMD pro-
gression. Indeed, the anti-complement component 5
(C5) agent ARC1905 RNA-aptamer (Ophthotech
Corp./Archemix Corp.) is currently in phase I clinical
trial for AMD. It is a 39-mer oligonucleotide
chemically modified with 2′-F-Py, 5′-conjugation with
Figure 2. Macugen sequence and secondary structure. The aptamer modifications are from published reported.
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40 kDa PEG, and 3′-terminus capping with an inverted
nucleotide to improve its pharmacokinetic and pharma-
codynamic properties (Biesecker et al., 1999). The
aptamer works by inhibiting C5, a central component
of the complement cascade, which plays multiple roles
in innate immunity and inflammatory diseases and
whose aberrant activation is implicated in the patho-
genesis of both exudative and dry (nonvascular) AMD
(Nozaki et al., 2006). A multicenter study in which
ARC1905 is administered with ranibizumab by intrav-
itreal injection in patients with exudative AMD is
ongoing. In addition, a study investigating ARC1905 in
patients with dry AMD was initiated in 2009.
Targeting blood clotting
Among aptamers currently in clinical trials, some are
directed against blood clotting factors. The ARC1779 is
a DNA-aptamer directed against the A1 domain of von
Willebrand factor (vWF) and is able to inhibit its bind-
ing to the glycoprotein Ib receptors on platelets, result-
ing in an antithrombotic effect (Diener et al., 2009 ).
ARC1779 is a 40-mer oligonucleotide chemically mod-
ified with a single phosphorothioate linkage to increase
target affinity, 5′-conjugation with a 20 kDa PEG mol-
ecule to reduce renal filtration, and capping at the 3′-
terminus with an inverted nucleotide and 2′-OMe-Pu. It
has been developed by Archemix Corp. for the treat-
ment of thrombotic microangiopathies (TMA), a group
of diseases that include thrombotic thrombocytopenic
purpura and hemolytic-uremic syndrome, caused by
increased vWF activity. In phase I clinical trials on
healthy volunteers, in which ARC1779 has been
administered intravenously at different doses, no seri-
ous adverse events were observed and the aptamer
resulted in inhibiting plasma vWF activity and platelet
function (Gilbert et al., 2007). Currently phase II clini-
cal trials are analyzing the effect of ARC1779 on
platelet function and vWF activity in patients with
TMA and the eventual adverse reactions. The therapeu-
tic utility of this aptamer is pronounced given the
absence of a drug treatment approved for any form of
TMA.
Another aptamer that prevents blood clotting is Nu172,
a 26-mer DNA aptamer, directed against thrombin with
no chemical modifications in its molecular structure. In
phase I clinical trials the aptamer resulted in inducing
an effective and dose-dependent anticoagulation effect
with a favorable safety profile. This aptamer is current-
ly being evaluated in phase II clinical trials by ARCA
Biopharma/Archemix Corp. as an anticoagulant for use
during acute coronary artery bypass surgery. Being
unmodified and unstable in vivo, it has to be adminis-
tered by continuous intravenous infusion.
REG-1 (RB006/RB007) is a therapeutic agent consist-
ing of an RNA-aptamer (34-mer) directed against the
coagulation factor IXa (RB006) and a single stranded
RNA oligonucleotide (17-mer) complementary to the
52 -terminal region of RB006 aptamer (RB007). The
inhibition of the factor IXa, consequent to RB006
administration, is blocked by RB007 treatment, thus
permitting a time-controllable therapy (Rusconi et al.,
2004). RB006 is modified with 2′-F-Py, conjugation
with 40 kDa PEG, and 3′-terminus capping with an
inverted nucleotide while RB007 is modified with 2′-
OMe-Pu. REG-1 is being developed by Regado
Biosciences/Archemix Corp. Phase I clinical trials
showed that it is effective and well-tolerated in both
healthy volunteers and patients with stable cardiovas-
cular disease taking oral antiplatelet drugs, such as
aspirin and clopidogrel (Chan et al., 2008a; Chan et al.,
2008b; Dyke et al., 2006). Phase II clinical trials have
been completed in patients affected by acute coronary
syndromes undergoing percutaneous coronary inter-
vention. In these studies the effectiveness of REG-1 has
been compared to that of heparin but results are not yet
available.
Development of unnatural enantiomers
NOXXON Pharma developed two anti-chemokine
spiegelmers, NOX-A12 and NOX-E36, for the treat-
ment of hematologic tumors and complications of type
2 diabetes, respectively. NOX-A12 is a 45-mer L-RNA
spiegelmer conjugated with 40 kDa PEG and is direct-
ed against the stromal cell-derived factor-1α (SDF-1α),
a chemokine which attracts and activates immune and
non-immune cells that bind to chemokine receptors
CXCR4 and CXCR7. There are lines of evidence indi-
cating that the inhibition of this binding could be an
effective therapeutic tool for the treatment of hemato-
logical and solid tumors (Hirbe et al., 2010; Kryczek et
al., 2007). A phase I single dose study demonstrated
that NOX-A12 was safe and well-tolerated up to the
highest tested dose (10.8 mg/kg) if administered intra-
venously to healthy volunteers. Pharmacodynamic
analysis from this study also revealed a long lasting and
dose dependent mobilization of white blood cells and
CD34 positive cells. A phase I multiple ascending dose
study in healthy subjects is ongoing to compare the
mobilization of hematopoietic stem cells obtained with
NOX-A12 alone with that obtained in combination
with filgrastim, a granulocyte colony-stimulating factor
analog used to stimulate the proliferation and differen-
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tiation of granulocytes in neutropenia conditions. The
results from this study will establish the basis for further
development of NOX-A12 for the treatment of lym-
phoma patients undergoing autologous hematopoietic
stem cell transplantation.
NOX-E36 is a 40-mer L-RNA conjugated with 40 kDa
PEG (Maasch et al., 2008; Ninichuk et al., 2008) that
interacts with the chemokine ligand 2 (CCL2), a protein
involved in the recruitment of monocytes and T cells to
sites of injury and inflammation. CCL2 has recently
been introduced as an “adipokine” playing an important
role in obesity and complications of type 2 diabetes
(Rull et al., 2010). In a phase Ia study the aptamer has
been administered by both intravenous and subcuta-
neous injection up to a maximum dose of 2 mg/kg in
healthy volunteers. Results of this study have shown
that NOX-E36 was safe and well tolerated at all doses
tested in both administration routes; furthermore, the
drug was able to induce a dose-dependent decrease of
peripheral blood monocytes. A phase Ib clinical trial is
currently ongoing to establish the effectiveness of
NOX-E36 in the treatment of patients affected by type
2 diabetes with multiple complications, including dia-
betic nephropathy. In this study healthy volunteers or
type 2 diabetic patients are treated with NOX-E36 intra-
venously and the safety, tolerability, pharmacokinetics,
and pharmacodynamics of the drug will be evaluated.
Cancer therapeutics
Very interesting for cancer therapy is the AS1411 DNA-
aptamer (AGRO001), directed against nucleolin (Bates
et al., 2009), a ubiquitous intranuclear and cytoplasmic
phosphoprotein implicated in cellular proliferation and
often overexpressed on the surface of tumor cells. This
aptamer is a 26-mer guanine-rich oligonucleotide
(GRO), which in solution folds into quadruplex struc-
tures that make it very stable and resistant to degrada-
tion by serum enzymes (Dapic et al., 2003). AS1411
was identified among a panel of GROs exposed to can-
cer cells and screened for antiproliferative activity.
Once bound to nucleolin, the AS1411 aptamer is taken
into the cancer cell, where it causes cellular death by
apoptosis through inhibiting nuclear factor-κB (NF-κB)
(Girvan et al., 2006) and Bcl-2 (Soundararajan et al.,
2008) pathways. In phase I and II clinical trials, con-
ducted by Antisoma/Archemix Corp., AS1411 showed
its effectiveness as an anticancer therapy for different
solid human malignancies as well as for acute myeloid
leukemia (AML), and was well-tolerated by intravenous
administration. On the basis of these positive results,
the aptamer is currently in a phase IIb trial to evaluate
its effectiveness in combination with high-dose cytara-
bine in patients with relapsed and refractory AML.
Aptamers of Therapeutic Interest Not Yet
Investigated in Clinical Trials
The enormous diversity of random oligonucleotide
libraries can exceed the diversity of antibodies in the
mammalian genome by several orders of magnitude. In
this regard, numerous aptamers have already been
selected against a wide array of proteins, and the possi-
bility of acquiring aptamers against proteomes has been
advanced by automation of the in vitro selection. In this
section, we discuss the aptamers that appear as excellent
drug candidates for a wide range of human pathologies
(Table 2).
Among them, several aptamers now appear as promis-
ing molecules to target specific cell-surface signaling
receptors of cancer cells in clinical diagnosis and thera-
py. Dysregulation of these receptor proteins by over-
expression or constitutive activation promotes prolifer-
ation and/or survival of tumor cells, and thus their inhi-
bition using neutralizing aptamers represents an innova-
tive method to interfere with the growth of many human
malignancies. Aptamers against the human transmem-
brane receptors such as epidermal growth factor recep-
tor 3 (Her3/ErbB3) (Chen et al., 2003), transforming
growth factor β type III receptor (TGF-β type III)
(Ohuchi et al., 2006), and receptor tyrosine kinase Ret
(Cerchia et al., 2005; Vento et al., 2008) have been gen-
erated that inhibit their target in vitro. Other examples
of aptamers against cancer cell surface epitopes show-
ing promise as anticancer therapeutics include the
RNAs against the prostate-specific membrane antigen
(PSMA) (Lupold et al., 2002) and the TN-C, an extra-
cellular matrix protein that is overexpressed during dif-
ferent cellular processes including tumor growth
(Daniels et al., 2003; Hicke et al., 2001). Both of these
aptamers were shown to be effective as imaging agents
and delivery tools in preclinical studies in mouse
xenograft models of human tumors.
Apart from the therapeutic utility of those aptamers that
bind and consequently inhibit the activity of their target
proteins, another promising application of aptamers
against cell surface molecules is to employ their excel-
lent targeting properties to specifically deliver a drug to
a cell or tissue thus increasing the efficacy of a given
therapy as well as attenuating the overall toxicity of the
drug (Cerchia and de Franciscis, 2010; Zhou and Rossi,
2010). To date the best-characterized aptamers for tar-
geted delivery are the RNAs directed against PSMA
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(Lupold et al., 2002) that were conjugated with
nanoparticles (Farokhzad et al., 2004), quantum dots
(Chu et al., 2006b), toxin (Chu et al., 2006a), or small
interfering RNA (siRNA) (Chu et al., 2006c; Dassie et
al., 2009; Wullner et al., 2008) in order to drive these
functional molecules toward the surface of prostate
cancer cells. Furthermore, the list of aptamers of being
able to be internalized by cells and being used as deliv-
ery agents for cytotoxic cargos into cancer cells is
growing rapidly and now includes those against the
extracellular proteins involved in cancer protein tyro-
sine kinase 7 (PTK7) (Huang et al., 2009), nucleolin
(Ko et al., 2009), mucin 1 (MUC1) (Cheng et al., 2009;
Ferreira et al., 2009), and epidermal growth factor
receptor (EGFR) (Li et al., 2010).
In addition to the inhibitory aptamers, aptamers with
agonistic-like activity have also been generated (Table
2) (Dollins et al., 2008; McNamara et al., 2008).
McNamara et al. (2008) generated a bivalent molecule
by linking two monomeric aptamers against the co-
stimulatory T-cell receptor 4-1BB through the addition
of 21 complementary nucleotides to the 3′ end of each
aptamer. The resulting aptamer was effective to induce
dimerization and consequent activation of 4-1BB
receptor leading to immune response induction in vitro
and tumor regression in vivo.
A major challenge in cancer therapy is to distinguish,
with high accuracy, between closely related cell popu-
lations or even the same cell population under various
growth conditions or insults. In this respect, counter-
selection strategies can be adopted during cell-SELEX
in the pursuit of aptamers that can bind to and discrim-
inate between distinct cell types. Aptamers that discrim-
inate cells from distant tumor types, like T-cell acute
lymphocytic leukemia (ALL) versus B-cell lymphoma
(Shangguan et al., 2006) and small lung cancer cells
versus large cell lung cancer (Chen et al., 2008), have
been generated. Recently, we have developed a differ-
ential cell-SELEX to isolate a panel of RNA-aptamers
that bind human malignant glioblastoma cells, discrim-
inating them from non-tumorigenic glioblastoma cells
(Cerchia et al., 2009).
The great advances in cell-SELEX now offer the oppor-
tunity to develop innovative approaches to identify and
isolate subpopulations of cancer stem cells, an emerg-
Table 2. Aptamers of Therapeutic Interest Not Yet Developed in Clinic
Function Target Therapeutic Indication Reference
Antagonistic Extracellular Proteins
Ret
Her3/ErbB3
TGF-β type III
gp120
HIV-1 reverse 
transcriptase
CD4
BACE-1
Cancer
Cancer
Cancer
HIV infection
HIV infection
Immune modulation
Alzheimer's disease
Cerchia et al., 2005; Vento et al., 2008
Chen et al., 2003
Ohuchi et al., 2006
Dey et al., 2005
Li et al., 2008
Kraus et al., 1998
Rentmeister et al., 2006
Intracellular Proteins
NF-κB
E2F
β-catenin
Inflammatory disease and 
cancer drug resistance
Cancer and cardiovascular  
disease
Cancer
Lebruska and Maher, 1999; Mi et al., 2007
Giangrande et al., 2007
Lee et al., 2007
Delivery Tools PSMA
PTK7
MUC1
EGFR
TN-C
gp120
CD4
Cancer
Cancer
Cancer
Cancer
Cancer
HIV infection
HIV infection
Chu et al., 2006a; Chu et al., 2006b;
Chu et al., 2006c; Dassie et al., 2009;
Farokhzad et al., 2004; Wullner et al., 2008
Huang et al., 2009
Cheng et al., 2009; Ferreira et al., 2009
Li et al., 2010
Hicke et al., 2001
Neff et al., 2011; Zhou et al., 2011
Guo et al., 2005
Agonistic 4- IBB
OX- 40
Cancer
Cancer
McNamara et al., 2008
Dollins et al., 2008
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ing target of more effective cancer treatments (Guo et
al., 2007; Hoffmann et al., 2008).
Intracellular proteins of biomedical interest (Table 2)
can be targeted with aptamers (so-called intramers) as
well by means of strategies allowing their entry into
intracellular compartments (Giangrande et al., 2007;
Lebruska and Maher, 1999; Lee et al., 2007; Mi et al.,
2007).
A serious effort has been initiated to find aptamers as
novel therapeutics for diseases other than cancer, with
several groups of aptamers dealing with human immun-
odeficiency virus (HIV) infection and neurodegenera-
tive diseases. The aptamers against HIV reverse tran-
scriptase (Li et al., 2008) and glycoprotein gp120 (Dey
et al., 2005) reduce the HIV virus infectivity, and the
anti-CD4 (Kraus et al., 1998) receptor aptamer modu-
lates the immune response. Both anti-gp120 and anti-
CD4 aptamers have been also validated as delivery
agents for anti-HIV siRNAs resulting in the simultane-
ous inhibition of HIV infection and replication (Neff et
al., 2011; Guo et al., 2005; Zhou et al., 2011). Among
the aptamers against targets whose role has clearly been
established for neurological disorders are those against
β-secretase BACE-1 (Rentmeister et al., 2006),
amyloid fibril constituent Aβ (Rahimi and Bitan, 2010),
and prion protein PrP (Sayer et al., 2004).
Future Perspectives 
Although the aptamer technology was first described in
1990 (Ellington and Szostak, 1990; Tuerk and Gold,
1990), aptamers’ widespread acceptance in therapeutics
and diagnostics is still being realized. Indeed, despite
the continuous advances in SELEX technology that
now allow to easily generate aptamers against virtually
any protein, the list of aptamers in clinical development
is still limited. Because only one aptamer has been
approved and is in the market, the costs for large scale
production and modification of aptamers are still high
and are affected by the absence of an adequate techno-
logical platform for their development as therapeutics
and by a limited number of companies that are engaged
in their development. Indeed, to date, it is Archemix
Corp., a biopharmaceutical company that leads the
development of aptamers as therapeutics. It is the
owner of patents of aptamer technology and it collabo-
rates with other pharmaceutical companies (Regado,
Antisoma, ARCA Biopharma, and Ophthotech) to
develop and commercialize a pipeline of partnered
aptamers in the areas of cardiovascular disease, hema-
tology, and oncology.
As discussed in this review, aptamers have a number of
advantages in their clinical usage over their antibody
counterparts, and it is plausible that the global interest
for developing nucleic acid aptamer therapeutics will
increase in the next few years. Accordingly, a new tech-
nical market research report from BCC Research
(Nucleic acid aptamers for diagnostic and therapeutics:
global markets, BIO071, www.bccresearch.com) esti-
mated that the aptamer global market value of $236
million in 2010 will grow to nearly $1.9 billion in 2014,
for a 4-year compound annual growth rate of 67.5%.
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Abstract: RNA-based approaches are among the most promising strategies aimed at 
developing safer and more effective therapeutics. RNA therapeutics include small  
non-coding miRNAs, small interfering RNA, RNA aptamers and more recently, small 
activating RNAs. However, major barriers exist to the use of RNAs as therapeutics such as 
resistance to nucleases present in biological fluids, poor chemical stability, need of specific cell 
targeted delivery and easy entry into the cell. Such issues have been addressed by several 
recent reports that show the possibility of introducing chemical modifications in small RNAs 
to stabilize the molecular conformation and increase by several fold their integrity, while still 
preserving the functional activity. Further, several aptamers have been developed as excellent 
candidates for the specific recognition of cell surface targets. In the last few years, by taking 
advantage of recent advances in the small RNA field, molecular bioconjugates have been 
designed that permit specific targeting and may act as cargoes for cell internalization of small 
RNAs acting on gene expression that will be discussed in this review. 
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1. Introduction 
Innovative targeted therapeutic strategies aim at developing new molecules with high target affinity 
and specificity with suitable pharmacokinetic properties for in vivo applications. From this optic short 
non-coding RNAs were revealed to be attractive molecules. In the last decades significant advances 
have been attained in the knowledge of molecular mechanisms leading to selective inhibition of gene 
expression and protein function. However, in order to successfully translate RNA-based therapeutics to 
the clinic several challenges must be addressed, including appropriate stability in biological fluids, 
high efficiency and specificity of delivery, durable safety and target selectivity. 
Several classes of molecules have been characterized with potential applications as RNA 
therapeutics in the treatment of human diseases. These include ribozymes, RNA decoys, aptamers, 
small interfering RNA (siRNA) and microRNA (miRNA) [1]. 
The discovery of RNA-mediated interference (RNAi) for gene silencing has provided a powerful 
tool for loss-of-function studies and therapeutic opportunities [2,3]. RNA interference is a natural 
process of gene specific silencing that occurs in organisms ranging from plants to mammals as a defense 
against viruses. si/miRNAs are formed from longer precursor molecules as short double-stranded RNAs 
(dsRNAs) of 20–24 base pairs [4]. One strand that directs silencing is the guide strand while the other 
strand, named the passenger, is degraded. In the cytoplasm, the RNA-induced silencing complex 
(RISC) drives the guide strand of the dsRNA to hybridize with the target mRNA to prevent translation 
or induce degradation depending on the degree of complementarity [5]. Base pairing between siRNAs 
and their targets generally shows full complementarity whereas, with the exception of the 2–8 bases 
seed region at the 5’ terminus, miRNAs usually show partial complementarity with their targets. 
miRNAs have the capacity to target multiple genes simultaneously and regulate important biological 
processes including, transcription, cell cycle, cell growth, proliferation and apoptosis. They have been 
shown to be involved in the pathogenesis of diverse diseases including cancer, stroke, diabetes, 
diseases of the liver, kidney, and cardiovascular system as well as neurodegenerative and infectious 
diseases [6-8]. On the other hand siRNAs are the best characterized RNA-based reagents that have 
been developed for several disease including cancer, kidney, ocular, retinal and metabolic disorders. 
As a difference with siRNAs and miRNAs, the function of ribozymes and aptamers doesn’t involve 
the formation of the RISC. The hammerhead small ribozymes are nucleolytic oligonucleotides that 
recognize and excise a given target RNA molecule [9]. Aptamers constitutes an emerging attractive 
class of therapeutic molecules able to tightly bind to specific protein or non-protein targets by folding 
into complex tertiary structures [10,11]. 
Recognition by toll-like receptors (TLRs) in immune cells represents a major obstacle to the use of 
RNA-based therapeutics. However, immune recognition the immune response of single stranded 
siRNAs (ss-siRNA) or ds-siRNAs by TLRs can be bypassed by the replacement of only uridines with 
their 2′-fluoro, 2′-deoxy, or 2′-O-methyl modified counterparts without reducing their silencing 
potency [12-15]. In addition, immunogenicity has been found to be either absent or limited when 
1,000-fold higher doses of a nucleic acid aptamer than would be required clinically were administered 
to monkeys [16]. This property depends on the fact that antibodies to synthetic oligonucleotides are not 
generally produced and, in addition, the innate immunity response against non-self RNAs does not 
hinder aptamer therapy because 2’-modified nucleotides abrogate TLRs responses [17].  
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A major impediment to the clinical development of RNA drugs is the lack of an appropriate and 
high efficiency in vivo delivery strategy to guarantee intracellular target accessibility and specificity of 
delivery. The use of viral vectors, despite their high efficiency, has been impaired greatly due to the 
associated mutagenicity or oncogenesis, several host immune responses, and high cost of production. 
Therefore, non-viral vectors continue to draw significant attention despite their low efficacy. 
2. RNA-Based Therapies 
Currently, the list of oligonucleotides of therapeutic interest is growing rapidly with over one 
hundred clinical trials and two therapeutic oligonucleotides that have been already approved by U.S. 
Food and Drug Administration (FDA) and marketed, the Vitravene antisense antiviral and the 
Macugen RNA-based aptamer. Two classes of therapeutic oligonucleotides have predominantly been 
developed: siRNA and aptamers, and several of them are currently in clinical trials (Table 1). 
Table 1. siRNAs and aptamers in clinical trials. 
 Name Company Target (s) Therapeutic Indication 
Clinical 
Stage 
siRNAs 
TD101  
 
Pachyonychia Congenita 
Project 
Keratin 6A N171K 
mutant 
Pachyonychia congenita  Phase I  
QPI-1007  Quark Pharmaceuticals Caspase 2  
Non-arteritic anterior ischaemic 
optic neuropathy 
Phase I  
AGN211745  Sirna Therapeutics VEGFR1  
AMD 
Choroidal neovascularization 
Phase II  
PF-655  Quark  RTP801  
Diabetic macular oedema (DME), 
AMD 
Phase I  
SYL040012  Sylentis 
β2 adrenergic 
receptor  
Glaucoma  Phase II  
CEQ508  MDRNA β-catenin  Familial adenomatous polyposis Phase I  
ALN-PLK1  Alnyam Pharmaceuticals  PLK1  Liver tumours Phase I  
FANG  Gradalis Furin  Solid tumours Phase II  
CALAA-01  Calando Pharmaceuticals RRM2  Solid tumours Phase I  
SPC2996  Santaris Pharm. BCL-2  Chronic myeloid leukaemia  Phase II  
ALN-VSP02  Alnylam Pharmaceuticals 
VEGF,kinesin spindle 
protein  
Solid tumours Phase I  
NCT00672542  Duke University 
LMP2, LMP7, and 
MECL1  
Metastatic melanoma Phase I  
Atu027  Silence Therapeutics PKN3  
Advanced, recurrent or metastatic 
solid malignancies 
Phase I  
QPI-1002/I5NP  Quark Pharmaceuticals p53  Acute kidney injury Phase II  
TKM-ApoB  
Tekmira Pharmaceuticals 
Corp. 
APOB  Hypercholesterolaemia Phase I  
PRO-040,201  
Tekmira Pharmaceuticals 
Corp. 
APOB  Hypercholesterolaemia Phase I  
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Table 1. Cont. 
 Name Company Target (s) Therapeutic Indication 
Clinical 
Stage 
siRNAs 
SPC3649  Santaris Pharma miR-122  Hepatitis C virus Phase II  
pHIV7-shI-
TAR-CCR5RZ  
City of Hope Medical 
Center/Benitec 
HIV Tat protein, HIV 
TAR RNA, human CCR5 
HIV Phase 0  
ALN-RSV01  Alnylam Pharmaceuticals  RSV nucleocapsid  RSV in volunteers Phase II  
Aptamers 
Macugen 
(Pegaptanib) 
Eyetech 
Pharmaceuticals/Pfitzer 
VEGF-165 AMD 
Diabetc retinopathy 
Approved  
Phase III 
E10030 Ophthotech 
Corp./Archemix Corp. 
PDGF-B  AMD Phase II 
ARC1905  
 
Ophthotech 
Corp./Archemix Corp. 
C5 AMD Phase I 
ARC1779  Archemix Corp. vWF TMA Phase II 
NU172 
 
ARCA Biopharma/ 
Archemix Corp. 
Thrombin Acute coronary artery  
bypass surgery 
Phase II 
REG-1 
(RB006/RB007) 
Regado Biosciences/ 
Archemix Corp. 
Factor IXa Percutaneous coronary 
intervention 
Phase II 
NOX-A12  
 
NOXXON Pharma SDF-1α Lymphoma patients 
(undergoing autologous stem 
cell transplantation) 
Phase I 
NOX-E36  
 
NOXXON Pharma CCL2 Type 2 diabetes and diabetic 
Nephropathy 
Phase I 
AS1411 
(AGRO001) 
Antisoma/Archemix Corp. Nucleolin AML Phase II 
2.1. siRNAs 
Recently, the use of RNAi-based gene silencing has been demonstrated in humans for treatment of 
several diseases, as discussed in multiple recent reviews [18]. We report here only few not exhaustive 
examples of the possible therapeutic applications.  
Various clinical studies have explored the direct tissue delivery of siRNA into the eye for macular 
degeneration in humans. Among the growth factors implicated in the age-related macular degeneration 
(AMD) process, the vascular endothelial growth factor (VEGF) has been shown to be a major inducer 
of choroidal neovascularization [19]. Several studies have recently addressed the silencing of  
VEGF [20,21] or the VEGF receptor 1 (VEGFR1) [22] by RNA interference (RNAi) using either 
intravitreous/periocular injection of siRNA or using adenovirus backbones to allow stable endogenous 
transgene expression of short hairpin (sh)RNAs resulting in a potent reduction of VEGF or VEGFR1. 
Silencing of gene expression by RNAi has been extensively studied to develop innovative cancer 
therapeutic strategies. Indeed, many of the siRNAs are in different stages of development for the 
treatment of different kind of tumors. For examples, among the siRNA therapeutics for the treatment 
of solid tumors, CALAA-01 and Atu027, targeting the M2 subunit of ribonucleotide reductase and 
protein kinase N3, respectively, are in Phase I, whereas, FANG against Furin is in Phase II.  
Further, SPC2996 against BCL-2 is in Phase II for treatment of chronic myeloid leukemia  
Pharmaceuticals 2011, 4 1438 
 
(from http://ClinicalTrials.gov). As shown in Table 1, the number of possible applications of RNAi 
therapeutics are growing rapidly and now include also viral infections, respiratory, brain, skin and 
metabolic diseases.  
In recent studies, given the strong impact of siRNAs for therapeutic applications, a great effort is 
focused on the optimization of the efficacy of the siRNAs through relatively minor chemical and 
structural modifications to canonical siRNA. The final aim is to improve loading of the guide strand 
into the RNAi machinery and reduce off-target effects and competition with endogenous miRNAs. 
The group of Rossi [23-26] has reported pioneering studies demonstrating that Dicer substrate 
interfering RNA (dsiRNA) are more potent than classical synthetic 21-mer siRNAs, showing more 
robust formation of a high molecular weight complex known to contain Dicer and TRBP (two primary 
members of the RISC-loading complex). 
2.2. Aptamers  
Aptamers are short single-stranded DNAs or RNAs that like antibodies, bind with high affinity to 
specific targets by folding into complex tertiary structures. They have some important advantages over 
antibodies and other protein-based reagents as therapeutics. A number of these advantages stem from 
the fact that aptamers are generated by an iterative in vitro evolution procedure named Systematic 
Evolution of Ligands by EXponential enrichment (SELEX) avoiding the use of animals or cells.  
In addition, aptamers can be readily chemically modified to enhance their bioavailability and 
pharmacokinetics [27-29]. Further, as discussed above, another important advantage of RNA aptamers 
over proteins is the fact that RNA is much less immunogenic than proteins [16].  
The list of aptamers against important therapeutic targets is growing rapidly and some of them have 
already entered the clinical pipeline (see Table 1) for the treatment of different diseases [30-32]. The 
most successful therapeutic application of an aptamer is represented by Macugen (or pegaptanib, 
marketed by Eyetech Pharmaceuticals/Pfizer), an RNA-aptamer that binds and antagonizes the action 
of VEGF. The aptamer has been fully approved by the FDA in December 2004 for the treatment of 
exudative AMD. In order to translate this aptamer into the clinic, it has been chemically modified with 
2′-fluoropyrimidines (2′-F-Py), 2′-O-Me-purines (2′-O-Me-Pu) and polyethylene glycol (PEG) to 
generate a better therapeutic agent [33,34]. 
Many other aptamers, not yet approved by the FDA, are currently in clinical trials. For example other 
two aptamers, named E10030 and ARC1905, are in Phase II and Ι of clinical trials for the treatment of 
AMD, respectively. E10030 is a DNA-aptamer directed against the platelet-derived growth factor-B 
(PDGF-B) chemical modified with 2′-F-Py and 2′-OMe-Pu and PEG [35]; while ARC1905 is a  
RNA-aptamer targeting the complement component 5 (C5) containing 2′-F-Py and PEG [36,37]. 
Furthermore, different aptamers targeting blood-clotting factors seems to be effective anticoagulant 
agents. The ARC1779 is a DNA-aptamer directed against the A1 domain of von Willebrand factor, 
currently in phase II clinical trials for the treatment of thrombotic microangiopathies (TMA) [38,39]; 
while Nu172 is a chemical unmodified DNA-aptamer directed against thrombin, currently in phase II 
clinical trials to evaluate its potential use as an anticoagulant during acute coronary artery bypass surgery. 
Particularly interesting is REG-1, an aptamer targeting the coagulation factor IXa. This is the first 
case of a modulator-controlled aptamer able to provide a time-controllable therapy. REG-1 is a  
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two-part therapeutic agent, consisting of an RNA aptamer specific for the coagulation factor IXa 
(RB006) and a single stranded RNA oligonucleotide complementary to the RB006 aptamer (RB007). 
Aptamer inhibition of the factor IXa by RB006 is structurally disrupted by administration of the 
antidote complementary strand RB007. The REG-1 aptamer-antidote therapy has been tested in Phase 
I and II clinical trials with promising results as an anticoagulation therapy to prevent clot formation 
during cardiac surgery [40]. 
Moreover, different aptamers for cancer therapy are also in clinical trials. NOX-A12 is an L-RNA 
spiegelmer directed against the stromal cell-derived factor-1α (SDF-1α), a chemokine which attracts 
and activates immune and non-immune cells that bind to chemokine receptors CXCR4 and CXCR7. 
This aptamer is in Phase I clinical trials for the treatment of hematologic tumors. The AS1411 aptamer, 
instead, showed effectiveness for the treatment of acute myeloid leukaemia (AML) in phase I and II 
clinical trials. AS1411 is a DNA-aptamer, directed against nucleolin [41], a protein often 
overexpressed on the surface of cancer cells. This DNA aptamer is part of the guanine-rich oligonucleotide 
class of aptamers that form G-quartets, a structural element that exhibits antiproliferative activity. 
Nucleolin has many functions, so inhibiting this protein with AS1411 affects a variety of signaling 
pathways, including NF-κB [42] and Bcl-2 [43]. 
Apart from the aptamers mentioned above, many other aptamers are not yet developed in clinic but 
target molecules of high therapeutic interest thus appearing as excellent drug candidates for a wide 
range of human pathologies [30]. 
2.3. miRNAs 
Although the clinical development of miRNAs has not yet been realized, they are attractive 
candidates as prognostic biomarkers and therapeutic targets in different diseases including cardiovascular 
disease and cancer. In addition, the use of complementary antisense oligonucleotides has been developed 
for miRNA silencing in research and therapy. Antisense inhibitors act by competing for miRNA binding 
to the proper sites on target mRNAs and include small synthetic RNAs, antagomir, and modified RNA 
oligonucleotides, as locked nucleic acid (LNA) [44]. 
Cardiovascular disease is the leading cause of death in industrialized nations. Several miRNAs have 
been recently implicated in cardiomyocyte hypertrophy, increased fibrosis and apoptosis during heart 
failure [45]. Using mice with induced cardiac hypertrophy it has been recently shown that miR21 is 
upregulated in hearth fibroblasts, increases the extracellular signal-related kinases (ERKs)-mitogen-
activated protein kinase (MAPK) activity and regulates cell survival and growth factor secretion. 
Cardiac hypertrophy and fibrosis can be attenuated and even prevented by the administration of a 
specific antagomir that suppresses miR-21 levels and reduces cardiac ERK-MAPK activity [46]. On 
the other hand, has been shown that miR-199a expression is sensitive to low oxygen levels and is 
rapidly downregulated in cardiac myocytes to undetectable levels, thus rapidly resulting in increased 
levels of mRNA target, hypoxia-inducible factor (Hif)-1alpha. Conversely, restoring miR-199a levels 
during hypoxia inhibits Hif-1alpha expression, reduces apoptosis and protects the cells from hypoxic 
injury [47]. Cardiac remodeling can be as well prevented by the administration of an inhibitory 
antagomir for the cardiac-specific miR-208a thus improving the overall survival of treated rats [48]. 
All together, these studies indicate the potential of RNA-based therapies for cardiovascular diseases. 
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Expression of several miRNAs has been shown to be deregulated in many cancer types. Further, 
based on their involvement in basic cellular functions, miRNAs may act as oncogenes (oncomirs) or 
tumor suppressor as critical players in cell transformation [49-51]. 
For example, it has been demonstrated that the let-7 family contains miRNAs regulating the RAS 
family of oncogenes [52]. Petrocca et al. [53] showed that the miR-106b-25 cluster plays a key role in 
gastric cancer interfering with proteins involved both in cell cycle and apoptosis. In other studies, miR-155 
was found overexpressed in Hodgkin lymphoma, pediatric Burkitt lymphoma and diffuse large B-cell 
Lymphoma [54-56]; miR-143 and miR-145 were significantly downregulated in colon cancer tissue 
compared with colonic mucosa [57]; miR-21 was overexpressed in many tumors [49], including 
glioblastoma [58], cholangiocarcinoma [59], multiple myeloma cells [60] and breast cancer [61,62]. 
Moreover, studies that investigated the expression of the entire microRNAome in various human solid 
tumors and hematologic malignancies have revealed differences in miRNA expression profiling 
between neoplastic and normal tissues [63-66]. miRNAs play a key role also in tumor metastasis. 
Indeed, for example miR-139 suppresses metastasis of hepatocellular carcinoma, while miR10-b was 
found highly expressed in metastatic breast cancer cells [67,68] even if its clinical utility is still 
questioned [69]. 
3. RNA-Based Bioconjugates Molecules for siRNA Delivery 
Potent sequence selective gene inhibition by siRNA ‘targeted’ therapeutics promises the ultimate 
level of specificity, but siRNA therapeutics is hindered by poor intracellular uptake, thus efficient 
delivery strategies remains the main challenge for their clinical development [70]. 
In this respect a promising application of aptamers is to use them to deliver a variety of secondary 
reagents, including therapeutic siRNAs, specifically to a targeted cell population (Table 2) [71,72].  
Table 2. Aptamers as delivery tools. 
Aptamer composition Target Cargos/targeted delivery Therapeutic Indication 
RNA, 2’-F-Py PSMA siRNA,Toxin, QDs, nanoparticles 
and chemiotherapeutics 
Prostate cancer therapy 
RNA, 2’-F-Py gp120 siRNA HIV infection 
RNA, 2’-F-Py CD4 siRNA HIV infection 
RNA EGFR Au NPs Cancer 
DNA PTK7 Doxorubicin, Au-Ag NPs  Cancer 
DNA  Mucin 1 QDs, photodynamic therapy agents  Cancer  
DNA  Nucleolin QDs  Cancer  
This means that aptamers function as specific recognition ligands to target cells, which is especially 
significant given the whole cell-SELEX strategy to target specifically cell surface epitopes [73]. Once 
delivered, the secondary reagents would then impart their therapeutic effect to this subset of cells 
within the treated individual. Because non-targeted cells would not be exposed to the secondary 
reagent, the potential for unwanted side-effects such as death of normal cells is substantially reduced.  
The cell-SELEX method allows for the generation of aptamers against cell surface targets by 
replicating the native conformation and glycosylation pattern of the extracellular regions of proteins. 
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Recently, multiple groups have reported selections using living cells as the target to identify  
receptor-specific aptamers and those that bind to a specific cell type [73,74]. Some of these aptamers 
have been used as delivery cargos to target cells giving the cell-type specific expression of cell surface 
proteins on cell populations of therapeutic value. 
In the aptamer-based delivery approach, the last goal is to develop an aptamer to the extracellular 
portion of such a protein and then use the aptamer to deliver the secondary reagent to the targeted cell 
population via binding the targeted protein on the surface of the targeted cell type. Because this 
binding in some cases also results in the endocytosis of the aptamer/secondary reagent complex, this 
approach can be used to deliver reagents such as siRNAs that depend on delivery to intracellular 
compartments for their proper function (Figure 1). 
Figure 1. Aptamers as delivery agents. Aptamers that bind to cell surface receptors can be 
used to deliver siRNA to target cells.  
Aptamer-mediated
internalization
siRNA processing Gene silencing
Aptamer-siRNA chimera
Target cell
Aptamer
Cell-surface receptor
siRNA
 
To date, the best-characterized aptamers for targeted delivery are the two 2′-F-Py-RNA aptamers 
(A9 and A10) that have been generated against the extracellular domain of the prostate-specific 
membrane antigen (PSMA) [75]. These aptamers bind with high affinity to the acinar epithelial cells of 
prostate cancer tissue. They have been used to deliver not only siRNA, but also nanoparticles, quantum 
dots (QDs) and toxins to prostate cancer cells [73]. Different approaches in which PSMA-aptamer has 
been linked to siRNAs have been reported (Figure 2). 
A first study reports the non-covalent conjugation of siRNA with A9 aptamer via a streptavidin 
connector [76]. The 27mer Dicer substrates targeting laminin A/C and GAPDH genes and the RNA 
aptamers were chemically conjugated with biotin. Thus, two biotinylated siRNAs and two aptamers 
were non-covalently assembled via a streptavidin bridge. The resulting conjugates were incubated with 
PSMA-positive LNCaP cells without any further preparation, and were taken up within 30 min. The 
inhibition of gene expression was mediated by the aptamers and as efficient as observed with 
conventional lipid-based reagents. 
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Figure 2. Anti-PSMA aptamer-siRNA chimeras. (a) The RNA duplex and RNA aptamers 
are chemically conjugated with biotin. Thus, two biotinylated siRNAs and two aptamers 
are non-covalently assembled via streptavidin; (b) The 3′ end of the aptamer is extended to 
contain the nucleotide sequence that is complementary to the antisense strand of the 
siRNA, and the chimera is formed by annealing the aptamer to the siRNA antisense strand; 
(c) optimized chimeras in which the aptamer portion of the chimera is truncated, and  
the sense and antisense strands of the siRNA portion are swapped. A two-nucleotide  
3′-overhang and a PEG tail are added to the chimera; (d) the 3′-terminus of the aptamer is 
conjugated to the sense strand of the siRNA, followed by a 10-mer loop sequence and then 
by the antisense strand of the siRNA. 
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In the same year, McNamara et al. [77] described the generation of the anti-PSMA A10  
aptamer-siRNA chimeras. The 3′ end of the aptamer was extended to contain the nucleotidic sequence 
complementary to the antisense strand of siRNA targeting the polo-like kinase 1 (PLK1) and BCL-2 
survival genes, and the chimera was formed by annealing the aptamer to the siRNA antisense strand. 
The resulting chimeras were effective in silencing target genes and inducing cell death specifically in 
PSMA-positive cancer cells.  
In addition, the PSMA-siRNA chimeric molecule has been further modified for in vivo  
application [78]. The aptamer portion of the chimera was truncated, and the sense and antisense 
strands of the siRNA portion were swapped. A two-nucleotide 3′-overhang and a PEG tail were added 
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to the chimera. The modified chimera was able to inhibit prostate cancer xenograft growth when 
administrated systemically. 
To date several groups have adapted the covalent assembly approach to aptamer-mediated siRNA 
delivery [72]. In these studies, the anti-PSMA A10 aptamer has been conjugated to siRNAs against 
eukaryotic elongation factor (EEF)2 [79] and two key components of the nonsense-mediated mRNA 
decoy (NMD) [80]. In addition, since short hairpin RNAs (shRNAs), like miRNA precursors are better 
substrates for Dicer, Ni et al. [81] linked a shRNA against the DNA-activated protein kinase (DNA-PK) 
to a truncated A10 aptamer (A10-3) generating a single intact nuclease-stabilized 2’ fluoro-modified 
pyrimidine molecule. The 3’-terminus of the A10 aptamer was conjugated to the passenger (sense) 
strand of the siRNA, followed by a 10-mer loop sequence and then by the guide or silencing 
(antisense) strand of the siRNA. 
Rossi and colleagues have extensively characterized the HIV glycoprotein gp120 as a target for 
aptamer-mediated siRNA delivery [82-84]. In these studies, an inhibitory RNA aptamer targeting the 
HIV envelope protein gp 120, has been used to deliver attached anti-HIV tat/rev siRNAs into HIV 
infected cells via binding to envelope expressed on the cell surface, resulting in internalization of the 
aptamer and delivery of a dicer substrate siRNA to RISC. In vivo delivery of the aptamer and  
aptamer-siRNA conjugates into a humanized mouse model for HIV infection suppressed HIV 
replication and completely protected T-cells from HIV mediated T-cell killing.  
With the development of the conjugation strategies, the list of aptamers against surface epitopes 
that are being used as delivery agents is growing rapidly and now includes those against PTK7 [85,86], 
nucleolin [87], mucin 1 [88,89], and EGFR [90] the have been used to deliver not only siRNA, but 
also nanoparticles, quantum dots (QDs), toxin and chemiotherapeutics to target cells (see Table 2). 
4. Market and Perspectives 
Even if only one nucleic acid aptamer has been approved and is on the market, aptamers hold an 
extraordinary potential in drug development and it is plausible that the global interest for their 
development will increase in the next few years. Accordingly, a new technical market research report, 
from BCC Research [91], estimated that the global aptamer market value of $236 million in 2010 will 
grow to nearly $1.9 billion in 2014, for a 4-year compound annual growth rate of 67.5%. 
To date, Archemix Corp. is a leading biopharmaceutical company in the development of aptamers 
as therapeutics. It is the owner of the aptamer technology patent and it collaborates with other 
pharmaceutical companies (Regado, Antisoma, ARCA Biopharma and Ophthotech) to develop and 
commercialize a pipeline of partnered aptamers in the cardiovascular disease, hematology  
and oncology areas. 
Moreover, the development of aptamers as delivery agents for therapeutic RNAs can have a 
considerable impact on aptamer market in the near future. Indeed, intracellular delivery has been a key 
challenge for RNA modalities and the potential of bringing together the properties of aptamers and 
microRNA therapeutics will allow to overcome this limitation and open further potential for  
RNA-based therapeutics. 
Recently Archemix Corp. started a collaboration with miRagen Therapeutics Inc., a biopharmaceutical 
company focused on developing innovative microRNA-based therapeutics for cardiovascular and 
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muscle disease, for the development of conjugated aptamer-microRNA molecules capable of 
intracellular delivery and subsequent microRNA targeting. Combining aptamers and microRNA 
therapeutics has the potential to solve the intracellular delivery challenge for certain RNA-based 
therapeutic approaches. In this perspective, even if aptamer-miRNA chimeras have not been already 
described in literature, it is plausible that the approaches discussed in this review for aptamer-siRNA 
conjugation could be as well adapted to generate aptamer-miRNA molecules of fundamental 
therapeutic value. 
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Abstract 
MicroRNAs (miRNAs) constitute a class of small non-coding RNAs that negatively regulate the expression 
of their target genes. They are involved in many biological processes, including cell proliferation, apoptosis 
and differentiation, and are considered as promising new therapeutic targets for cancer. However, the identity 
of miRNAs involved in apoptosis and their respective targets remain largely unknown. Given the elevated 
complexity of miRNA regulation of gene expression, we performed a functional screening as an alternative 
strategy to identify those miRNAs that in lung cancer cells may interfere with the apoptotic process. To this 
aim we generated a derivative of the non-small cell lung carcinoma A549 cell line in which caspase-8, a 
critical upstream initiator of apoptosis, can be activated by the administration of the small dimerizer drug 
AP20187. 
We found a number of miRNAs that may rescue cell viability from caspase-8 activation. They included 
miRNAs already described as oncogenic such as miR-17, miR-135, miR-520, but also some miRNAs such 
as miR-124-1 and miR-34c for which a tumor suppressive role has been instead described or expected. 
Among them, miR-34c-5p markedly increased resistance to paclitaxel induced apoptosis. We demonstrate 
that Bmf (Bcl-2 modifying factor) is a target of miR-34c-5p and that its silencing, together with that of c-
myc, a known target of miR-34c-5p, contributes to resistance to apoptosis induced by paclitaxel via p53 
downregulation. 
 
 
Key words: A549, p53, AP20187 
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Introduction 
MicroRNAs (miRNAs) are a class of short endogenous non-coding RNAs that act as key regulators of cell 
proliferation and apoptosis through the control of gene expression either inhibiting translation or triggering 
degradation of multiple target mRNAs (Bartel, 2009). MiRNAs have been found deregulated in different 
malignancies, implicating them as oncogenes or tumor suppressors and thus considered as promising new 
therapeutic targets for cancers (Farazi et al., 2011; Garofalo and Croce, 2011). Indeed, the selective 
induction of cell death by oligonucleotide-based drugs is a challenging goal for a rationale approach to novel 
therapeutic strategies in cancer treatment. 
Programmed cell death, or apoptosis, is mediated through two major pathways, the death receptor pathway 
and the mitochondrial pathway. In the death receptor pathway, stimulation of death receptors leads to the 
formation of a death-inducing signaling complex which includes the initiator caspases such as caspase-8 that 
drives its activation through self-cleavage and then activates several downstream effectors including caspase-
9 and the ultimate effector caspase-3 (Ashkenazi and Dixit, 1998). In the mitochondrial pathway, stimuli 
such as drugs, radiation, infectious agents and reactive oxygen species transmit the death signals to 
mitochondria through the activation of BID, a pro-apoptotic member of the Bcl-2 family (Hengartner, 2000). 
Caspase-8-mediated cleavage of BID thus provides integration of the death-receptor with the mitochondrial 
pathway. 
Identifying miRNAs that selectively regulate the expression of proteins involved in apoptosis could be 
helpful in the development of new tools for the diagnosis and the treatment of cancer. However, the potential 
for combinatorial regulation of gene expression by miRNAs makes it difficult to understand which are the 
targets involved and what are their coordinate mechanisms of action (Inui, et al., 2010). 
Therefore, as alternative to high-throughput screening, here we developed a functional selection-based 
screening to identify those miRNAs able to rescue cells from apoptosis in lung cancer cells. This approach 
has the advantage to identify unique functional combinations of miRNA molecules without any assumption 
about the targets involved. Since a pivotal upstream event in the death receptor pathways is the activation of 
caspase-8, the screening has been based on the use of an engineered lung cancer cell line in which the 
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activation of caspase-8 has been placed under the control of the dimerizing agent AP20187. Here we show 
that this is an unbiased approach able to uncover unpredicted effects of miRNA expression. Indeed, miR-
34c, a p53 effector miRNA (Chang, et al., 2007; He, et al., 2007), revealed to be able to antagonize 
paclitaxel-induced apoptosis, with obvious fall-outs in the design of miRNA-based new therapeutic agents 
for cancer treatment. 
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Results 
Identification of protective miRNAs by functional selection 
In order to identify miRNAs able to rescue cells from caspase-8 induced cell death we adopted a functional 
selection screening based on a FKBP caspase-8 inducible chimera (puro-DD-FKC8) (Carlotti 2005; Chang 
and Yang 2003). The human non small cell lung cancer (NSCLC) A549 cells have been transduced with a 
retroviral vector with inserted the caspase-8 chimera. The most responsive cell clone, the A549-FK, was then 
transduced with a pooled miRNA library and subjected to selection for resistance to caspase-8 induction of 
cell death, as described in Supplementary Information and in Figure S1a.  
In out of 16 cell clones analysed we found integrated miRNAs (see SI for more details) already described as 
oncogenic such as miR-17, miR-135 (Nagel et al., 2008), miR-520 (Huang et al., 2008). However, we also 
found some miRNAs such as miR-124-1 and miR-34c for which a tumor suppressive role has been instead 
described or expected. The most frequent integrated miRNA was miR-34c that was as well the only miRNA 
that was found not only in combination with other miRNAs but also alone in two independent cell clones, 
thus suggesting to be sufficient by its own to confer resistance to caspase-8 activation (Figure S1b). The 
other miRNAs were always found to be present as a combination of at least two different molecules (not 
shown). By qt-RT-PCR we thus evaluated in all cell clones the expression levels of transduced miRNAs (as 
compared to non-transduced control cells) and assessed that, with the only exception of miR-645 in the clone 
Cl-Y (see Supplementary Information), all transduced miRNAs are expressed in the corresponding surviving 
clones (not shown). In the case of miR-34c the expression levels of both the -5p and -3p strands were 
analysed (see Figure S1c). 
 
MiR-34c-5p protects cells from capase-8 induced apoptosis 
Given the high frequency of integration of miR-34c in surviving clones, we wondered if, in our system, 
forced over-expression of the most expressed isoform, miR-34c-5p, might protect cells from caspase-8 
induced apoptosis. As determined by MTT assay (Figure 1a) all clones transduced with miR-34c are resistant 
to 10 nM AP20187 regardless if it was present alone (in two clones, Cl-T; Cl-8) or in combination with other 
miRNAs (in clones Cl-H; Cl-K; Cl-Y; Cl-1; Cl-2; Cl-12; Cl-17; Cl-53) (see legend to Figure S1 c). In A549-
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FK cells, caspase-8 dimerization activates caspase-3 (Fig 1b, lanes 1-3) through cleavage of the BH3-only 
protein BID (Figure 1c), that leads to activation of Bax (Figure 1d) and caspase-9 (Figure 1b middle panel) 
(Jost et al., 2009). In contrast to parental A549-FK, both cell clones analysed (Cl-T and Cl-K), in which 
miR-34c was integrated either alone (Cl-T) or together with miR-124-1 and miR-362 (Cl-K), were resistant 
to AP20187-induced apoptosis (Figure 1 b-d). Resistance is unlikely due to the occurrence of new clonal 
mutations impairing caspases that are indeed activated following cisplatin treatment (Figure 1e). Conversely, 
transfecting cell clones with a miR34c-5p inhibitor sensitizes cells to AP20187-induced cell death with a 
consequent increase of caspase-3 and caspase-9 activity in both Cl-T (Figure 1f) and in Cl-K (not shown). 
Further, upon AP20187 treatment, the presence of miR-34c-5p, but not of miR-34c-3p (not shown), makes 
the cells more resistant to caspase-8 induced cell death, reducing the per cent of apoptotic cells from 70% (of 
scrambled control) to around 30% (Figure 2a). Consistently, resistance to apoptosis conferred by miR-34c-5p 
is accompanied by the lack of activation of caspase-9 and of its effector, caspase-3, with an increase in the 
overall cell survival (Figure 2 b-d). These data indicate that while in a proliferating cell population miR-34c-
5p may induce an increase in apoptosis (Chang, et al., 2007; He, et al., 2007), in the presence of a strong 
acute pro-apoptotic signal, as the dimerization of caspase-8, it may, in contrast, elicit a clear protective 
effect. 
 
miR34-c-5p protects cells from paclitaxel induced apoptosis 
We thus determined whether miR-34c-5p has antiapoptotic function toward broadly used chemotherapeutic 
agents. As shown in Figure 3a, treating parental A549 cells with 100 nM paclitaxel for 24 h induces caspase-
3 and caspase-9 activation that were partially reverted by trasfecting cells with miR-34c-5p mimic (left 
panel) but not with miR-34c-3p mimic (right panel) . Consistently, transfecting miR-34c-5p in A549 induces 
a clear reduction in the per cent of paclitaxel-induced apoptosis (Figure 3b). On the other hand, antagonizing 
with specific LNA-based miR inhibitors the miR34c-5p, but not the miR34c-3p, rescued the sensitivity to 
paclitaxel-induced apoptosis in Cl-K cells (Figure 3c). A similar protective effect against paclitaxel is 
elicited by miR-34c in A549-FK, but not in the more sensitive H460 NSCLC cells (not shown). Further, 
differently from what observed with paclitaxel, transfecting miR-34c-5p mimic doesn’t reduce the levels of 
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active caspase-3 and caspase-9 neither upon TRAIL (200 ng/ml) nor cisplatin (50 µg/ml) treatments. 
However, at least in transient, miR-34c-5p may cooperate with cisplatin (Figure 3 d-e). Taken together these 
results well support the notion that the protective potential of miR-34c may be only unveiled in a cell context 
and pathway specific manner. 
 
Targets of miR-34c-5p 
In an attempt to understand the molecular events elicited by high levels of miR-34c-5p on apoptosis, and 
thus which are the target proteins involved, we first used a small antibody array to analyze the relative 
expression of a selected number of apoptosis related proteins in A549-FK cells transfected with miR-34c-5p 
(not shown). Since, using this assay, no major changes were observed we thus decided to take advantage of 
the information coming from the functional screening by assuming that the pathways involved may be shared 
between the different miRNAs selected for their ability to rescue A549-FK cells from caspase-8 DD-FKC8 
chimera-induced cell death. We thus combined the bioinformatic prediction (Diana-microT3 ) for targets 
common to those miRNAs transduced and expressed in three independent cell clones together with miR-34c: 
i.e. in Cl-17 (miR-345 and miR362), in Cl-K (miR-362 and miR-124-1), in Cl-Y (miR-346). Among the 
candidate targets considered, even if with different score values (see legend to Figure 4), Bmf (Bcl2-
modifying factor) was predicted to be a common target for all of miRNAs analysed. In the 3’ UTR of Bmf 
two recognition sites are predicted for miR-34c-5p, one at position 737-765, and one at position 2283-2311 
(Diana-microT3) (Figure 4a). Therefore, we determined whether Bmf might be a direct target of miR-34c-5p. 
As shown in Figure 4b, transfecting miR-34c-5p either in A549-FK or in parental A549 cells resulted in a 
decrease of Bmf protein (of approximately 60%). Furthermore, in two miR-34c infected cell clones analysed, 
that overexpress miR-34c-5p either alone (Cl-T) or in combination with other miRNAs (Cl-K), the levels of 
Bmf are reduced as compared to parental A549-FK cells (Figure 4c). Conversely, by using specific LNA 
based inhibitors to antagonize the miR34c (either -5p and -3p) in Cl-T we rescued the expression of BMF 
(Figure 4d). To prove a direct interaction between miR-34c-5p and Bmf mRNA, two Bmf 3′-UTR sequences 
(BMF S1 and BMF S2), which include each of the two potential target sites for miR-34c-5p, were fused 
downstream of the luciferase gene. The two constructs containing either BMF S1 or BMF S2, either 
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individually and in combination, were cotransfected into MEG-01 cells together with miR-34c-5p, or a 
scrambled miRNA as negative control. As shown in Fig 4e, luciferase activity of BMF S2 was decreased of 
around 30% by cotrasfecting miR-34c-5p. In contrast luciferase activity of both the BMF S1 and a deletion 
mutant of BMF S2 are poorly affected by miR-34c-5p cotransfection. Taken together these data indicate that 
miR-34c-5p may decrease Bmf expression by recognizing a binding site on its 3’ UTR starting at position 
2283. As mentioned above, we identified Bmf as promising target for miR-34c-5p based on the assumption 
that common messangers should be targeted by miRNAs found in independent cell clones together with 
miR-34c. In order to verify this assumption we determined whether miR-362 and miR-124 may affect as 
well Bmf levels. As shown transfecting either miR-362 or miR-124 decreases Bmf levels (Figure 4f). Further 
we determined by luciferase assay whether miR-362 interacts with the predicted sites for the miR-362-5p 
and -3p strand in the Bmf 3’ UTR (BMF S3 and S4 respectively). As shown in Figure 4g, luciferase activity 
of BMF S3 was decreased of around 60% by cotrasfecting miR-362-5p. In contrast, luciferase activity of the 
BMF S3 mutant is poorly affected by miR-362-5p cotransfection. These results well support the working 
hypothesis that miRNAs for common targets may be preferentially selected during the functional screening. 
 
Mechanism of action 
In order to understand if the decrease of Bmf levels by miR-34c-5p is sufficient to cause protection to 
apoptosis, we transfected A549-FK cells with either the miR-34c-5p or with an siRNA for Bmf and analysed 
the activation of caspases-9 and -3 after forced dimerization of caspase-8. Interfering with Bmf expression 
either by miR-34c-5p and, even if at less extent, by Bmf specific siRNA protects the cells from AP20187-
induced caspases activation (not shown). Further, to understand whether Bmf mediates the effects of miR-
34c-5p we silenced Bmf in the A549 cells with a specific shRNA and determined the residual abilty of miR-
34c-5p to elicit protection from paclitaxel-induced caspase-3 activation. As compared to Bmf silenced cells, 
overexpression of miR-34c-5p was able to further reduce caspase-3 activation thus indicating that Bmf 
doesn’t fully mediate miR-34c-5p protective effects (Figure 5a).  Intriguingly, miR-34c, belongs to a family 
of evolutionarily conserved miRNAs (miR-34a, miR-34b, and miR-34c), whose expression has been shown 
to be under the transcriptional control of the tumor suppressor protein p53 and known to be implicated in the 
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negative control of the cell cycle, senescence and apoptosis (Corney et al., 2007; Bommer et al., 2007; He et 
al., 2007; Hermeking 2010). Therefore, with the aim to reconcile this with the protective effect of miR-34c-
5p on paclitaxel-induced apoptosis we asked whether c-myc, a known target of miR-34c (Cannell and 
Bushell, 2010), may as well participate to inhibit apoptosis. Indeed, c-myc, acting on the protein deacetylase 
Sirt1, regulates p53 acetylation, and thus its activity (van Leeuwen and Lain, 2009). As expected, 
transfecting A549-FK cells either with miR-34c-5p, or with a c-myc specific siRNA, resulted in a partial 
decrease of c-myc protein levels (Fig 5b). Interestingly, attenuation of c-myc expression protects cells from 
AP20187 and most importantly from paclitaxel-induced caspase-3 activation (Figure 5c). In order to 
determine whether c-myc downregulation mediates miR-34c-induced protection, we depleted A549 cells of 
c-myc by transfecting a specific siRNA. As shown in Figure 5d, we found that miR-34c-5p become poorly 
efficient to further increase protection over that induced by c-myc silencing. Even though, the contribution to 
protection of the passenger -3p strand remains to be elucidated, we show that the miR-34c-3p mimic we used 
may decrease the Bmf levels, but it is less effective on the regulation of c-myc levels (Figure 5e). Together 
these results suggest that c-myc is a critical target of miR-34c that may act by protecting cells from 
paclitaxel-induced apoptosis. 
Paciltaxel is a microtubule destablizer and cell cycle integrity has been shown to be required for sensitization 
(Chabalier et. al. 2006; Zachos et al., 2007). We thus determined whether perturbation of c-myc levels by 
miR-34c-5p affects cell cycle thus providing an explanation for resistance. As assessed by FACS analysis, 
cell cycle is not appreciably impaired by the transfection of miR-34c-5p (Figure 5f). Accordingly, as 
determined by immunoblot, no drastic changes were observed upon transfection of the miR-34c-5p, neither 
in cyclins B1, D1 nor in Chk1 levels (Figure 5g). Similarly, induction of cyclin B1 levels by treatment with 
paclitaxel was not impaired by miR-34c-5p thus indicating that resistance is unlikely attributable to an 
abnormal mitotic checkpoint response (Figure 5h). On the other hand, the levels of cyclin D1, that mediate 
p53-dependent cell cycle arrest (Del Sal et al., 1996), were increased by paclitaxel, while in the presence of  
miR-34c-5p such increase was impaired (Figure 5h). 
We then wondered whether transfecting miR-34c-5p may act on the activity of p53, monitoring p53 
acetylation that is essential for maximal p53-dependent apoptosis (Sykes et al., 2006; Tang et al., 2006; 
Mellert et al., 2011). As shown in Fig 6a in untreated, exponentially growing, A549 cells the levels of 
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acetylated p53 are very low and are strongly induced by paclitaxel treatment (24 h). Interestingly, miR-34c-
5p overexpression counteracts paclitaxel effects by reducing the induction of acetylated p53 levels to less 
than 2 fold over basal. The interference of miR-34c-5p on the levels of acetylated p53 is well mirrored by the 
corresponding decrease in the paclitaxel-induced expression of total p53. This suggests that miR-34c-5p, by 
regulating p53 synthesis or stability, may indirectly act on its activity. To confirm that miR-34c-5p may 
interfere with paclitaxel-induced p53 activity we performed luciferase assays transfecting a construct 
expressing the luciferase reporter gene under the transcriptional control of the p53-responsive human 
ubiquitin ligase MDM2 (mouse/human double minute 2) promoter. As shown in Figure 6b miR-34c-5p 
overexpression abolishes the induction of p53 activity by paclitaxel as assessed by the corresponding levels 
of luciferase activity. Consistently, miR-34c-5p abolishes the induction of the MDM2 protein and decreases 
the levels of the deacetylase SIRT-1, that is in turn a known direct target of miR-34c (Yamakuchi et al., 
2008) (Figure 6c). Therefore, in the attempt to understand how MDM2 is implicated in the attenuation of p53 
response to paclitaxel we inhibited MDM2 activity. The treatment of A549 cells with Nutlin-3, a direct 
inhibitor of MDM2, increases the levels of p53, likely by increasing its stability. At difference of what 
happens with paclitaxel-induced p53, transfecting miR-34c-5p in the absence of MDM2 didn’t result in the 
attenuation of p53 (Figure 6d, upper panel). Conversely, we show that following inhibition of MDM2 the 
balance between the levels of miR-34c-5p and p53 cannot be interfered by antagonizing miR-34c-5p with a 
specific LNA based inhibitor (Figure 6d, lower panel). 
As shown in Figure 6e both cisplatin and paclitaxel-induced activation of caspase-3 is decreased in stable 
A549 cells silenced for p53 (Figure 6e). However, at difference of paclitaxel, the cisplatin-induced levels of 
p53 were unaffected by miR-34c-5p (Figure 6f) thus suggesting that resistance of cisplatin might involve the 
way to induce p53 in these cells. 
Taken together these data indicate that transfecting miR-34c-5p in the presence of a proapoptotic insult, as 
paclitaxel, may protect cells from apoptosis likely by interfering with the levels of  p53 likely by tuning the 
levels of c-myc and suggest that miR-34c-5p-induced p53 attenuation depends on MDM2 activity. 
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Discussion 
Signaling initiated by death receptors causes the recruitment and activation of the initiator caspases (caspase-
8 and caspase-10) thus triggering the activation of either intrinsic or extrinsic apoptotic pathways that 
ultimately leads to cell death. However, distinct multiple signaling pathways have been recently shown to be 
initiated by some of these receptors that rather promote activation of pro-survival proteins such as NF-KB, 
protein kinase B (PKB)/Akt, and MAP kinases that ultimately lead to a number of  non-cytotoxic functions 
as cell proliferation or inflammation (Guicciardi and Gores, 2009). 
In order to dissect miRNAs implicated in the pro-apoptotic pathway we engineered a NSCLC derived cell 
line to induce caspase-8 dependent cell death. By using a functional selection we identified miRNAs whose 
expression may protect cells to undergo apoptosis. Eleven different miRNAs have been selected that if 
expressed, either alone or in combination, confer resistance to caspase-8 dimerization. Among these 
miRNAs, miR-34c revealed to be of particular interest. Indeed, miR-34c belongs to a conserved miRNA 
family consisting of three members: miR-34a, generated from a transcriptional unit on the human 
chromosome 1p36; miR-34b and miR-34c, which are generated by processing of a bicistronic transcript from 
chromosome 11q23. Both transcripts have been shown to be under the direct positive control of p53 (Chang 
et al., 2007; He et al., 2007a; Raver-Shapira et al., 2007; Tarasov et al., 2007; Bommer et al., 2007; Corney 
et al., 2007) and Elk1  (Christoffersen et al., 2010). Several converging evidence demonstrated that miR-34 
members mediate p53 action to negatively regulate cell cycle thus acting as “bona fide” tumor suppressor 
genes (Hermeking, 2010; Liu et al., 2011; Li et al., 2009; He et al., 2007b). Though exceptions exist (Dacic 
et al., 2010: Lee et al., 2011), miR-34a/b/c have been consistently found poorly expressed in several tumor 
and tumor derived cell lines (He et al., 2007a; Corney et al., 2010;).  
In apparent contradiction with its tumor suppressive potential, here we demonstrate that forced expression of 
miR-34c may confer resistance to caspase-8-induced apoptosis thus allowing to the selected cell clones to 
survive and proliferate even in the presence of lethal doses of the caspase-8 dimerizer AP20187. Indeed, in 
A549-FK cells, the drug induces the activation of the mitochondrial pathway through the activation of 
several proapototic members of the Bcl2 family, including BID, Bmf, and Bax, that is clearly impaired by 
ectopic miR-34c. Resistance is unlikely due to the occurrence of new clonal critical mutations in the 
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apoptotic pathway, indeed, 1): in two analysed cell clones, Cl-K and Cl-T, caspase-8 sensitivity is restored 
by antagonizing miR-34c-5p action with a specific antimiR; 2) apoptosis is readily activated by treating the 
same cell clones with an unrelated proapototic drug; and 3) transfecting miR-34c-5p mimics protects the 
A549-FK cells by AP20187-induced cell death.  
Furthermore, our data clearly show that protection is not restricted to the non-physiological pathway induced 
by the artificial caspase-8 dimerizer that we used for selection, in fact activation of the mitochondrial 
pathway by paclitaxel was as well specifically impaired by miR-34c. Paclitaxel is a lead anticancer 
compound that prevents cell progression through mitosis (Allan et al., 2007; Shiff et al., 1979) causing cells 
to arrest and undergo apoptosis through activation of BID and caspase-9. However, even if our data indicate 
that miR-34c acts by interfering with the complete activation of the mitochondrial pathway, two observations 
show that its protective action is only unveiled under specific conditions. First, transfection of miR-34c 
doesn’t protect cells from other pro-apoptotic compounds, as TRAIL, or cisplatin; second, transfecting miR-
34c has no protective effect on the more sensitive H460 NSCLC cell line, raising the question of which are 
the mechanisms that determine miR-34c to play opposite roles on cell survival or death. Yet, in the absence 
of definitive evidence on the critical players involved, it seems plausible that the action of miR-34c may 
depend on the balance of specific intracellular mediators of apoptosis. On the other hand, the protective 
action of miR-34c is not completely unexpected. Indeed, it has been recently shown that the cognate miRNA, 
miR-34a, may confer resistance to bortezomib-induced apoptosis by downregulating p53 and that survival 
and p53 downregulation depend on the expression levels of c-myc (Sotillo et al., 2011). Indeed, c-myc is a 
key regulator of cell proliferation since its induction sustains cell proliferation and transformation. However, 
in concert with p53, elevated levels of c-myc may sensitize tumor cells to proapoptotic stimuli and promote 
cell death (Maclean et al., 2003; Cannell et al., 2010; Murphy et al., 2008; Soucek and Evan, 2010; Allen et 
al., 2011).  
In an attempt to understand which are the critical targets of miR-34c we assumed that, given the protocol of 
functional selection adopted, some of these targets should be common to multiple miRNAs selected and 
found in combination with miR-34c (see Legend to Fig. 4 and Text for details). Based on this assumption, 
we identified among the genes with predicted consensus sites for miR-34c, the proapoptotic protein Bmf, a 
common target with predicted consensus binding sites for all the miRNAs analysed. Indeed, attenuation of 
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Bmf expression, even poorly, protects cells from caspase-8-induced apoptosis and thus is a promising target 
candidate of miR-34c, likely by directly targeting one of the predicted consensus sites in its 3’ UTR at 
position 2283. Further, according with recent reports that indicate c-myc as target of miR-34a/c (Cannell and 
Buschell, 2010; Christoffersen et al., 2010; Kress et al., 2011) here we show that c-myc is downregulated by 
miR-34c-5p and that its downregulation is by its own sufficient to mediate much of the protective effects of 
miR-34c, thus proving that in A549 cells regulation of c-myc is critical to mediate survival. On the other 
hand, in good agreement with previous reports (Sotillo et al., 2011) our results indicate that the effects of 
miR-34c involve, besides c-myc, the MDM2 and p53 loop. Indeed, miR-34c attenuates the paclitaxel-
dependent induction of p53 by a mechanism that is unlikely determined by a decrease in the extent of p53 
acetylation since the levels of the deacetylase SIRT-1 (a target of miR-34c) are as well decreased. Our results 
rather show that inhibiting MDM2 induces p53 expression, but induction becomes insensitive to the 
intracellular levels of miR-34c thus indicating that MDM2 activity could be required for attenuation. 
Therefore, a plausible explanation of the fact that miR-34c is unable to attenuates the levels of cisplatin-
induced p53, while the silencing of p53 confers resistance to both cisplatin and paclitaxel, may likely rely on 
the genotoxic action of cisplatin that, at difference of paclitaxel, causes MDM2 inhibition. A primary way by 
which c-myc regulate MDM2 activity implicates the regulation of the MDM2 regulatory protein, p14/Arf, 
that is however deleted in A549 cells (Lu et al., 2002) thus making elusive in these cells the link between c-
myc and MDM2 for protection by miR-34c. On the other hand, it has been shown that active p53 directly 
induces miR-34c expression that in turn indirectly increases p53 activity thus establishing a positive 
feedback loop leading to cell cycle arrest (Corney et al., 2007; Yamakuchi et al., 2008; Yamakuchi et al., 
2009; Hermeking, 2010). How this loop is attenuated is still unknown. In light of our results, it seems 
reasonable to hypothesize that increased levels of miR-34c may contribute to switch off the loop and thus 
interfering with paclitaxel-induced cell cycle arrest. 
These results can be relevant both for the understanding of molecular mechanisms that governs the interplay 
between miR-34c, p53 and c-myc to control cell proliferation and apoptosis, and for the development of 
targeted specific new therapeutic agents. 
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Materials and Methods 
Cell Cultures 
Human NSCLC A549 and H460 (American Type Culture Collection) were grown in RPMI 1640 (Life 
Technologies, Karlsruhe, Germany) supplemented with 10% heat-inactivated fetal bovine serum (Sigma-
Aldrich Corp. Saint Louis, MO, USA), 2mM L-glutamine and 100 U/ml penicillin–streptomycin. A549 cells 
carry a deletion in the ARF locus (Lu et al., 2002). A549-FK, clone Cl-K and clone Cl-T were cultured in the 
same medium supplemented with 5 µg/ml puromycin, while A549 stably silenced for p53 were cultured in 
medium supplemented with 1 µg/ml puromycin. 
 
Immunoprecipitation and immunoblotting 
Total cell lysates were prepared in JS buffer (50 mM Hepes ph 7.5, 150 mM NaCl, 1%Glicerol, 1%Triton X-
10, 1.5 mM MgCl2, 5 mM EGTA, 1 mM Na3VO4 and protease and phosphatase inhibitors) and then boiled 
in SDS/β-mercaptoethanol sample buffer. 40 or 30 μg samples were loaded into 15% or 12% polyacrylamide 
gels and the proteins were separated by electrophoresis and then blotted onto PVDF membranes (Millipore, 
Billerica, MA, USA) by electrophoretic transfer. The membranes were then blocked with 5% dried milk in 
TBS containing 0,1% Tween 20 and incubated at 4°C overnight with the following primary antibodies: anti-
caspase 3, anti-caspase 9, anti-BID, anti-Bcl-Xl, anti-Bmf, anti-Acetyl-p53 (Lys382), anti-cyclin D1 (Cell 
Signaling Technology, Inc., Danvers, MA, USA), anti-procaspase-3 and anti-procaspase-9 (Abcam plc, 
Cambridge, UK), anti-c-myc (9E10), anti-p53 (DO-1), anti-Chk1 (G-4), anti-cyclin B1 (H-433), anti-SIRT1 
(H-300) (Santa Cruz, CA, USA), anti-α-tubulin (Sigma-Aldrich Corp. Saint Louis, MO, USA) and anti-
MDM2 (mAB 2A10) (Calbiochem). 
For Bax activation analysis total cell lysates were, instead, prepared in 1% Chaps buffer (5mM MgCl2, 137 
mM NaCl, 1 mM EDTA, 1mM EGTA, 1% Chaps, 20 mM Tris-HCl ph 7.5 and protese inhibitors. 500 µg  
proteins were immunoprecipitated with anti-Bax antibody (6A7; BD Pharmingen) at 4°C for 2 h. 
Immunoprecipitates were captured by a Protein A/G PLUS-Agarose (Santa Cruz, CA, USA) in lysis buffer at 
4°C overnight. Immunoprecipitates were then recovered by centrifugation and washed three times in 1% 
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Chaps buffer. Immunoprecipitates and total extracts (40 µg) were separated on 12% polyacrylamide gel. 
After SDS-PAGE, proteins were transferred onto PVDF membranes (Millipore, Billerica, MA, USA) and 
then blocked with 5% dried milk in PBS-0,1% Tween 20. Membranes were then incubated with primary 
anti-Bax (N20) (Santa Cruz, CA, USA) and peroxidase (HRP)-conjugated secondary antibodies in 10% dried 
milk in PBS containing 0,1% Tween 20 and detected with ECL Western blotting detection reagents 
(Amersham Bioscience, Piscataway, NJ). 
 
Cell proliferation and cell death analysis 
Cells were plated in 96-well plates in triplicate and incubated at 37°C in a 5% CO2 incubator. 
AP20187 (ARIAD Pharmaceuticals, Inc.,Cambridge, MA, USA) was used for 3 h, 6 h and 24 h at 10 nM. 
Cell viability was examined with 3-(4,5-dimethylthiazol-2-yl)-2,5-dipheniltetrazolium bromide (MTT)-Cell 
Titer 96 AQueous One Solution Cell Proliferation Assay (Promega BioSciences Inc. San Luis Obispo, CA, 
USA), according to the manufacturer’s protocol. Metabolically active cells were detected by adding 20 μl of 
MTT to each well. After 20 min of incubation, the plates were analysed in a Absorbance Microplate Reader 
(ELx800 BioTek Instruments, Inc.). Apoptosis was assessed using propidium iodide assay followed by flow 
cytometric analysis and caspase-3 and -9 fluorimetric assays. For propidium iodide assay, 24 h after 
transfection, cells were seeded in triplicate in 96-well plates at 3.6×103 cells per well and grown overnight at 
37°C in a 5% CO2 incubator. Then cells were treated with 10 nM AP20187 (ARIAD Pharmaceuticals, 
Inc.,Cambridge, MA, USA) for 6 h or with 100 nM Paclitaxel (Sigma-Aldrich Corp. Saint Louis, MO, USA) 
for 24 h. The next day analysis of DNA content by propidium iodide (Sigma-Aldrich Corp. Saint Louis, MO, 
USA) incorporation was performed in permeabilized cells by flow cytometry.  
For caspase-3 and -9 fluorimetric assays, 50 µg of total cell lysates were incubated for 1 h at 37°C with 
DEVD-AFC or LEHD-AFC substrate respectively, according to the manufacturer’s protocol (BioVision Inc. 
Mountain View, California). After incubation samples have been read in a fluorimeter equipped with 400 nm 
excitation filter and 505 nm emission filter. 
For cell cycle analysis cells transfected with 70 nM of miRNA precursor hsa-miR-34c-5p or a scrambled 
molecule were recovered 48h and 72h post-transfection, fixed in 70% ethanol, stained with 50 µg/ml 
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propidium iodide (Sigma-Aldrich Corp. Saint Louis, MO, USA) and analysed by FACS (Fluorescence-
activated cell sorter).. 
 
Cell transfections 
The day before transfection cells were seeded in 10% FBS medium without antibiotics. All transfections 
were performed in serum-free Opti-MEM using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s protocol. To alter miRNA level cells were transfected with 70 nM of 
miRNA precursor hsa-miR-34c-5p, hsa-miR-34c-3p, hsa-miR-124, hsa-miR-124*, hsa-miR-362-5p, hsa-
miR-362-3p and Negative Control #1 (Ambion) or 50 nM of LNA anti-miR-34c-5p, anti-miR-34c-3p and 
anti-miR negative control inhibitor (Exiqon). To alter c-myc and Bmf level cells were transfected with 60 
nM siRNA c-myc (Sigma-Aldrich Corp. Saint Louis, MO, USA) and 120 nM siRNA Bmf (Santa Cruz, CA, 
USA). 
For p53 and Bmf stable gene silencing, A549 cells were transfected in 100 mm dishes with 10 µg of 
shRNAp53, shRNA Bmf or shRNAcntrl (Open Biosystems). For stable clone selection RPMI medium 
supplemented with 1 µg/ml puromycin was used. 
 
Luciferase assays 
For target validation the two Bmf 3’ UTR sequences were PCR amplified using the following primers: BMF 
S1 Fw: 5’-CTAGAAGGATTCCTGGCCAGCTCCT-3’, BMF S1 Rw: 5’ -TCTAGATTTT 
CCGGCCCCACTGCAAACTTG-3’ ;  BMF S2 Fw: 5’–TCTAGAGGATCAAGGTGGTGACAGGCAG-3’ ;  
BMF S2 Rw: 5’-TCTAGATACCTCCTGGGTTTTGTTGGTGGGGAA-3’; BMF S3 Fw: 5'-TCTAGAATT 
GCTTTAACCCAGCAGGGCTTCG-3'; BMF S3 Rw: 5'-TCTAGACACTGTCCTGGCTTCTTCTGTATCC 
CA-3'; BMF S4 Fw: 5’-TCTAGATGGGGCTACTTCTCCCAAGAAGAAG-3’; BMF S4 Rw: 5’-TCTAGA 
GAGGGGAGAACAACGTATGTCCCAT-3’ and cloned downstream of the Renilla luciferase stop codon in 
pGL3 control vector (Promega BioSciences Inc. San Luis Obispo, CA, USA). We deleted a sequence in S2 
and S3 miRNA-binding site by using the QuikChange Mutagenesis Kit (Stratagene, La Jolla, CA) using the 
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following primers: BMF S2 mut Fw  5’-CTGGGGCAGGTGGAAGCTGCACTGTC-3'  BMF S2 mut Rw 5'-
GACCCCGTCCACCTTCGACGTGACAG-3'; BMF S3 mut Fw: 5’-GGTTCTTACTT 
CTCAGCCTGCCACCTCCAGCA-3’; S3 mut Rw:  5'-TGCTGGAGGTGGCAGGCTGAGAA 
GTAAGAACC-3'. 
The megakaryoblastic cell line, MEG-01, as widely used efficient recipient was use for luciferase assays. 
Cells were cotransfected with 1,2 μg of each generated plasmid and 400 ng of a Renilla luciferase expression 
construct pRL-TK (Promega BioSciences Inc. San Luis Obispo, CA, USA) with Lipofectamine 2000 
(Invitrogen). Cells were harvested 24 h post-transfection and assayed with Dual Luciferase Assay (Promega 
BioSciences Inc. San Luis Obispo, CA, USA) according to the manufacturer’s instructions. Three 
independent experiments were performed in triplicate. 
For p53 promoter activity analysis cells were transfected with Lipofectamine 2000 (Invitrogen) with 500 ng 
of pLuc-MDM2 expression vector (kindly provided by S. Soddu), 900 ng of miRNA precursor hsa-miR-34c-
5p or Negative Control #1 (Ambion), together with 40 ng of pCMV-Renilla in 6 well plates. Luciferase and 
Renilla activity were assessed with Luciferase assay system and Renilla Luciferase assay system (Promega 
BioSciences Inc. San Luis Obispo, CA, USA) 48 h after the transfection. The Luciferase activity was 
normalized for the Renilla activity. All the experiments were performed three times in triplicate and the 
mean±s.d. was reported. 
 
qt-RT-PCR analysis  
Reverse transcription reaction was done starting from 1 µg total RNA and using miScript Reverse 
Transcription Kit (QIAGEN, Milan Italy), according to the manufacturer’s protocol. The expression of 
mature hsa-miR-34c-5p, has-miR-34c-3p, hsa-miR-362-5p, hsa-miR-362-3p, hsa-miR-124,  hsa-miR-124* 
and of U6 RNA, as housekeeping gene, was assayed using the miScript SYBR Green PCR Kit (QIAGEN) 
and Real-time PCR was done in triplicate for each case. MiRNA expression was measured using Ct 
(threshold cycle). The ΔΔCt method for relative quantization of gene expression was used to determine 
miRNA expression levels. The ΔCt was calculated by subtracting the Ct of U6 RNA from the Ct of the 
miRNA of interest. The ΔΔCt was calculated by subtracting the ΔCt of the reference sample (A549-FK  cells 
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not transduced with miRNAs) from the ΔCt of each sample. Fold change was generated using the equation 2-
ΔΔCt.  
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Legend to Figures 
Figure 1 Cell clones expressing miR-34c-5p are protected from AP20187 induced apoptosis. 
(a) MTT assay for resistance to AP20187 of cell clones that express miR-34c. A549-FK (Cntrl) cells and 
individual cell clones were plated in triplicate in 96-well plates and treated with 10 nM AP20187 for 3 h. 
Values are expressed as the per cent of the untreated control; (b) parental A549-FK (lanes 1-3) or Cl-K 
(transduced with miR-34c, miR-362 and miR-124-1) or Cl-T (transduced with miR-34c) were treated for the 
times indicated with AP20187 (10 nM) and levels of caspase-3 and caspase-9 cleaved products were 
analysed by immunoblot. Filters were hybridized with anti α-tubulin to confirm equal loading. (c) The same 
as in (b) except that levels of BID cleaved products were analysed. (d) A549-FK, Cl-K or Cl-T were treated 
for 3 h with AP20187 (10 nM) or left untreated and cell lysates analysed by immunoblot with anti Bax N-20 
antibody. Lysates were either first immunoprecipitated with anti Bax6A7 antibody, specific for the active 
conformation of Bax (upper panel) or directly used for immunoblot analysis (lower panel). Intensity of bands 
was measured by ImageQuant analysis on at least two different expositions to assure the linearity of each 
acquisition. Values were each normalized for the corresponding values in the direct blot and are expressed as 
the per cent of the intensity measured in the second lane (labeled with asterisk). (e) Parental A549-FK cells 
or Cl-K or Cl-T were treated for 24 h with cisplatin (50µg/ml) and levels of caspase-3 cleaved products were 
analysed by immunoblot. Filters were hybridized with anti α-tubulin to confirm equal loading. The blots (in 
b,c,d,e) are representative of at least four independent experiments. (f) A549-FK or Cl-T cells were treated 
for 3 h with AP20187 (10 nM) (white columns) or left untreated (black columns). Where indicated either 
anti-miR-34c-5p inhibitor sequence or a corresponding scrambled sequence was transfected and cell lysates 
analysed for caspase-3 (upper panel) and caspase-9 (lower panel) activity as measured by hydrolysis of Ac-
DEVD-AFC or Ac-LEHD-AFC respectively. The value of miR-34c-5p in Cl-T+antimiR-34c-5p, quantified 
by qt-RT-PCR and expressed as 2-ΔΔct, is 0.09±0.01 compared to Cl-T+scrambled.  
 
Figure 2 miR-34c-5p interferes with AP20187 induction of apoptosis. 
(a) A549-FK cells (Cntrl) were treated for 3 h with AP20187 (10 nM) (white columns) or left untreated 
(black columns). Where indicated either miR-34c-5p mimic sequence or a corresponding scrambled 
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sequence was transfected. The per cent of cells in the pre-G1 fraction was determined by FACS analysis as a 
measure of apoptotic cells. (b, c) A549-FK cells were treated for 3 h with AP20187 (10 nM) (white columns) 
or left untreated (black columns). Where indicated either miR-34c-5p mimic or a corresponding scrambled 
sequence was transfected and caspase-9 (b) and caspase-3 activity (c) analysed as in Figure 1f. (d) A549-FK 
cells (Cntrl) cells were treated with AP20187 (10 nM) as indicated. Where indicated two different scrambled 
sequences, miR-34c-5p, miR-34c-3p mimic sequences or both miRNAs together were transfected and cell 
viability was determined by MTT assay as per cent of corresponding untreated cells (see legend to Figure 
1a). The values of miR-34c-5p in A549-FK cells tranfected with the mimic, quantified by qt-RT-PCR and 
expressed as 2-ΔΔct, are: 112.87±5.56 (a), 135.02±7.09 (b,c); 130.21±7.25 in A549-FK+miR-34c-5p and 
101.26±6.31  in cotranfected cells (d). The values of miR-34c-3p, quantified by qt-RT-PCR and expressed as 
2-ΔΔct, are 137.55±5.30 in A549-FK+miR-34c-3p and 138.03±9.28 in cotranfected cells (d). For all samples 
levels are compared to the scrambled controls.  
 
Figure 3 miR-34c-5p protects from paclitaxel-induced apoptosis. 
(a) A549 cells were transfected with either miR-34c-5p mimic sequence (left panel) or miR-34c-3p (right 
panel) and treated for 24 h with paclitaxel (100 nM). Levels of caspase-3 and caspase-9 cleaved products 
were analysed by immunoblot. Filters were hybridized with anti-α-tubulin to confirm equal loading. Each 
blot is representative of at least four independent experiments. (b) A549 cells (Cntrl) were treated for 24 h 
with paclitaxel (100 nM) (white columns) or left untreated (black columns). Where indicated either miR-34c-
5p mimic sequence or a corresponding scrambled sequence was transfected. The per cent of cells in the pre-
G1 fraction was determined by FACS analysis as a measure of apoptotic cells. (c) A549 cells were 
transfected with LNA anti-miR-34c-5p, anti-miR-34c-3p or anti-miR negative control inhibitor. Levels of 
caspase-3 and caspase-9 cleaved products were analysed by immunoblot. Filters were hybridized with anti-α-
tubulin to confirm equal loading. Values below the blot indicate signal levels of the 17kDa fragment of 
caspase-3 relative to control cells (lane 1, labeled with asterisk). Quantization was done as in Figure 1. Each 
blot is representative of at least four independent experiments. (d,e) A549 cells transfected with either miR-
34c-5p mimic sequence or a corresponding scrambled sequence were treated with TRAIL (d) or cisplatin (e) 
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for times and concentrations indicated. Levels of caspase-3 and caspase-9 cleaved products were analysed by 
immunoblot. Filters were hybridized with anti-α-tubulin to confirm equal loading. Each blot is representative 
of at least four independent experiments. The values of miR-34c-5p, quantified by qt-RT-PCR and expressed 
as 2-ΔΔct, are: 110.92±5.43 (a left panel); 96.37±5.02 (b) 0.19±0.02 (c); 133.72±4.43 (d); 129.77±6.07 (e). 
The values of miR-34c-3p are: 141.27±7.52 (a right panel) and 0.32±0.03 (c). For all samples levels are 
compared to the scrambled controls.  
 
Figure 4 Bmf as target of miR-34c-5p.  
 (a) Bmf 3’UTR contains two predicted miR-34c-5p binding sites. In the figure is shown the alignment of the 
two seed regions (S1 and S2) of miR-34c-5p with Bmf 3’UTR. The sites of target mutagenesis (deletion) are 
indicated by red dashes and red XXX.  (b) A549 or A549-FK cells were transfected with either miR-34c-5p 
or control scrambled sequence and cell lysates analysed for the expression of Bmf. Values below the blot 
indicate signal levels relative to control cells (lane 1, labeled with asterisk). Quantization was done as in 
Figure 1. (c) A549-FK, Cl-K and Cl-T cell lysates were analysed for the expression of Bmf. Values below 
the blot indicate signal levels relative to control cells (lane 1, labeled with asterisk). Quantization was done 
as in Figure 1. In the insert are reported the miRNAs transduced in the Cl-K and Cl-T and their relative (as 
compared to A549-FK control cells) expression levels. (d) Cl-T was transfected with LNA anti-miR-34c-5p, 
anti-miR-34c-3p or anti-miR negative control inhibitor and levels of Bmf were analysed compared with that 
of A549-FK control cells. Filters were hybridized with anti-α-tubulin to confirm equal loading. The blots are 
representative of at least four independent experiments..(e) pGL3-Bmf luciferase constructs, containing a 
wild type (left side of the histogram) or mutated (right side of the histogram) Bmf 3’ UTRs, are transfected 
into MEG01 cells. Relative repression of firefly luciferase expression was standardized to a transfection 
control. The reporter assays were performed three times with essentially identical results. The predicted 
recognition site of BMF at position 737-765 (S1) is less conserved (only bosTau2 genome) than that at 
position 2283-2311 (S2) that is conserved in bosTau2 and rat (rn4). The predicted free energies were 
calculated and are: -15.1 kJ for BMF S1 and -24.2 kJ for BMF S2, (f) A549 cells were transfected with miR-
124, miR-124*, miR-362-5p, miR-362-3p or a control scrambled sequence and Bmf protein levels were 
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analysed at indicated times by immunoblot. Filters were hybridized with anti-α-tubulin to confirm equal 
loading The blots are representative of at least three independent experiments. (g) Bmf 3’UTR contains 
predicted binding sites for miR-362-5p and miR-362-3p. In the figure is shown the alignment of the two seed 
regions of miR-362-5p (S3) and miR-362-3p (S4) with Bmf 3’UTR. The sites of target mutagenesis 
(deletion) are indicated by red dashes and red XXX. pGL3-Bmf luciferase constructs, containing wild type 
(either for miR-362-5p and miR-362-3p) or mutated (for miR-362-5p) Bmf 3’ UTRs, are transfected into 
MEG01 cells. Relative repression of firefly luciferase expression was standardized to a transfection control. 
The reporter assays were performed three times with essentially identical results. 
Diana Lab: miTG score for Bmf (miR-34c, 5.72; miR-124, 10.89; miR-362-5p, 3; miR-362-3p, 2.11; miR-
345, 5.0; miR-346, 2). 
 The values of miR-34c-5p, quantified by qt-RT-PCR and expressed as 2-ΔΔct, are: 133.53±4.96 (b left panel); 
148.84±6.58 (b right panel); 0.20±0.02 (d); 184.05±8.46, 153.27±6.33, 142.26±7.07, 154.27±5.93, 
112.37±4.13 (in Bmf S1, Bmf S2, Bmf S1+S2, Bmf S2 mut and Bmf S1+S2 mut respectively, e). The value 
of miR-34c-3p, quantified by qt-RT-PCR and expressed as 2-ΔΔct, is 0.34 ±0.02 (d). The values of miR-362-
5p, quantified by qt-RT-PCR and expressed as 2-ΔΔct, are 227.98±9.54 in Bmf S3 and 198.33±5.26  in Bmf 
S3 mut (g). The value of miR-362-3p in Bmf S4 is 239.85±13.98 (g). For all samples levels are as compared 
to the scrambled controls. 
 
Figure 5. c-myc mediates miR-34c-5p effects. 
(a) Bmf stable silenced A549 cells (shRNA Bmf) were transfected either with miR-34c-5p mimic or with a 
scrambled control molecule. After paclitaxel treatment, as indicated, levels of caspase-3 cleaved products 
were analysed by immunoblot and compared to control cells (shRNAcntrl) transfected with scrambled. 
Reported folds were calculated as reported in Figure 3c. (b) A549-FK cells transfected with the control 
scrambled sequence, the miR-34c-5p mimic or a c-myc siRNA were treated with 10 nM AP20187 and levels 
of caspase-3 and c-myc were analysed by immunoblot as indicated. (c) A549 cells were transfected with a c-
myc siRNA or a control siRNA and treated with paclitaxel, as indicated, and and the levels of caspase-3 
cleaved products and c-myc were analysed by immunoblot. Values below the blot (in b and c) indicate signal 
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levels of c-myc relative to control cells (lane 1, labeled with asterisk). Quantization was done as in Figure 1. 
(d) A549 cells were transfected with a c-myc siRNA alone or together with miR-34c-5p. In all samples the 
amount of transfected molecules was kept constant using corresponding scrambled controls as indicated. 
After treatment with paclitaxel levels of caspase-3 cleaved products, c-myc and Bmf were analysed by 
immunoblot.. (e) A549 cells were transfected with miR-34c-3p mimic or with a scrambled sequence and 
levels of Bmf and c-myc were analysed by immunoblot 72h post-transfection. The target prediction 
algorithms (Diana-microT3) predicts Bmf but not c-myc as target of miR-34c-3p. (f,g) A549 cells were 
transfected with miR-34c-5p mimic or with a scrambled sequence and 48h or 72h post-tranfection cells were 
recovered, stained with 50 µg/ml propidium iodide and analysed by FACS (f), or cell lysates were extracted 
for cyclin B1, cyclin D1 and Chk1 analysis by immunoblot (g). (h) A549 cells transfected with miR-34c-5p 
mimic or with a scrambled sequence were treated with paclitaxel as indicated and cyclin B1, cyclin D1 and 
Chk1 levels were evaluated by immunoblot analysis. Filters in a,b,c,d,e,g and h were hybridized with anti-α-
tubulin to confirm equal loading. The blots are representative of at least three independent experiments. 
 The values of miR-34c-5p, quantified by qt-RT-PCR and expressed as 2-ΔΔct, are: 115,62±5,56 (a); 
103,98±5,13 (b) 127,89±6,43 (d); The value of miR-34c-3p, quantified by qt-RT-PCR and expressed as 2-
ΔΔct, is 109,73±4,92 (e). For all samples levels are as compared to the scrambled controls. 
 
Figure 6. miR-34c-5p attenuates p53 activity. 
(a) A549 cells were treated with paclitaxel 100 nM for 24h. Cell lysates of untransfected cells (Cntrl) and of 
cells trasfected with a control scrambled sequence or with miR-34c-5p mimic were analysed with anti-
Acetyl–p53 and anti-p53 antibodies. (b) A549 cells were tranfected with a reporter construct containing the 
promoter region of MDM2 gene fused to luciferase. Luciferase activity was measured after treatment with 
paclitaxel of cells tranfected with the reporter gene together with miR-34c-5p mimic or with a scrambled 
sequence as control. The reporter assays were performed three times with essentially identical results. (c) 
A549 cells transfected with either scrambled or miR-34c-5p mimic were treated with paclitaxel, as indicated, 
and were analysed for MDM2 and SIRT-1 protein expression.. (d) A549 cells were trasfected with a control 
scrambled sequence and with miR-34c-5p mimic (upper panel) or with an LNA anti-miR negative control 
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inhibitor and an anti-miR-34c-5p inhibitor (lower panel). After treatment with 10 µM Nutlin-3 for 24h p53 
protein levels were analysed by immunoblot compared to untrasfected cells (Cntrl). Fold decrease of miR-
34c-5p (lower panel), quantified by qt-RT-PCR, was 0.5 (untreated), 0.33 (10 µM Nutlin-3) and 0.88 (20 µM 
Nutlin-3) for samples in the presence of antimiR-34c-5p as compared to the respective controls. (e) p53 
stable silenced A549 cells (shRNAp53) or mock stable trasfected cells (shRNAcntrl)  were treated with 
paclitaxel or cisplatin as indicated and levels of caspase-3 and caspase-9 cleaved products were analysed by 
immunoblot. (f) A549 cells were transfected with either miR-34c-5p mimic or with a scrambled sequence 
and treated for 24 h with cisplatin (50 µg/ml). Levels of p53 were analysed by immunoblot. Filters (in a,c,d,e 
and f) were hybridized with anti-α-tubulin to confirm equal loading. Each blot is representative of at least 
three independent experiments.. 
The values of miR-34c-5p, quantified by qt-RT-PCR and expressed as 2-ΔΔct, are: 135.11±7.12 (a); 
118.55±4.44 (b) 105.95±5.92 (c); 139.88±6.81 (f). For all samples levels are as compared to the scrambled 
controls. 
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